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Chronic Kidney Disease (CKD), is a major health problem in India. As per the 
Kidney Diseases Improving Global Outcomes (KDIGO) 2012, CKD is defined
1
 as 
abnormalities of kidney structure or function present for more than three months. 
Presence of either of the following markers of kidney damage (one or more) present 
for > 3 months is considered as criteria for CKD.   
1. Decreased Glomerular Filtration Rate (GFR) < 60 ml/min/1.73 m
2
.  
2. Albuminuria (Albumin Excretion Rate (AER)  30 mg/ 24 hrs, Albumin Creatinine 
Ratio (ACR)  30 mg/g).                                                                                        
3. Urine Sediment abnormalities.                                                                                       
4. Electrolyte and other abnormalities due to tubular disorder.        
5. Abnormalities detected by histology.  
6. Structural abnormalities detected by imaging. 
7. History of Kidney transplantation.                             
As per the Screening and Early Evaluation of Kidney Disease (SEEK) India, 
study the prevalence of CKD in India is 17.2%(Stage1-5).
2
 The prevalence of CKD 
globally remain up to 13.4%.
3
As per KDIGO 2012, CKD stages are determined 
according to estimated Glomerular Filtration Rate (eGFR) categories as G1-G5 and 
Albuminuria Categories as A1-A3, stressing the importance of albuminuria in 
predicting the prognosis of CKD.
1
 
An upsurge in CKD has been attributed to the following risk factors age, sex, 
race, hypertension, diabetes mellitus, obesity, smoking, cardiovascular disease, 
exposure to nephrotoxic drugs, agrochemicals, herbal medication and food 
additives.
4,5
 Serum elevation of excretory products like metabolites of purines, amino 





There is growing evidence that abnormalities in lipid metabolism may also 
contribute to progression of renal dysfunction.
9
 High level of Triglycerides (TGL) and 
low High Density Cholesterol (HDLc) are identified as risk factors of renal 
dysfunction.
10,11
 The ratio of TGL/HDLc and renal dysfunction is under study and a 
study among adult Koreans has stated that elevated TG/HDLc ratio is associated with 
renal dysfunction.
12
 Injury induced by cellular TGL accumulation can cause 
disruption and damage to the cellular homeostasis. TGL accumulation caused renal 
tubular damage in both, in vivo and in vitro models.
13
 HDLc promote TGL clearance 




Thyroid hormones were also found to influence GFR, tubular secretion and 
absorption.
16,17
One study has shown that normal to high levels of Thyroid Stimulating 
Hormone (TSH) and normal to low levels of free triiodothyronine (FT3) were 
associated with increased risk of CKD in euthyroid subjects.
18
 It is also said that high 
level of serum free thyroxine (FT4) was associated with increased risk of CKD rather 
than TSH and FT3.There was also associated rapid decline in eGFR.
19
Many studies 
have found that hypothyroidism is associated with dyslipidemia and renal 
dysfunction.
20,21,22
 The association of thyroid dysfunction and dyslipidemia may play 
an important role in pathogenesis of renal dysfunction.Heat stress and dehydration are 
considered as risk factors for CKD. The pathophysiology is due to dehydration, 
decreased renal blood flow and increased level of uric  acid.
23
 
Agrochemicals like 2,4 D and paraquat dichlorate, non-steroidal anti-
inflammatory drugs(NSAID), heavy metal exposure are  associated with acute kidney 
injury.
23,24,25
 Studies suggest that in obesity, adipose tissue may contribute to renal 
damage by oxidative stress, abnormal plasma lipid, coagulation abnormalities, 
 
3 
endothelial dysfunction, inflammation and insulin resistance.
26,27
 Smoking is 
associated with CKD, the possible mechanism includes increased blood pressure and 
heart rate, cell proliferation, fibronectin, arteriosclerosis of renal artery and arterioles, 
increased production of  growth factors like angiotensin II, endothelin-I, transforming 
Growth Factor-1, oxidative stress, tubular toxicity, increased aggregation of platelet 
and vasopressin mediated antidiuresis.
28,29
 
There is not much of study in India to assess the risk factors and early 
detection of renal dysfunction in a heterogeneous group of population. Community 
based screening programs for early detection of renal dysfunction will prevent 
progression to CKD and decreases morbidity and mortality. Identification of novel 






AIM OF THE STUDY 
 To assess the risk factors for renal dysfunction in a heterogeneous population. 
 
OBJECTIVES OF THE STUDY 
1. To determine the age and sex wise distribution of eGFR and Urinary spot 
Protein- Creatinine ratio (UPCR) in a heterogeneous population. 
2. To find out prevalence of various CKD stages based on eGFR . 
3. To estimate the lipid profile and thyroid profile and assess their role as risk 
factor in renal dysfunction. 
4. To find out the association between lipid profile and thyroid profile and 
different stages of CKD. 
5. To find out the association between the risk factors like Obesity, Diabetes 














REVIEW OF LITERATURE 
 
KIDNEY 
The kidney is a functionally diverse organ and participates in many of the 
body‟s homeostatic mechanisms. Kidneys are a pair of bean shaped organs located in 
the retroperitoneal space. Each kidney is divided into an outer cortex and inner 
medulla. The Nephron is the functional unit of kidney. Each kidney consists of about 
a million nephrons. Each nephron consists of  
1. Glomerulus, which is a tuft of capillaries surrounded by expanded end of renal 
tubule called Bowman‟s capsule, supplied by an afferent and efferent arteriole. 
2. Proximal Convoluted tubules, which are tightly coiled in the beginning called 
as pars convoluta, which towards the medulla become straightened to form 
pars recta. 
3. Loop of Henle, consists of the thin descending limb and the thick ascending 
limb. 
4. Distal convoluted tubule. 
5. Collecting duct, formed by two or more distal convoluted tubules that drains 
urine from each nephron. Collecting ducts merge and empty their content into 
the renal pelvis.30 
 
Figure: 1shows the anatomy and organization of kidney.  



































The basic functions of kidney are
30 
1. Urine formation 
2. Fluid and electrolyte balance 
3. Regulation of acid base balance 
4. Excretion of waste products of metabolism 
5. Secretion of hormones 
 Renin 
 Erythropoietin 




The kidney diseases have been classified as  
1. Acute Kidney Disease (AKD). 
2. Chronic Kidney Disease (CKD). 
3. End Stage Renal Disease (ESRD). 
 
PATHOPHYSIOLOGY OF KIDNEY DISEASES 
Irrespective of the etiology of the kidney disease, the pathogenesis leading to 
renal dysfunction remain the same. The pathological process is characterized by,early 
inflammation followed by accumulation and deposition of extracellular matrix, 






The local Renin Angiotensin Aldosterone System (RAAS) has an important 
role in the pathological process of kidney disease.
32
 Angiotensin II produces toxic 
reactive oxygen species (ROS) within the renal cells and affect signal transduction. It 
also induces many inflammatory mediators like cytokines, chemokines and growth 
factors which activates the lymphocytes and macrophages. The activated cells further 
causes lysis of cells and proliferation of interstitial fibroblast which causes increase in 
the extracellular matrix and fibrosis of the glomerulus and tubules. Blood supply will 
be affected leading to cell death.
31,32
 The figure 4,gives an outline of the pathological 




Role of Angiotensin II in renal pathology 
 
 
The kidneys increase their functional capacity after injury. Symptoms or major 
biochemical changes occur occur only if 50-60% of the functioning kidney mass is 
lost.There will be increase in workload of the nephron and is considered as an 
important cause of progressive renal injury.
31,33
 A hypothesis is that a point at which 
 
9 
the decline in nephron number is reached, further loss in nephron will lead to 





CHRONIC KIDNEY DISEASE 
The increasing incidence of lifestyle disorders may cause resource crunch in 
economy of our country. One such disease which India faces is Chronic Kidney 
Diseases. CKD constitute a major cost burden in health care system worldwide. The 
incidence of CKD is increasing worldwide. As per the Screening and Early 
Evaluation of Kidney Disease (SEEK) India,study the prevalence of CKD in India is 
17.2%.
2 






According to Kidney Diseases Improving Global Outcomes (KDIGO) 2012, 
Chronic Kidney Disease(CKD) is defined as abnormalities of kidney structure or 
function present for more than three months. 
Criteria of CKD (either of the following present for > 3 months) 
1. Markers of Kidney damage (one or more)
35,36,37
 
 Albuminuria  (AER  30 mg/24 hours, ACR  30 mg/g /  30 mg/mmol) 
 Structural abnormalities detected by imaging. 
 Urine Sediment abnormalities. 
 Electrolyte and other abnormalities due to tubular disorders. 
 Abnormalities detected by histology. 




 GFR <60 ml/min/1.73 m2 (GFR categories G3a-G5) 
 
10 
 The criteria GFR <60 ml/min/1.73m2 for CKD is selected because at this value 




RISK FACTORS OF CKD 
Risk factors which are associated with renal dysfunction include 
hypertension(HT), diabetes mellitus (DM), cardiovascular disease (CVD), proteinuria, 
anaemia.
40
The non-traditional CKD risk factors include nephrotoxin exposure, renal 
stones, acute kidney injury (AKI), infections,
41
 dyslipidemia are associated with renal 
disease progression.
42






As per KDIGO 2012, CKD is classified based on  
1. GFR category and 




G1 -  eGFR   90ml/min/1.73 m2   – Normal or High 
G2 -  eGFR  60-89ml/min/1.73 m
2
 – Mildly decreased 
G3a - eGFR  45-59ml/min/1.73 m
2
 – Mildly to moderately decreased 
G3b - eGFR  30-44ml/min/1.73 m
2
 – Moderately to severely decreased 
G4 -  eGFR   15-29ml/min/1.73 m
2
 – Severely decreased 
G5-   eGFR   <15ml/min/1.73 m
2
    -  Kidney failure 











Predicting prognosis of CKD 
For predicting the prognosis of CKD, the cause or aetiology for CKD should 
be identified. Then CKD is categorized based on GFR and Albuminuria. Figure 5, 

















CKD progression is defined based on one or more of the following  
 Decline in GFR category, a certain drop in eGFR is defined as a drop in GFR 
category accompanied by a drop of 25% or greater of drop in eGFR from 
baseline. 
 Rapid progression is defined as a sustained decline in eGFR more than 
5ml/min/1.73m
2
 per year. 
 The confidence in assessing progression is increased with number of serum 
creatinine measurement and duration of follow up.
36
 
 The factors associated with CKD progression are GFR, albuminuria, hypertension, 
diabetes, smoking, obesity, age, ethnicity etc. 
 
ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) 
  Serum creatinine is an endogenous marker of Glomerular filtration rate (GFR). 
In clinical practice, serum creatinine is used as an index of renal function.
44
 Plasma 
concentration of creatinine is affected by muscle mass, diet, age, gender, exercise and 
ethnicity, so there will be false estimation of renal function.
45
 A 24 hours urine 
creatinine clearance is considered  as a sensitive tool for detection of renal 
dysfunction. Creatinine is freely filtered at glomerulus, but there is some tubular 
secretion. Also the timed urine collection is difficult. There was a wide(11%) within 




  The National Kidney Foundation Disease Outcomes Quality Initiative (K-
DOQI) recommended the use of estimated GFR (eGFR)calculated by using formulas 
based on plasma or serum creatinine.
36
 Cockcroft and Gault in 1976 published an 
 
13 
equation based on age, weight, height and plasma creatinine with correction 
factors.
46
The limitation of this formula is that, it was derived from hospitalised 
individuals mostly men. Also the need for height and weight measurement for 
calculation is a limitation.
45
 
  A Modification of Diet in Renal Disease (MDRD) study, evaluated the effect 
of protein restricted diet on renal disease progression and created an equation for 
calculation of eGFR, which included age, gender, plasma creatinine and race 
differentiation (white or black).
47
MDRD did not require body weight or height. As 
MDRD was originally derived from a group of CKD patients, its use in healthy 
individuals is unclear. It is not validated for children, pregnant women, obesity and 
elderly patients (>70 years).
45




  Chronic Kidney Diseases-Epidemiology Collaboration group (CKD-EPI) 
developed a new formula in 2009, to have greater accuracy even at high GFR. It 
includes race, gender, and age.
49
 Many studies have found cystatin C derived equation 
for eGFR is better than creatinine in predicting renal function.
50,51
 Schwartz formula  
developed in 1970 is used to estimate GFR in chidren. 
 
Schwartz Formula for children
52
 
eGFR=0.41x height (cm)/ Scr (mg/dl) (updated Schwartz bedside formula) 

























Proteinuria is an independent risk factor for renal disease and cardiovascular 
disease.
54
 The proteins of molecular weight of < 20,000 Da can be filtered by the 
glomerulus, the negative charge of the glomerular membrane restrict the passage of 
albumin through the membrane.
55
 Normally the filtered protein are reabsorbed and 
catabolized in the proximal convoluted tubules. The normal protein excreted in urine 
is 150 mg/day. Excretion of albumin 30mg/day to 300mg/day is termed as 
microalbuminuria. Protein excretion >300mg/day is known as proteinuria or macro 
albuminuria.
56
 Of the proteins excreted in urine, the high molecular weight 
albumin(65,000Da) is about 40%, low molecular weight like light chain 







Pathologic Proteinuria can be classified into three types 
1. Glomerular proteinuria 
2. Tubular proteinuria 
3. Overflow proteinuria 
Glomerular proteinuria is due to the permeability of glomerulus to high 
molecular weight proteins like albumin.
56
Glomerular proteinuria is the one which is 
used for staging of Chronic Kidney Disease. Measurement of albumin in urine 
determines the glomerular proteinuria.
55
 
Tubular proteinuria results from decreased reabsorption of the protein present 
in the glomerular filtrate or due to the excretion of proteins produced due to tubular 
injury due to tubulointerstitial diseases like hypertensive nephrosclerosis, nephrotoxic 
drugs like nonsteroidal anti-inflammatory drugs etc.
55,56
 
Overflow proteinuria is due to excess low molecular weight protein, which 
when excreted in normal amounts will be reabsorbed. Low molecular weight proteins 
that occur in overflow nephropathy are Bence–Jones protein of multiple myeloma, 
lysozyme in myelomonocytic leukemia, myoglobin in rhabdomyolysis.
55,56
 
A 24–hour urine collection is considered as the gold standard in determining 
the urinary protein excretion. A 24-hour urinary protein collection show variation in 
urinary protein due to variation in intake of water, excretion of water, exercise, 
posture, diet etc. Nowadays expressing a spot urine protein as ratio to spot creatinine 
concentration is used. When the GFR remains constant the protein and creatinine 
excretion rates are constant during day
54
.Currently spot urine protein- creatinine ratio 
(UPCR) is widely used to estimate the daily urinary protein excretion.
57
 
Microalbuminuria is an early sign of progression of renal and cardiovascular disease 
in patients who has hypertension and diabetes.
58
 Proteinuria is a combination of 
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albuminuria and non albumin proteinuria(NAP). Isolated non albumin proteinuria 
(NAP) is a condition when urine total protein is elevated without elevation of urine 
albumin.
55
 Non albumin proteinuria include alpha–microglobin, beta2 macroglobulin 
and IgG which are associated with renal damage in renal transplant patients.
59
 
Non albumin proteinuria = Total protein – albuminuria.60 Studies advice measurement 
of both urine spot albumin and total protein to identify the non albumin protein which 
may occur earlier than microalbuminuria.
55,60,61
 
The KDIGO 2012 guidelines suggest early morning spot urine protein 
estimation in the following descending order,
37
 
1. Urinary albumin –creatinine ratio (ACR). 
2. Urine protein-creatinine ratio (PCR). 
3. Reagent strip urinalysis for total protein with automated reading. 
4. Reagent strip urinalysis for total protein with manual reading. 
  
 KDIGO also states that if non-albumin proteinuria is suspected, assays for 
specific urine proteins like Bence Jones protein is done.
37
 
Consequences of proteinuria: 
Proteinuria is not just a marker of renal dysfunction but it is also a risk factor 
for progression of kidney disease. The proteins accumulate in the tubular lumen 
causes inflammation and leads to interstitial structural damage and progression of 
kidney disease.
62
 Also studies state that glomerular filtration of large amounts of 
protein by glomerulus causes mesangial cell injury and thus causing 
glomerulosclerosis
63






DIABETES AND CHRONIC KIDNEY DISEASE 
Diabetic nephropathy, one of the microvascular complications of diabetes 
mellitus, is one of the most important etiology for CKD and ESRD. Chronic 
hyperglycemia is the cause for pathogenesis of the microvascular complication.
64
 The 
pathological finding in advanced diabetic nephropathy are glomerulosclerosis and 
tubulointerstitial fibrosis.
65
 Experimental animal model studies have shown that in 
renal glomerulus and tubules there was increase in gene expression for synthesis of 
extracellular matrix proteins.
66
 Hyperglycemia activate the polyol pathway of glucose 
metabolism and this leads to collagen accumulation in the  renal tubular 
interstitium.
67,68,69,70
 Hyperglycemia induces increased formation of advanced 
glycated end products of proteins,
71,72
 growth factors/ cytokines  like transforming 
growth factor- (TGF-),73,74 platelet derived growth factors (PDGF),75,76insulin-like 
growth factor-I (IGF-I),
77,78
 hepatocyte growth factor (HGF),
79
 Vasoactive substances 
like angiotensin–II,80,81 endothelin-I,82 thromboxane,83 which through autocrine and 
paracrine mechanism causes cell proliferation and growth.
84
 
 Figure 6, explains the mechanism of renal toxicity of hyperglycemia 
Figure  6:
85




With increase in glucose, the mitochondria generate reactive oxygen species 
(ROS), which leads to break in DNA strands and activation of poly ADP ribose 
polymerase(PARP). PARP inactivates Glyceraldehyde 3-phosphate 
dehydrogenase(GAPDH) and the normal glucose metabolism is altered.  
There will be  
1. Activation of polyol pathway  
2. Activation of Phosphokinase C(PKC) via diacyl glycerol. 
3. Activation of Hexosaminase pathway and glucosamine gets accumulated. 
4. Formation of Advanced glycated end products due to non enzymatic glycation of 
proteins. 
All these mechanism produces increased growth factors and causes glomerular 
pathology.
64,85
 Studies have shown that PKC stimulate the mitogen activated protein 
kinase (MAPK) pathway. The MAPK pathway, is an intracellular signal transduction 
pathway of cell growth, which activate cell growth and mesangial proliferation.
86,87
 
Further studies have proven that advanced glycated end products (AGE) also activate 
the MAPK pathway in proximal tubular LLC-PK1 cells.
88
 
Apoptosis causes the tubular atrophy and tubulointerstitial fibrosis.
89
 Gene 
products like bcl2 is protective against apoptosis.
90
 In a study there was increase in 
apoptotic cells in diabetic, db/db mice than in non-diabeticlittermates. Theapoptotic 
cells were found in the tubulointerstitium and not in glomeruli. There was increased 









DYSLIPIDEMIA OF CHRONIC KIDNEY DISEASE 
Dyslipidemia is a common finding among CKD patients and is responsible for 
associated morbidity and mortality.
92
 The plasma lipid profile in CKD shows elevated 
levels of triglycerides(TGL), low high density lipoprotein(HDLc),
93
 increased very 
low density lipoprotein(VLDL), remnants and intermediate density lipoprotein,
94
 
accumulation of small dense low density lipoprotein(LDLc), glycated and 
carbamylated apolipoprotein,
95
 prolonged persistent chylomicron remnant post 
prandially.
96
 The composition of plasma lipoprotein is also altered in CKD.
97,98,99,100
 
In CKD the  cholesterol content of VLDL is increased and there is relative decrease in 
TGL content. In LDLc the cholesterol content is decreased and there is relative 
increase in TGL content in CKD. In HDLc the cholesterol ester and free cholesterol 
content are reduced and TGL content is elevated.
54,55,56,57
There is hepatic lipase 
deficiency in humans and animals in CKD.
101
 Normally hepatic lipase catalyses 
hydrolysis and removal of triglyceride content of HDLc. As there is deficiency of 
hepatic lipase there is increase in TGL content of HDL.
58
 Elevated TG/HDL ratio can 
cause renal dysfunction.
102
 The atherogenic lipoproteins like lipoprotein(a) and 
oxidized LDL are present in hemodialysis patients.
103
 
Dyslipidemia causes renal damage and can cause progression of renal 
failure.
104
 Dyslipidemia cause damage to mesangial cells, podocytes and glomerular 
capillary endothelial cells. Mesangial cells express LDL and oxidized LDL receptors, 
on activation there will be mesangial cell proliferation, increased mesangial matrix 
deposition, increase in cytokines like interleukin -6 or growth factors.Oxidized LDL 
increases the adhesion of monocytes to glomerular endothelial cells and causes 
monocyteinfiltration and causes tubular epithelial damage.
42,105
 Hypercholesterolemia 





In vivo studies have shown that there is increased expression of a transcription factor, 
sterol regulatory element binding protein(SREBP) which is associated with 
lipogenesis and increase in accumulation of lipid in the glomerulus and 




THYROID AND CKD 
Thyroid hormones have its direct effect on kidney by causing systemic or local 
hemodynamic changes.
109
Thyroid hormone directly influence renal development and 
growth, GFR, renal transport systems and electrolyte homeostasis.
16,17,110
The presence 
of renal abnormalities in congenital hypothyroid children
111
 indicate that thyroid 




Effect of Thyroid Hormone on Renal physiology: 
Thyroid hormone influences the renal function by action on cardiovascular 
system and there by the blood flow to the kidneys. Thyroid also affects the GFR, 
tubular secretion and reabsorption. In the proximal convoluted tubules, Na/K ATPase 
is influenced by thyroid hormones and thus the sodium reabsorption.
113
 Thyroid 
hormone also influence the tubular potassium handling.
114
 The renin angiotensin 
aldosterone axis is influenced by thyroid 







Both hyperthyroidism and hypothyroidism has effects on kidney. 
Role of Hyperthyroidism on Kidney function: 
In hyperthyroid patients, an increase of 18-25% GFR has been noticed,
17
 due 
to increased renal blood flow and renin angiotensin aldosterone system (RAAS) 
activation. There will be increased -adrenergic activity in hyperthyroidism. Studies 
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have shown that thyroid hormone influence, increase in -adrenergic receptors in 
renal cortex and is the cause for RAAS activation.
118
 RAAS activity causes dilatation 
of afferent arteriole and constriction of  efferent arteriole and increase filtration 
pressure leading to increase in GFR. Due to efferent arteriolar constriction, there will 
be decrease in the perfusion in proximal convoluted tubule (PCT) and there will be 
increased sodium and chloride reabsorption in PCT.
119
 
Hyperthyroidism increases heartrate, raises cardiac output, decreases the 
systemic vascular resistance and thus increases systolic blood pressure.
120
 
Hyperthyroidism causes CKD by increasing the renal blood flow leading to intra 
glomerular hypertension and increased filtration pressure. Associated proteinuria in 
hyperthyroidism also causes renal  injury.
121
 
Role of Hypothyroidism on Kidney function 
In adults and children, primary hypothyroidism is associated with a reversible 
increase in serum creatinine and decrease of GFR.
122,123,124,125,126,127
 It has been 
reported that these defects were corrected with thyroid hormone replacement.
128
 GFR 
measurement using Inulin or 
51
Cr-EDTA has proved that hypothyroidism is associated 
with reduced GFR.
124
 Hypothyroidism  causes alteration in hemodynamics and  
structure of kidney.
129
 The decrease in GFR in hypothyroidism is due to decreased 
renal blood flow.
130
 Hypothyroidism also causes decreased cardiac output and low 
circulating volume. Decreased activity of renin angiotensin system(RAAS) and 
decreased levels of atrial natriuretic factor(ANF) are found in hypothyroidism and 
these cause decrease in renal perfusion.
109
 Decreased expression of vascular 
endothelial growth factor(VEGF) and insulin like growth factor(IGF) which are renal 











Effect of Thyroid dysfunction on Kidney 
 
Chronic Kidney Disease and Thyroid disease 
Primary and subclinical hypothyroidism is common among CKD patients
132
. 
Decrease in T3(low T3 syndrome or euthyroid sick syndrome) is noticed in CKD 
patients.
133
This decrease in  T3 (mainly total T3 and not free T3) is due to chronic 
protein  malnutrition and metabolic acidosis affecting the iodothyronine deiodination 
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and decrease in T3 binding to protein.
134
 Also  decrease in deiodinase activity in CKD 
is due to inflammatory cytokines, which causes decrease in peripheral conversion of 
T4 toT3.
135
There is also decrease in thyroid hormone synthesis due to accumulation 




OBESITY AND CKD 
Obesity, overweight and metabolic syndrome are emerging as important 
independent risk factor for CKD.
137,138
 Epidemiological studies have shown the 
association of obesity with CKD and end stage renal disease (ESRD).  Studies showed 
that high BMI was associated with ESRD as an independent risk factor, independent 
of hypertension, proteinuria
139
 smoking and diabetes.
140
 Obesity was found toaffect 
the progression of preexisting renal diseases like IgA nephropathy,
141
 unilateral renal 
agenesis
142
 or after unilateral nephrectomy.
143
 These studies suggest that obesity 
initiates CKD. A study of 6,500 nondiabetic subjects showed that increasing body 
mass index (BMI) and waist circumference(WC), had decreased eGFR and increased 
CKD.
27
 Also obesity is closely associated with Type II diabetes and hypertension 
which are considered as important risk factors for CKD and ESRD.
144,145,146
 
Mechanism of Obesity associated Kidney disease 
Obesity causes renal damage directly by hemodynamic and hormonal 
effect
147,148



















Animal and human studies have shown that obesity causes increased renal 
tubular sodium reabsorption which causes renal vasodilatation
150
 causing glomerular 
hyper perfusion and hyper filtration, which may cause focal segmental 
glomerulosclerosis and proteinuria.
148,151
The mechanism for early rise in GFR in 
obesity may be due to maculadensa feedback mechanism.
152
 The visceral obesity 
causes compression of kidneys which may increase the sodium reabsorption in the 
loop of Henle
153
 and hence less sodium in the macula densa and causes a tubulo 
glomerular feedback and increases renin secretion, increased blood flow and GFR. 
The glomerular hyper filtration then gradually subsides and there will be a gradual 
decrease in GFR with renal injury associated with prolonged obesity induced 
hypertension and diabetes. There will be increased glomerular wall tension and 
glomerular hypertrophy that leads to injury, glomerular sclerosis and nephron 
loss.
153,154
 Activation of sympathetic nervous system(SNS)
155,156
and renin angiotensin 





Obesity related glomerulopathy has been documented from kidney biopsy 
specimens.
148
 Changes in the structure of kidney is noticed within few weeks of rapid 
weight gain. In animal experiments with dogs, enlargement of bowman‟s space, 
increase in glomerular cell proliferation, mesangial matrix and basement membrane 
thickening were observed. Glomerular transforming growth factor , expression was 
also  increased.
148
Also the leptin from adipose tissue might cause renal 
fibrosis.
157
Deposition of lipids in non adipose tissue like kidney leads to accumulation 
of diacylglycerol and ceramides, which may cause mitochondrial dysfunction, 
endoplasmic reticulum stress, apoptosis and renal injury and dysfunction.
158,159
 
Inflammatory changes in Obesity causing CKD 
Insulin resistance is present in metabolic syndrome, which is a 
proinflammatory state.
160,161
Visceral fat produce increased level of adipokines like 
interleukine-6 (IL-6), tumor necrosis factor, C-reactive protein (CRP) and resistin. A 
study has shown that in patients with obesity related glomerulopathy, the glomeruli 
showed increased expression of genes related to lipid metabolism, inflammatory 
cytokines and insulin resistance.
162
 Leptin an adipocyte derived hormone, that 
suppresses appetite (hypothalamus) and increases insulin sensitivity. In obesity the 
hypothalamic effect of leptin is lost.
160,163,164
The leptin receptor (Ob-Ra) is expressed 
in kidney.
165
 Recombinant leptin stimulate proliferation of cultured glomerular 
endothelial cells and also in rats.
166
 Leptin stimulate type I collagen in cultured 
mesangial cells,
167
 these show that leptin is involved in glomerulosclerosis. Figure 
9,
149














FFA- Free Fatty Acid;RAS –Renin Angiotensin System; HTN-Hypertension; AA- 
Afferent Arteriole; EA –Efferent Arteriole;Na –Sodium 
 
 
CARDIOVASCULAR DISEASE AND CKD 
Accelerated cardiovascular disease is a complication of renal disease. 
Mortality and morbidity due to cardiovascular disease is common in CKD patients. 
Studies have shown that prevalence of CKD is more among cardiovascular disease 
patients, CKD is also a risk factor for Cardiovascular disease (CVD),
168
 and its 
recurrence.
169
 The common risk factors like hypertension, obesity, dyslipidemia, 
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smoking for CVD and CKD may be the cause for increase in incidence of CVD 
among CKD.
 170,171




1. Coronary artery disease (CAD) and myocardial infarction (MI). 
2. Congestive heart failure (CHF). 
3. Peripheral arterial disease (PAD). 
4. Arrhythmias. 
5. Cerebrovascular disease (CVA). 
6. Sudden cardiac death. 
Hypertension (HT) is one of the most common cause for CVD in CKD. 
Activation of RAAS and sodium retention is the mechanism for developing HT in 
CKD. Increased sympathetic activity and elevated catecholamine concentration is 
seen in CKD.
173
 Renalase, a soluble monooxygenase which degrades catecholamines, 
is expressed in renal glomeruli, PCT and cardiomyocytes is absent in CKD, so 
increase in catecholamine activity is seen in CKD.
174
Endothelial dysfunction is 
common in glomerular microalbuminuria and causes hypertension. Hypertension 
causes left ventricular hypertrophy causing ventricular dysfunction.
175
 Asymmetric di 
methyl arginine (ADMA), which is a competitive inhibitor of nitric oxide synthase is 




In CKD there will be pressure overload and volume overload that causes 
cardiomyopathy and left ventricular failure. Arterial stiffening due to medial and soft 
tissue calcification also contribute to CVD in CKD.
177
 All these contribute to the 
cardio renal syndrome. 
Figure 10,
178





Pathophysiology of Cardio-renal Syndrome 
 
 
ADH-Anti Diuretic Hormone, ANP- Atrial natriuretic peptide, BNP-B type 
natriuretic peptide, EPO-Erythropoietin, HTN –Hypertension, DM-Diabetes, LV-left 
ventricular, N-GAL-Neutrophil gelatinase associated lipocalin, KIM -1- Kidney 
Injury molecule, NSAID- Non steroidal anti inflammatory drug, OSAS-Obstructive 
sleep apnoea syndrome, PTH-Parathyroid hormone, SNS-Sympathetic nervous 
system, TNF-- Tumor necrosis factor-, TZD-Thiazolidinediones, VSMC-Vascular 
smooth muscle cell. 
 
OCCUPATION AND CKD 
Several studies in different parts of the world has shown association between 
lower socioeconomic status (LES) and CKD. Lower socioeconomic status is defined 
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by educational status and occupational levels.
179,180
Low occupational level people are 
exposed to lot of nephrotoxins like metals (lead, mercury, silica, copper, silver etc), 
organic solvent, grain dust, and welding fumes (glycol ether).
181,182,183
 Agricultural 
labourers are prone for heat stress and hence CKD. Strenuous work done in hot 
environment leads to volume depletion and rhabdomyolysis.
184
 Our body tries to 
maintain the temperature at approximately 37
o
C. Any increase in temperature 
stimulate the thermoregulatory center in the hypothalamus and causes vasodilatation 
and sweat glands stimulation and there will be regulation of temperature by 
convection, conduction and evaporation. There will be loss of electrolytes and 
extracellular fluid causing a stress to the kidneys.
185
When there is heat stress there 
will be release of cytokines and heat shock proteins which causes inflammatory 
response.
25
 Persons exposed to heat stress are prone to develop both acute kidney 
disease(AKD) and chronic kidney disease(CKD).
185,186
In a study in El Salvador, about 
the Mesoamerican nephropathy (MeN), the renal biopsy showed tubulointerstitial 
injury and glomerulosclerosis with minimal vascular changes.
187
 
Agrochemical exposure (commonly used 2,4-Dichlorophenoxyacetic acid(2,4-
D), paraquat dichlorate, glyphosate) is also associated with renal dysfunction.
25
 In a 
study among sugar cane workers for MeN have mentioned that the workers eat 
sugarcane and they are exposed to agrochemicals,
4
 also the high fructose intake 
causes metabolically induced inflammatory renal damage.
4,188,189
Fructose are 
transported by the glucose transporters GLUT5 /GLUT2, mainly expressed in the 
proximal convoluted tubule. In the liver and kidney fructose is metabolized to 
fructose-1-phosphate by the enzyme fructokinase [Ketohexokinase(KHK)]. 
ThenAldose-B acts on fructose-1-phosphate to form dihydroacetone phosphate and 
glyceraldehyde. During the fructokinase activity there is depletion of ATP. The 
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depletion of ATP activates the enzyme of purine metabolism, to yield uric acid 
leading to hyperuricemia, oxidants and inflammatory mediators leading to tubular 
injury and inflammation.
188,189,190
 Also when they eat sugarcane they are at risk of 
getting exposed to leptospiral infection.
24
 Leptospirosis produces acute kidney injury, 
by a tubulointerstitial process with interstitial oedema and mononuclear cell 
infiltration. Associated electrolyte abnormalities (sodium wasting and hypokalemia) is 
due to the inhibition of the NaK2Cl (NKCC2) transporter in the ascending Loop of 
Henle.
191
 In some studies, tubular dysfunction persisted and progressed to CKD when 
there was associated diseases like hypertension.
192
Occupational activities involving 
metals like lead, cadmium etc contaminate the environment. The source of lead 
contamination is from gasoline and paint.
193
 These metals get accumulated in 
proximal tubule producing chronic tubulointerstitial nephritis. Nephritis may be due 




SMOKING AND CKD 
Smoking is a preventable cause for many non-communicable diseases. In a 
metaanalysis Xia et al has stated smoking as an independent risk factor for developing 
CKD.
195
 In patients with diabetes and hypertension smoking contributes to the 
progression of CKD and CVD.
196,197,198
 Renal function loss was noticed in persons 
with history of current smoking of more than 20 cigarettes a day.
199
 In diabetic 
nephropathy, smoking develops micro and macro albuminuria and progression to end 
stage renal disease.
196,198 
Mechanism of Smoking and renal disease: 
Several factors affect the toxic effect of smoking on renal dysfunction. The 
genetic susceptibility of the individuals decide the amount of damage. The potential 
mediators and mechanism of smoking causing renal damage can be classified as 
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1. Non hemodynamic mechanism 
2. Hemodynamic mechanism 
 
Non Hemodynamic mechanism: 
Smoking causes endothelial dysfunction, growth factor activation, oxidative 
stress, toxic effects on tubules, altered metabolism of lipoprotein and 
glycosaminoglycans and insulin resistance.
196,198
 Studies have shown that nicotine 
induces mesangial cell proliferation and fibronectin production.
200
 There is expression 










 : Potential Mechanism of Smoking induced Kidney damage 
 




Smoking increases the blood pressure and heart rate due to the action of 
nicotine present in cigarettes.
197
The increase in concentration of epinephrine and 
norepinephrine and direct stimulation of postganglionic nerve ending by the nicotine 
causes the increase in BP and heart rate.
202
 In smokers there is an associated decrease 
in BP at night,
203
which may lead to renal dysfunction.
204
 Ritz et al in their study has 
found that nicotine, increased the activity of sympathetic nervous system causing 
increased heart rate, blood pressure, intra glomerular capillary pressure leading to 
decrease in GFR, filtration fraction and renal plasma flow.
205
 John main et al has 
stated that smoking causes cholesterol micro embolism causing atherosclerotic 
changes in renal artery and progression to end stage renal disease (ESRD).
206
 
Pathological finding in kidney of smokers: 
An increase in arteriolar wall thickness due to fibroelastic proliferation and 
intimal hyaline thickening is seen.
207
 There is increased myointimal hyperplasia of 
intrarenal arterioles which is absent in hypertension, so smoking is the causative agent 
behind this change.
208




ALCOHOL AND CKD 
Chronic excessive alcohol intake is considered as a risk factor for liver 
disease, cardiovascular illness and cerebrovascular illness.
210
The association between 
chronic alcohol intake and kidney disease is under controversy. Experimental studies 
states that alcohol has an acute nephrotoxic effect.
211
Chronic alcohol consumption 
indirectly causes CKD by causing alcohol induced hypertension.In certain specific 
situations chronic alcohol dependency causes renal papillary necrosis, infection 





Studies report that an inverse association exist between high 
alcohol consumption and CKD risk.
215
The inverse association may be due to the 
increase in high density lipoprotein (HDLc) and plasma endogenous tissue type 
plasminogen activator levels and decrease in platelet aggregation by alcohol. HDLc is 
less atherogenic and may be responsible for the inverse association of 
CKD.
216,217
Animal studies state that antioxidant property of polyphenol present in red 
wine may reduce renal damage by the induction of glutathione peroxidase and 
superoxide dismutase.
218
 Another animal model study has said that alcohol prevent 




KIDNEY STONE AND CKD 
Kidney stone is considered to be a risk factor for CKD. Hippisley et al have 
found an increased risk of ESRD among female than male kidney stone formers.
220
 
Some studies state that there is no relationship between renal stone and CKD.
221
 
Junger‟s et al in a study has found that 3.2% of the 1391 patients with ESRD had 
renal stones, and stones caused ESRD. They have found that 40% of patients with 
stones in the study group had solitary functioning kidney.
222
 There is association of 
development of CKD and the kidney stone type, in a study of community stone 
formers struvite stones were found to be a risk factor for CKD.
223
 Brushite stone type 




Many pathways have been postulated for the development of CKD in kidney 
stone patients. Obstruction by stones causing obstructive uropathy can cause acute or 
irreversible chronic injury. There can be renal vasoconstriction and inflammation due 
to increase in the intratubular pressure.
225,226
 In animal studies, in unilateral uretral 
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obstruction, osteopontin mediated interstitial influx and interstitial fibrosis have been 
noticed.
227
Infective struvite stones form chronic pyelonephritis, which can cause 
destruction of renal parenchyma.
228
 In uric acid stones, the hyperuricemia causes uric 






MATERIALS AND METHODS 
 
STUDY CENTRE: 
 The study was conducted among the adult population who attended the out-
patient departments at Trichy SRM Medical College Hospital and Research Centre, 
Irungalur, Trichy. 
STUDY DESIGN: 
 Cross sectional Observational study 
STUDY PERIOD: 
 One year, June 2017 to May 2018  
GEOGRAPHICAL DISTRIBUTION: 
 Both rural and urban areas in and around Trichy. 
SAMPLE SIZE: 
 The calculated sample size using prevalence of CKD as 17.2%, power of the 
study of 80% and significance level as 5% from the SEEK study
2
 was 463.Atotal of 
500 subjects who attended the medicine and allied out-patient department were 
included as study participants. 
ETHICAL CONSIDERATION: 
 Ethical clearance for the study was obtained from the Institutional Ethical 
Committee(IEC) of Trichy SRM Medical College Hospital and Research Centre, 
Irungalur. All study subjects were explained about the study and informed written 
consent was obtained and the confidentiality of their results were maintained.  
INCLUSION CRITERIA: 






 Patients with Acute Kidney Injury (AKI) were excluded on the basis of 
oliguria and rapid increase in creatinine from previous recent records. 
STUDY PROTOCOL: 
 After enrollment in the study a detailed history was taken, which included 
history of presenting illness, past illness, occupation, any exposure to agrochemicals, 
personal history likesubstance abuse, smoking, alcohol intake was noted. The patient 
was enquired about history of any renal stones, cardiovascular illness, thyroid illness, 
diabetes mellitusand hypertension. A detailed history of treatment and drugs 
takenwere documented 
CLINICAL EXAMINATION: 
 Routine clinical examination of various systems was carried out. 
Blood Pressure (BP): 
 Blood pressure was recorded in the sitting position in the right arm using 
mercury sphygmomanometer. Participants whose BP  140/90 mm Hg was 
considered as hypertensive, JNC-7 guidelines.
230
 Participants who were already on 
anti hypertensives were considered as hypertensive irrespective of the BP 
measurement. 
Anthropometric measurements: 
 Height and weight of the study subjects were measured. Body mass index was 
calculated from height and weight. Height was measured using a stadiometer in 
centimeters. The individual was asked to stand in the upright posture barefoot, heels 
kept together in close approximation, with the subject‟s back against the vertical 
backboard and eyes directed forward. Weight was measured in kilograms using an 
electronic weighing machine, kept on a firm horizontal surface with light clothing. 
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Waist circumference(WC) was measured in centimeters using a non-stretchable 
measuring tape. WC was measured at the smallest horizontal girth between the costal 
margin and the iliac crest at the end of expiration. Body mass index (BMI)was 
calculated using the formula  






BMI Categorization WHO Guidelines :
231
 
Under weight: < 18.5 kg/ m
2
 
Normal          :    18.5 to 24.9 kg/m
2
 
Over weight   :    25- 29.9 kg/m
2
 
Obese             :  > 30  kg/m
2
 
Systemic Examination was done. 
Biochemical Investigation (Estimated Parameters): 
Sample Collection: 
 An overnight 12 hours fasting venous sample was collected in a blood clot 
activator (BCA) tube, for analysis of fastingblood glucose, fasting lipid profile [Total 
cholesterol(TC), Triglycerides(TGL), High Density Lipoprotein Cholesterol(HDLc), 
Low Density Lipoprotein(LDLc)],thyroid function tests [Thyroid Stimulating 
Hormone(TSH),Free thyroxine (FT4)], Renal Function test(serum urea, serum 
creatinine).  
 A spot urine sample was collected in a clean 100ml urine collection container 
for spot UPCR. The samples were processed within 30 minutes to1 hour of collection. 
Thyroid Hormone assay was done by Electro Chemiluminescence Immunoassay 
(ECLIA) using Roche, cobas e411 analyzer. All other tests were performed using 
autoanalyser, Mindray BS 420. 
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Diagnosis of DM was made based on WHO criteria of fasting blood glucose level of 
more than 126 mg/dl.
232
Known diabetics on treatment were considered diabetic 
irrespective of their glycemic status. 
Thyroid Function: 
Euthyroid state was diagnosed with TSH – 0.4 – 4.2IU/L and FT4 level 0.8- 2 ng/dl. 
Overt hypothyroidism was diagnosed with TSH  5IU/L and Free T4 level < 0.8 
ng/dl; Subclinical hypothyroidism was diagnosed when TSH  5IU/L and with 
normal Free T4 levels. Hyperthyroidism was diagnosed when TSH 0.25IU/L and 
Free T4>2 ng/dl. Subclinical Hyperthyroidism was considered when TSH 0.25IU/L 
and Free T4 within normal range. Patients who were on treatment with Thyroxine 
supplementation were considered as hypothyroid. 
Renal Function: 
Serum Urea and Serum Creatinine were measured. 
Estimated Glomerular Filtration Rate (eGFR) : 
Using serum creatinine Estimated Glomerular Filtration Rate (eGFR) was calculated 




The CKD-EPI equation, expressed as a single equation  










Scr is serum creatinine(mg/dl), K is 0.7 for female and 0.9 for males,∞ is -0.329 for 
females and -0.411 for males, min indicates the minimum of Scr/K or 1, and max 





Staging of CKD was done as per GFRcategory based on KDIGO 2012
39
 
G1 -  eGFR  90ml/min/1.73 m2  – Normal or High 
G2 - eGFR 60-89ml/min/1.73 m
2
  – Mildly decreased 
G3a - eGFR 45-59ml/min/1.73 m
2
 – Mildly to moderately decreased 
G3b - eGFR 30-44ml/min/1.73 m
2
 – Moderately to severely decreased 
G4 - eGFR 15-29ml/min/1.73 m
2
  –  Severely decreased 
G5- eGFR <15ml/min/1.73 m
2         
-   Kidney failure 
CKD was defined as eGFR  <60ml/min/1.73 m
2
 
Urine Spot Protein- Creatinine Ratio(UPCR) Categorisation
35
 
1. Normal, P1 - UPCR < 0.15 
2. Moderate proteinuria, P2 - UPCR > 0.15-0.5 
3. Overt Proteinuria, P3 -  UPCR > 0.5  
Cardiovascular disease was considered present or absent based on the diagnosis made 















ESTIMATION OF PLASMA GLUCOSE 
Method: 
Glucose Oxidase Peroxidase method (GOD-POD) (End point) 
Principle: 
   Plasma glucose is first oxidized to Gluconic acid by the enzyme Glucose 
Oxidase(GOD)with release of Hydrogen peroxide, which is further converted into 
nascent oxygen  and water by the enzyme peroxidise (POD). 4-Aminoantipyrine takes 
up the oxygen, simultaneously with phenol,forms a pink coloured chromogen, 
measured at 505 nm. 
 
 Glucose + O2                                        Gluconic acid + H2O2  
 
2 H2O2 + 4-Aminoantipyrine+Phenol                            Quinoneimine+ 4 H2O 
Reagents: 
Glucose Oxidase  :  ≥10 KU/L 
Peroxidase   :  ≥ 1 KU/L 
Phosphate buffer (pH) 7.5  : 250mmol/L 
Phenol               : 5 mmol/L 
4-Aminoantipyrine  : 0.5 mmol/L 









   Take three test tubes and label as Blank (B), Test (T) and Standard (S) as 
follows, Incubation period: 10 min,Temperature at 37
0
C.Mix well and read 
absorbance of Test (T) and Standard(S) against distilled water at 505 nm 
 
Calculation: 
Glucose concentration (mg/dl)  =( ∆ Abs-Test / ∆ Abs-Standard) x100 
Reference value: 
Plasma Fasting Glucose : 70-100 mg/dl 














ESTIMATION OF SERUM UREA 
 
Method: 
Urease –Glutamate Dehydrogenase(“Urease-GLDH”) 
Principle: 
 Urea is hydrolysed into ammonia and carbon dioxide by the presence of water 
and urease. The ammonia combines with 2-oxoglutarate and NADH in the presence 
of glutamate-dehydrogenase (GLDH) to produce glutamate and NAD
+
. The GLDH is 
the rate limiting enzyme. The rate of  decrease in NADH  is proportional to the 
concentration of urea, within the given time intervals. As the kinetic is very fast, this 
test is preferably designed for analyzer application. 
 
Urea+ 2H2O                              2NH4
+











Tris buffer (pH 7.8)            : 125 mmol/L 
Urease                                  : ≥ 20 kU/L 
GLDH                                : ≥ 0.3 kU/L 
 ADP       : 0.88 mmol/L 
 Sodium Azide    : 0.095 % 
2. Substrates: 
2-oxoglutrate                         : 25 mmol/L 





Sodium Azide                        : 0.095% 
3.Standard: 
Urea                                       : 80mg/dl  
Sodium Azide                         : 0.095% 
Preparation of reagent: 




Wavelength         : 334nm, 340nm, 365nm 
Temperature        : 25°C, 30°C or 37°C 
Optical path         : 1cm 
Measurement       : Against reagent blank(RB). 






















C= 80.0× ΔA Sample/ ΔA standard [mg/dl]  
Measuring range: 
The test has a measuring range of 2 to 300mg/dl or 0.3to 50mmol/l. 
Reference values: 








  Blank Standard 
Sample /standard - 10µl 
Reagent 1 1000µl 1000 µl 
Mix, incubate  approximately for 5 minute. 
Reagent 2 250µl 250µl 
Mix, read absorbance of Sample /standard after 60 seconds and read 
after exactly 1 minute (A2). 
Calculate the absorbance difference: 
ΔA Sample /standard= (A2-A1)-ΔARB. 
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ESTIMATION OF SERUM CREATININE 
 
Method: 
Modified Jaffe‟s kinetic method 
Principle: 
 Creatinine, in the sample reacts with picric acid in alkaline medium to form 
creatinine picrate (red coloured complex), measured at 500 nm.  




Standard                           : 2 mg/dl 
Reagent-1  
Sodium Hydroxide            : 0.2 mol / L 
Reagent 2 
Picric acid                          : 20 mmol / L 
Storage:      2º-8ºC 
Preparation of working solution: 
The reagents are brought to room temperature. 4 parts of reagent 1 and 1 part of 
reagent 2 are mixed. 
General system parameters: 
Reaction slope                        : Increasing 
Reaction Type                        :         Fixed Time 
Flow cell Temp.                    : 25°C, 30°C or 37°C 
Wavelength                            : 500 nm (490-510 nm) 
No. of Readings                  : 120 sec. 
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Delay Time                        :          30 sec. 
Reagent Volume                     :          1.0 ml 
Sample Volume                      :          100 µl 
Std. Concentration                  :         2 mg/dl 
Path length                     :         1 cm 
Zero Setting With                   : Distilled water 
The instrument is set with above system general parameters.       
Procedure: 
 The sample and working solution are allowed to attain room temperature, prior 
to use Three test tubes are taken and labelled as Standard (S), Blank (B), Test (T). 1 
ml of working reagent is added to all three test tubes.  100µl of sample is added to test 
tube „T‟ and 100µl of standard is added to test tube „S‟. Then mixed and reading is 
taken absorbance A1 after 60 seconds and A2 after further 120 seconds. ΔA = A2-A1.  




Serum creatinine(mg/dl) =Concentration of standard× (ΔA Sample/ ΔA standard ) 
Urine spot creatinine(mg/dl) = Concentration of standard× (ΔA Sample/ ΔA standard) 
Linearity:  
This method is linear up to 10 mg/dl 
 Blank Standard Test 
Reagent 1ml 1ml 1ml 
Standard - 100µl - 




 Serum Creatinine: 
            Males         : 0.9-1.3 mg/dl 
            Females     : 0.6-1.1mg/dl 
Spot Urine Creatinine, morning sample 
Male  : 39-259 mg/dl 























ESTIMATION OF SERUM TOTAL CHOLESTEROL (TC) 
 
Method 
“CHOD-POD”–Cholesterol Oxidase Peroxidase. 
Principle: 
 Determination of cholesterol after enzymatic hydrolysis and oxidation. Then 
photometric estimation of cholesterol is done by coupling reactions with free 
cholesterol. The calorimetric indicator is quinoneimine(red coloured complex), 
generated from 4-aminoantipyrine and phenol by hydrogen peroxide under catalytic 
action of peroxidase (Trinder‟s reaction) 
The reactions are as follows: 
Cholesterol ester + H2O Chol.Esterase                Cholesterol + Fatty acid 
 
    Chol.Oxidase             
Cholesterol + ½ O2 + H2O            Cholest-4en-3-one + H2O2 
 
      Peroxidase 




The intensity of the red colour is proportional to the concentration of cholesterol in 
the serum. 
Reagents 
Good‟s buffer (pH 6.7)     : 50mmol/L 
Phenol                                 : 5 mmol/L 
4-Aminoantipyrine              : 0.3 mmol/L 
Cholesterol esterase            :  200 U/L 
Cholesterol oxidase            : 50 U/L 
 
49 
Peroxidase                         : 3 kU/L 
Standard                            : 200 mg/dl (5.2 mmol/L) 





Preparation of working solution: 
Ready to use reagents and standard are allowed to attain room temperature.  
Procedure: 
Prior to use, the sample and working solution are brought to room temperature. 
System parameters: 
Reaction Type                        : End point assay 
Reaction slope                    :         Increasing 
Flow cell Temp.                      : Room temperature / 37°C 
Sample Volume                  : 10 µL 
Reagent Volume                  : 1 mL 
Delay Time                             : 5 sec 
Wavelength                             : 500 ± 10 nm 
Optical Path                            : 10 mm 
Standard Concentration       : 200 mg/dl 
Zero Setting                           : With Distilled water 
Procedure: 
Three test tubes are labelled as blank (B),Test (T) and Standard (S), one  ml of 
working reagent is added to all 3 test tubes. 10µL of standard is added to test tube 
„S‟and 10µL of sample is added to test tube „T‟. Then it is mixed, incubated for 10 






Cholesterol (mg/dl) =     Absorbance of sample      ⨯ Concentration of standard 
     Absorbance of standard 
Measuring range:  
Linearity is up to 3-750mg/dl. 
Lower limit of detection: 3 mg/dl 
Reference values 
Serum Total Cholesterol: 
Desirable              :  < 200 mg/dl 
Borderline       :  200 - 240 mg/dl 








 Blank Standard Test 
Distilled water 10µl -- -- 
 Reagent 1ml 1ml 1ml 
Standard -- 10µl -- 
Sample -- -- 10µl 
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ESTIMATION OF SERUM TRIGLYCERIDES(TGL) 
 
Method: 
Colorimetric Enzymatic test using Glycerol-3- phosphate oxidase (GPO) 
Principle 
 Estimation is based on enzymatic splitting with lipoprotein lipase. The 
glycerol formed is converted to Glycerol – 3- phosphate which is further oxidised to 
Dihydroacetone phosphate and Hydrogen peroxide. The oxygen formed by peroxidase 
is accepted by 4-aminoantipyrine in the presence of 4-chlorophenol to form 
Quinoneimine (red colour complex) which is measured at 500nm. 
 
                                    Lipoprotein Lipase 
Triglycerides                                              Glycerol + Fatty acid 
 
                                    Glycerol Kinase 
Glycerol + ATP                             Glycerol -3-phosphate + ADP 
 
      Glycerol -3-Phosphate Oxidase  
Glycerol -3-phosphate+O2                               Dihydroxyacetone phosphate+H2O2 
 
               Peroxidase       
2H2O2 + Aminoantipyrine + 4- Chlorophenol                 Quinoneimine +HCl + 4 H2O  
 
Reagent: 
4-Chlorophenol           : 4 mmol / l 
Mg
2+
                                : 15mmol/l 
ATP                               : 2 mmol / l 
4-Aminoantipyrine           : 0.5mmol/l 
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Glycerolkinase                 : ≥0.4 kU/l 
Peroxidase                          :           ≥ 2 kU/l 
Lipoprotein lipase                   :           ≥ 2 kU/l 
Good‟s buffer       pH7.2       : 50 mmol / l 
 Glycerol-3-phosphate–oxidase: ≥0.5 kU /l 
 Standard               : 200mg/dl  (2.3 mmol/l) 
Specimen: 
Serum 
Storage:    at 2ºC-8ºC 
General system parameters: 
Reaction Type                    : End point 
Wavelength                            :         500 nm 
Reaction slope                        :         Increasing 
Delay Time                            :          5 seconds. 
Flow cell Temp.                     :         Room temperature or 37°C 
Reagent Volume                    :          1.0 ml 
Sample Volume                      :          10 µl 
Std. Concentration                  :          200 mg/dl 
Optical Path                            :         1 cm 
Zero Setting with Distilled water 








  The sample and working solution are brought to room temperature. Three test 
tubes are taken and labelled as Standard (S), Test (T), blank (B). One ml of working 
reagent is added to three test tubes.  10µL of sample is added to test tube labelled as 
„T‟ and 10µL of standard is added to test tube labelled as „S‟. Then mixed and 




Triglyceride (mg/dl)  = Absorbance of Sample ⨯ Concentration of standard 
                                   Absorbance of Standard 
 
To correct for free glycerol subtract 10mg/dl from the triglycerides value. 
Measuring range:  
This method is used from the measuring range of 2-1000mg/dl. 
Lower limit of detection is 2mg/dl 
Reference values: 
Serum Triglycerides: 
   Normal                     : < 200 mg/dl 
   Borderline High          : 200-400mg/dl 
   Elevated                      : >400  mg/dl 
 
 Blank Standard Test 
Distilled water 10µl -- -- 
Reagent 1ml 1ml 1ml 
Standard -- 10µl -- 
Sample -- -- 10µl 
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ESTIMATION OF SERUM HIGH DENSITY LIPOPROTEI CHOLESTEROL (HDLc) 
 
Method 
Direct enzymatic method 
Principle: 
 Antibodies against human lipoproteins are utilized to form antigen-antibody 
complexes with chylomicrons, LDL, VLDL and in a way that only HDL-cholesterol 
is selectively estimated by an enzymatic cholesterol measurement. 
The reaction sequence is, as follows: 
      
        Anti-human β – lipoprotein antibodies 
LDL, VLDL, Chylomicrons                         Antigen – antibody complexes +HDL 
 
       CHE &CHO 
HDL –Cholesterol + H2O +O2                       Cholest-4-en-3-one + Fatty acid +H2O2 
 
             Peroxidase 
H2O2  + F- DAOS + 4- Aminoantipyrine                         Blue Complex +  H2O       
 
CHE – Cholesterol esterase; CHO-Cholesterol oxidase; F-DAOS-N-Ethyl-N-(2-
Hydroxy-3-sulfopropyl)-3,5-Dimethoxy-4-Fluoroaniline, sodium salt 
Reagents: 
Reagent 1: 
Good‟s buffer pH        7.0      : 25 mmol / L 
Peroxidase                         : 2000 U/L 
Ascorbate oxidase                   : 2250 U/ L 
Anti-human β – lipoprotein Antibody (sheep) 





Good‟s buffer  pH 7.0           : 30 mmol / L 
Cholesterol oxidase              : 20000U/L 
Cholesterol esterase      : 4000 U/L 
N-Ethyl-N-(2-hydroxy-3-sulfopropyl): 0.8mmol/L 
Sodium salt (F-DAOS), 3, 5- dimethoxy-4-fluoroaniline. 
Calibrator: 
 HDL-Cholesterol   50.6 mg/dl 
Storage:     at 2º-8ºC 
Specimen: 
Serum  
General system parameters: 
Reaction Type              : End point 
Wavelength                             :         600/700 nm 
Reaction slope                       : Increasing 
Delay Time                             : 5 seconds 
Flow cell Temp.                 : Room temperature or 37°C 
Reagent 1 Volume              : 240 µL 
Reagent 2 Volume               : 60 µL 
Sample Volume                    : 2.4 µL 
Calibrator                             : 50.6 mg/dL 
Zero Setting                            : with Distilled water 





 The sample and working solution are allowed to attain room temperature prior to 
use Three test tubes are labelled as Test (T), Calibrator (C), blank (B), 240 µL of 
working reagent 1 is added to all three test tubes. 2.4µL of sample is added to Test „T‟ 
and 2.4 µL of calibrator is added to Calibrator „C‟. Then mixed and incubated for 5 
minutes at room temperature. Read the absorbance A1, then 60 µL of working reagent 
2 is added to all three test tubes. It is mixed and incubated for 5 minutes at room 
temperature. Read the absorbance A2.  ΔA = ( A2 - A1) sample or calibrator. 
Calculation: 
HDLc (mg/dl) =  ΔA Sample   ⨯ Calibrator concentration  
                          ΔA Calibrator  
Measuring range:  
This method is used to determine HDL-c concentration within a measuring range 
from 1-180mg/dl. 
Lower limit of detection is 1 mg/dl 
Reference values: 
Serum HDL-C  
  Low     : < 40 mg/dl 
  Desirable : 40-60 mg/d 
 Blank Calibrator Test 
Calibrator -- 2.4 µL -- 
Sample -- -- 2.4 µL 
Distilled water 2.4 µL -- -- 
Reagent 1 240 µL 240µL 240 µL 
Mixed, incubated 5min at 37°C,read absorbance A1Then add: 
Reagent 2 60 µL 60µL 60µL 
Mixed, incubated 5 min at 37°C, read absorbance A2. 
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ESTIMATION OF SERUMLOW DENSITY LIPOPROTEIN CHOLESTEROL 
Method: 
Direct enzymatic method 
Principle  
 In the first step, LDL is selectively protected while non-LDL-lipoprotein are 
enzymatically processed. In the second step, LDL is released and LDL-cholesterol is 
selectively determined in a blue colour producing enzymatic reaction. 
The reaction sequence is as follows: 
 
1. LDL + Reagent 1                          Protected LDL 
 
                                             CHE &CHO 
          HDL, VLDL, Chylomicrons                                   Cholestenone +  H2O2   
 
                                            Catalase 
          H2O2                                         H2O   
 
2. Protected LDL +  Reagent 2                          LDL 
 
                            CHE &CHO 
          LDL-C                                  Cholestenone + H2O2 
        
  
             H2O2 + 4-Aminoantipyrine +H-DAOS                             Blue Colour   
 
 









Cholesterol oxidase (CHO)   : ≥2.5 kU/L 
Cholesterol esterase (CHE)    : ≥2.5 kU/L 
Catalase                         : ≥500 kU/l 
N-(2-hydroxy-3-sulfopropyl) : 0.5mmol/L 
3, 5- dimethoxyaniline, (H-DAOS) 
Good‟s buffer pH 6.8         : 20 mmol / L 
Reagent 2: 
4-Aminoantipyrine              : 3.4mmol/L 
Peroxidase (POD)                  : ≥15 kU/L 
Good‟s buffer pH 7.0     : 25 mmol / L 
Calibrator: 
LDL-Cholesterol 132 mg/dL 
Storage:     at 2ºC-8ºC 
Preparation of working solution 
 The reagents are brought to room temperature.  Both reagent and standard are 
supplied as ready to use. 
Sample 
Serum 
General system parameters: 
Reaction Type                     : End point 
Wavelength                           : 600/700 nm (bichromatic measurement)  
Reaction slope                     : Increasing 
Delay Time                             : 30 seconds. 
 
59 
Flow cell Temp.                      : 37°C 
 Sample Volume                      : 3.0 µL 
Reading Time                    : 180 seconds. 
Optical Path                         : 1 cm 
Reagent 1 Volume                  : 280 µL 
Reagent 2 Volume             : 70 µL 
Calibrator                              : 132 mg/dL 
Zero Setting with Distilled water 
The instrument is set with above system parameters. 
Procedure: 
Three test tubes are labelled as Test (T), Calibrator (C), blank (B). 280 µL of working 
reagent 1 is added to all three test tubes. 3.0µL of sample is added to „T‟ and 3.0 µL 
of calibrator is added to „C‟. Then mixed and incubated for 5 minutes at room 
temperature. Read the absorbance A1, then 70 µL of working reagent 2 is added to 
three test tubes. It is mixed well and incubated for 5 minutes at room temperature. 
Read the absorbance A2. 
ΔA = (A2 - A1) sample or calibrator- (A2 - A1) blank. 
 Blank Calibrator Test 
Calibrator -- 3.0 µl -- 
Sample -- -- 3.0 µl 
Reagent 1 280 µl 280µl 280 µl 
Distilled water 3.0 µl -- -- 
Mix, incubate 5min at 37°C,read absorbance A1Then add: 
Reagent 2 70 µl 70µl 70µl 




LDLc (mg/dl)   = ΔA Sample     ⨯Calibrator concentration  
                            ΔA Calibrator  
 
Measuring range: 




          Desirable      : ≤ 130 mg/dL 
          Borderline        : 130 - 160 mg/dL 
















SPOT URINE PROTEIN ESTIMATION 
 
Method: 
Photometric test using pyrogallol red. 
Principle: 
 Proteins form a red complex with pyrogallol red /molybdate. The absorbance 
is directly proportional to the protein concentration. 
Reagents: 
Pyrogallol red      : 60mol/L 
Sodium molybdate    : 40mol/L 
Standard    : 1300 mg/L  
Storage: 2-8
o
C, do not freeze the reagent 
Specimen:  




C     : 1 day 
At 4-8
o
C          : 7 days 
At -20
o
C          : 1 month 
Assay procedure: 
Wavelength    : 600 nm 
Optical path    : 1 cm 
Temperature    : 37
o
C 






 Take three test tubes label them as Blank (B), Test (T), Standard (S).Take 
1000l of reagent to the three test tubes .Add 20l of distilled water to the blank(B), 
20l of sample to the test(T) and 20l of standard to the standard (S) 
 
Mix and incubate for 10 minutes and read absorbance against reagent blank 
Calculation  
With standard or calibrator 
Spot urine protein (mg/L) =  (A Sample /AStandard) x   Conc. Standard (mg/L) 
Measuring range:  
Range 20-3000 mg/L 









 Blank Standard Test 
Reagent 1000l 1000l 1000l 
Distilled water 20l - - 
Standard - 20l - 
Sample - - 20l 
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ESTIMATION OF THYROID STIMULATING HORMONE (TSH) 
Method:  
Electro Chemiluminescence Immunoassay (ECLIA) 
Assay Principle: 
Sandwich principle 
 First incubation: 50L of sample, a biotinylated monoclonal TSH specific 
antibody and a monoclonal TSH specific antibody labelled with a ruthenium 
complex to form a sandwich complex. 
 Second incubation: Streptavidin coated microparticles bind to the complex by 
interaction between biotin and streptavidin 
 The reaction mixture is aspirated into the measuring cell where the 
microparticles are magnetically captured on to the surface of the 
electrode.Unbound substances are removed with Procell. Application of a 
voltage to electrode then induces chemiluminescent emission which is 
measured by a photomultiplier 
 Results are determined via a calibration curve which is instrument specifically 
generated by two point calibration and master curve provided via a reagent 
barcode 
Reagent- working solution: 
The reagent pack is labelled as TSH 
M   Streptavidin coated micro particles transparent cap 1 bottle,12 ml 
Streptavidin coated micro particles 0.72mg/ml, preservative 
R1  Anti –TSH- Ab-biotin(gray cap) 14 ml; Biotinylated monoclonal anti-TSH 
antibody   (mouse) 2 mg/L; phosphate buffer 100mmol/L, pH 7.2; preservative 
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R2 Anti –TSH- Ab-Ru(bpy) (black cap) 12 ml; Monoclonal anti-TSH antibody 
(mouse/human). Labeled with ruthenium complex 1.2 mg/L; phosphate buffer 
100mmol/L. pH 7.2; preservative 
Storage and stability: 2-8 
0
C, store upright, so that the micro particles are completely 




This method has been standardized against the 2
nd
IRP WHO reference standard 
80/558 
Calibration is performed once per reagent lot using fresh reagent. 
Measuring range: 
Measuring range is 0.005-100 IU/ml  
Lower detection limit 0.005 IU/ml 
Values below lower detection limit is reported as < 0.005 IU/ml and above the 
measuring range is given as > 100 IU/ml. 











ESTIMATION OF FREE THYROXINE (FT4) 
Method:  
Electro Chemiluminescence Immunoassay (ECLIA) 
Assay Principle: 
Competition principle 
A specific anti-T4 antibody labeled with a ruthenium complex Tris (2,21-
bipyridyl)ruthenium(II)-complex (Ru(bpy) ) is used to determine free thyroxine is 
used. 
 First incubation: 15 L of sample and a T4 –specific antibody labeled with a 
ruthenium complex. 
 Second incubation: After addition of the biotinylated T4 and streptavidin –
coated micro particles, the still-free binding sites of labelled antibody become 
occupied with formation of an antibody-hapten complex. The entire complex 
interact via biotin and streptavidin. 
 The reaction mixture is aspirated into the measuring cell where the 
microparticles are magnetically captured onto the surface of electrode. 
Unbound substances are then removed with Procell/Procell M.Application of 
voltage then induces chemiluminescent emission which is measured by auto 
multiplier. 
 Results are determined via a calibration curve which is instrument specifically 
generated by 2 point calibration and a master curve provided via the reagent 
bar code. 
Reagent-working solutions: 




R1-Anti-T4-AbRu(bby)- 18 ml: polyclonal anti-T4-antibody (sheep) labelled with 
ruthenium Complex  75 ng/ml; phosphate buffer 100mmol/L, pH7.0; Preservative. 
R2- T4biotin 18ml; biotinylated T4 2.5ng/ml ;phosphate buffer 100mmol/L, pH 7.0; 
Preservative 
Storage and stability: 2-8 
0
C, Store upright, so that the microparticles are completely 




This method is standardized against the the Elecsys FT4 method.Calibration must be 
performed once per fresh reagent lot. 
Calculation: The analyzer calculates the analyte concentration of each sample either 
in pmol/L, ng/dl or ng/L. 
Measuring range:  
Measuring range = 0.3-100pmol/L. 
Limit of Blank=0.3pmol/L 
Limit of detection=0.5pmol/L 
Limit of Quantitation= 3pmol/L with a total allowable error of 30% 
Values below limit of detection are reported as <0.3pmol/L. 
Values above the range are reported as >100pmol/L 
Conversion formula pmol/Lx0.077688=ng/dl 








 Data was entered in Microsoft Office Excel and data was analyzed by using 
Statistical Package for Social Sciences(SPSS) software, version 21.0. 
 Prevalence of CKD and other risk factors were expressed as percentage. 
Continuous variables like Body Mass Index(BMI), Blood Pressure (B.P), Blood 
glucose, estimated Glomerular Filtration Rate(eGFR), Serum Lipid Profile, free 
Triiodothyronine(FT3), free Thyroxine(FT4) which had normal distribution were 
presented as mean along with the standard deviation (SD). For continuous variables 
which had non normal distribution like Thyroid stimulating hormone(TSH), Serum 
Urea, Serum Creatinine and Urinary Protein Creatinine Ratio(UPCR) median and 
Inter Quartile Range(IQR) were used. Categorical variables such as gender were 
presented as percentage. Student „t‟ test was used to analyze the difference in the 
mean between two groups. Chi square test was used to analyze the presence of 
association between the outcome variable (Stage1-2 / Stage 3a-5, CKD) and other 














  A total of 500 individuals were included in the study. Of the study population 
there were 211(42.2%) females and 289(57.8%) males. The mean age of the study 
population was 48.31±12.76 years. There were 83(16.6%) participants who were 
farmers by occupation. Among the 500 study population 22(4.4%) gave a history of 
exposure to agrochemicals, 11(2.2%) had renal calculi, 68(13.6%) gave a history of 
smoking and 104(20.8%) were alcoholics. 
  The mean eGFR of the study population was 74.3± 23.88 ml/min/1.73 m
2
.The 
study population was categorised based on their CKD stages, as CKD stage (1 and 2) 
whose eGFR was above 60 ml/min/1.73 m
2
 and CKD (stages 3a, 3b, 4 and 5), whose 




Further results are presented under the following headings, 
 
A) Age and gender wise distribution of eGFR among study population. 
B) Prevalence of various UPCR stages among the study population and their 
association with different stages of CKD. 
C) Prevalence of CKD stages based on eGFR. 
D) Association of thyroid function and lipid profile with different stages of CKD.  








A) Age and gender wise distribution of eGFR among study population 
Table 3: Age and gender wise distribution of mean eGFR 
 
 
Table 3, shows the distribution of mean eGFR  of the study group by age and gender. 
 
Among the study population there were 211 (42.2%) females and 289 (57.8%) males. 
The number of males were comparatively more than females in each age group, 
except for age group (20-29 years) female participants were more than males. The 
average eGFR among the age group of 20-29 years(n=43 patients) was 94.76 ± 
21.01,which was normal. There was decreasing trend in eGFR as age increases. 
Among the individuals aged   >70 years, the eGFR was 53.73±16.25 ml/min/1.73m
2 
which was lowest among the study population. The mean eGFR of the males was 
73.03±24.76 ml/min/1.73 m
2


















20-29 years 21(48.8) 22(51.2) 43(8.6) 94.76±21.01 
30-39 years 46(57.5) 34(42.5) 80(16) 87.40±19.13 
40-49 years 67(53.2) 59(46.8) 126(25.2) 78.78±21.88 
50-59 years 89(61.8) 55(38.2) 144(28.8) 68.24±22.45 
60-69years 49(60.5) 32(39.5) 81(16.2) 60.88±20.42 
>70 years 17(65.4) 9(34.6) 26(5.2) 53.73±16.25 
Total 289(57.8) 211(42.2) 500(100) 74.30±23.88 
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Table 4: Baseline Characteristics of the study population 
*pvalue < 0.05 is statistically significant 
 
BMI- Body Mass Index, SBP- Systolic Blood Pressure, DBP-Diastolic Blood 
Pressure, FBS- Fasting Blood Sugar, TGL- Triglycerides, TC- Total Cholesterol, 
LDLc- Low Density Lipoprotein Cholesterol, HDLc- High Density Lipoprotein 
Cholesterol, TSH- Thyroid Stimulating Hormone, FT4- Free Thyroxine, FT3- Free 
Triiodothyronine, UPCR- Urinary Protein Creatinine Ratio 
 
Table 4, shows the baseline characteristics ofthe study population. Mean values of 
age, WC, SBP, TGL, LDLc, HDLc, FT4, Sr.Urea, Sr.Creatinine and UPCR, 
significantly differed between the different stages of CKD. The mean values of other 
parameters BMI, DBP, FBS, TC, TSH did not show any statistical significance 
between the different stages of CKD. 
Variables 
CKD stage 1-2 
Mean±SD/Median(IQR) 
CKD stage 3a-5 
Mean±SD/Median(IQR) 
pvalue 




) 25.69±4.88 25.71±4.87 0.96 
WC(cm) 93.23±11.19 93.99±12.72 0.02
* 
SBP(mmof Hg) 120.88±16.87 129.29±21.58 0.001
* 
DBP(mm of Hg) 78.24±10.32 80.21±12.32 0.088 
FBS(mg/dl) 123.24±65.88 127.67±60.31 0.589 
TGL(mg/dl) 125.75±71.30 149.17±79.23 0.003
* 
TC(mg/dl) 168.4±47.36 159.17±45.00 0.066 
LDLc(mg/dl) 101.23±30.86 94.70±29.64 0.046
* 
HDLc(mg/dl) 39.71±9.48 37±11.01 0.010
* 
FT4(ng/dl) 1.28±0.50 1.31±0.74 0.046
* 
TSH(µIU/L) 2.54(1.9) 2.62(2.49) 0.268 
Urea(mg/dl) 21.00(6) 33.00(20) 0.000
* 
Creatinine(mg/dl) 0.98(0.3) 1.5(0.84) 0.000
* 




B) Prevalence of various UPCR stages among the study population and their 
association with different stages of CKD. 













As seen in table 5, among the 500 study population 302 (60.4%) had a spot urine PCR 
of < 0.15 which was normal(P1), 133 (26.6%) study participants had a UPCR between 
0.15 and 0.5 which was moderate proteinuria(P2), and 65 (13%) had UPCR more than 
0.5 which was overt proteinuria(P3). 
 
B-2) Table6: Association of UPCR with different stages of CKD 
UPCR 
Category 
CKD stage 1- 2  
n(%) 
CKD stage3a- 









P2(0.15-0.5) 100(75.2) 33(24.8) 
P3(>0.5) 27(41.5) 38(58.5) 
Total 387(77.4) 113(22.6) 
*pvalue < 0.05 is statistically significant 
Table 6, shows the association between spot UPCR and different stages of CKD. In 
the CKD (stage1-2) 86.1% had normal protein excretion, 75.2% had moderate 
proteinuria and 41.5% had overt proteinuria. There were 13.9%, 24.8% and 58.5% of 
Spot Urine PCR Number of patient(n) Percentage (%) 
             P1  (< 0.15) 302 60.4 
             P2 (0.15-0.5) 133 26.6 
             P3 (> 0.5) 65 13 
                 Total 500 100 
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patients who had CKD(stage 3a-5) in spot UPCR category of less than 0.15, 0.15 to 
0.5 and more than 0.5 respectively. As the proteinuria increased quantitatively the 
proportion of patients who had CKD (stage 3a-5) also increased, which was 
statistically significant (pvalue=0.000). There is significant association between 
proteinuria and different stages of CKD. 
 
C) Prevalence of CKD stages based on eGFR 
 
Table 7: Prevalence of various stages of CKD based on eGFR 
 
Table7; shows the prevalence of various stages of CKD among the study population, 
22.2% (n= 111) of the study participants were in stage1(G1), 55.2% (n=276) were in 
stage 2 (G2), 13.2% (n=66) were in stage3a(G3a), 3.8% (n=19) were in Stage 
3b(G3b), 4.2% were in stage4(G4 )category and 1.4% (n=7) had stage 5(G5) or  End 
stage renal disease(ESRD). The prevalence of CKD (eGFR of < 60ml/min/1.73 m
2
, ie 
Stage 3a -5) among the study group was 22.6%(n=113). There were 387(77.4%) study 









G1 (≥90) 111 22.2 
G2 (60-89) 276 55.2 
G3a (45-59) 66 13.2 
G3b (30-44) 19 3.8 
G4 (15-29) 21 4.2 
G5 (<15) 7 1.4 
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D) Association of thyroid function and lipid profile with different stages of CKD.  
D-1) Prevalence of Thyroid Status: 
Among the study population 406(81.2%) were euthyroid and 94(18.8%) had thyroid 
dysfunction. Among the 94 thyroid dysfunction patients, 51 had subclinical 
hypothyroidism, 38 had overt hypothyroidism, 3 had subclinical hyperthyroidism and 
2 had overt hyperthyroidism. 
 
Table 8: Prevalence of Thyroid status among the different stages of CKD 
Thyroid status CKD stage 1-2 n(%) CKD stage 3a-5 n(%) 
Euthyroidism 318(82.2) 88(77.9) 
Subclinical hypothyroidism 39(10.1) 12(10.6) 
Overt hypothyroidism 28(6.5) 13(11.5) 
Subclinicalhyperthyroidism 3(0.77) Nil 
Overthyperthyroidism 2(0.51) Nil 
Total 387(100) 113(100) 
 
Table 8, shows the prevalence of thyroid status among different stages of 
CKD.AmongCKD (stage 1-2) patients 318(82.2%) wereeuthyroid and in the CKD 
(stage 3a-5) patients 88(77.9%) were euthyroid.Among the CKD (stage1-2) 
participants 39(10.1%) had subclinical hypothyroidism and among CKD (stage 3a-5) 
patients 12(10.6%) had subclinical hypothyroidism.Among the CKD (stage 1-2) study 
individuals 25(6.5%) had overt hypothyroidism, in the CKD(stage3a-
5)patients,13(11.5%) had overt hypothyroidism.Among the CKD (stage1-2) 3 patients 
had subclinical hyperthyroidism and overt hyperthyroidism was found among 2 





D-2) Table 9: Association between Thyroid status and different stages of CKD 

















51 39(76.5%) 12(23.5) 
Hypothyroidism 38 25(65.8) 13(34.2) 
Hyperthyroidism 5 5(100) 0 
Total 500 387(77.4) 113(22.6) 
 
Table 9, shows the association between thyroid status and different stages of CKD. 
Among the 51, subclinical thyroid patients 39(76.5%) had CKD (stage1-2) and 
12(23.5%) of them had CKD (stage3a-5). Among the 38 hypothyroid patients, 
25(65.8%) had CKD(stage 1-2) and 13(34.2%) patients had CKD(stage 3a-5). There 
were only 5 patients with hyperthyroidism and they had CKD(stage 1-2). There was 











D-3) Prevalence of Dyslipidemia: 
Among the study population 98(19.6%) had hypercholesterolemia,121(24.2%) had 
hypertriglyceridemia, 272(54.4%) had low HDLc and 69(13.8%) had high level of 
LDLc. 
 


















TC 309(79.8) 78(20.2) 387(100) 93(82.3) 20(17.7) 113(100) 
TGL 305(78.8) 32(21.2) 387(100) 74(65.5) 39(34.5) 113(100) 
HDLc 190(49.1) 197(50.9) 387(100) 38(33.6) 75(66.4) 113(100) 
LDLc 329(85) 58(15) 387(100) 102(90.3) 11(9.7) 113(100) 
 
Table 10,shows the prevalence of dyslipidemia among the different stages of 
CKD.Among the CKD (stage 1-2) individuals 78(20.2%) had hypercholesterolemia 
and among the CKD (stage 3a-5) patients 20 (17.7%) had hypercholesterolemia. 
Among the CKD (stage1-2) subjects 32(21.2%)had hypertriglyceridemia and among 
the CKD (stage 3a-5) patients, 39(34.5%) had hypertriglyceridemia.  
Among the CKD(stage1-2) persons 197(50.9%) had low HDLc and among the 
CKD(stage3a-5) patients 75(66.4%) had low HDLc. 
Among the CKD (stage1-2) subjects 58(15%) had high LDLc and in the CKD 






D-4) Table 11: Association between Dyslipidemia and different stages of CKD 
* p value < 0.05 is considered significant 
Table11, shows the association between Lipid profile and different stages of 
CKD.Among the 98(19.6%) study subjects with raised total cholesterol levels, 78 
(79.6%) had CKD (stage1-2) and 20 (20.4%) patients had CKD(stage3a-5). Among 
the 402(80.4%) participants with normal total cholesterol levels 76.9% had 
CKD(stage1-2) and 23.1% had CKD(stage3a-5). There was no significant association 
between total cholesterol and different stages of CKD (p value =0.563). 
The Triglyceride level was raised in 121(24.2%) of the study subjects, among them 
82(67.8%) had CKD (stage1-2) and 39(32.3%) patients had CKD(stage3a-5). There 
were 379(75.8%) subjects with normal triglyceridemia, among them 80.5% had CKD 
(stage 1-2) and 19.5% hadCKD(stage3a-5). There was significant association between 
hypertriglyceridemia and different stages of CKD (p value= 0.004). 






















0.563 Normal 309(76.9) 93(23.1) 402(80.4) 







Normal 305(80.5) 74(19.5) 379(75.8) 







Normal 190(83.3) 38(16.7) 228(45.6) 





0.154 Normal 329(76.3) 102(23.7) 431(86.2) 
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CKD(stage 1-2) and 75(27.6%) of the patients had CKD(stage3a-5).Among the 
228(45.6%)participants with normal HDLc level,  83.3% had CKD (stage1-2) and 
16.7% hadCKD(stage3a-5). There was significant association between low HDLc and 
different stages of CKD (p value 0.004). 
There were 69(13.8%) patients with raised LDLc level, among them 58(84.1%) had 
CKD  (stage 1-2 and 11(15.9%) patients had CKD(stage3a-5).Among the 431(86.2%) 
of patients with normal LDLc level 76.3% had CKD(stage1-2) and23.7% had 
CKD(stage3a-5).  There was no significant association between high LDLc and 
different stages of CKD(p value 0.154). 
 
 
E) Association of risk factors like BMI, DM, HT and CVD and different stages of 
CKD 
E-1) Prevalence of different categories of BMI: 
Among the study population 190(38%) had normal BMI, 26(5.2%) were underweight, 
206(41.2%) were overweight, 78(15.6%) were obese. 
 
Table 12: Prevalence of BMI category among different stages of CKD 
BMI Category CKDstage1-2 n(%) CKDstage3a-5 n(%) 
Normal 147(38) 43(38.1) 
Under weight 19(4.9) 7(6.2) 
Over weight 160(41.3) 46(40.7) 
Obese 61(15.6) 17(15) 
Total 387(100) 113(100) 
 
Table 12, shows the prevalence of various BMI categories among different stages of 
CKD. In the CKD (stage 1-2) subjects 38% had normal BMI, 4.9% were underweight, 
41.3% were overweight and 15.6% were obese and in the CKD (stage 3a-5) patients 






E-2) Table 13:  Association between BMI and different stages of CKD 
 
Table 13, shows the association between BMI and different stages of CKD. Among 
the participants with normal BMI,77.4% had CKD(stage1-2), 22.6% had CKD (stage 
3a-5);77.8% of overweight category had CKD(stage1-2), 22.2% of overweight 
category of study group had CKD(stage 3a-5). Among the obese, 78.2% had CKD 
(stage 1-2), 21.8% had CKD (stage 3a-5). There was no significant association 
























Underweight 19(73.1) 7(26.9) 
Overweight 160(77.8) 46(22.2) 
Obese 61(78.2) 17(21.8) 




E-3) Prevalence of DM, HT and CVD: 
Among the study population 179(35.8%) had DM, 217(43.4%) had HT and 29(5.8%) 
had CVD. 
 
Table14:P revalence of risk factors, Diabetes mellitus, Hypertension and CVD in 
different stages of CKD 
 
Table 14, shows the prevalence of risk factors like DM, HT and CVD. Among the 
individuals in CKD (stage 1-2), 30% had DM and among the CKD (stage 3a-5) 
patients, 55.8% had DM.Among CKD(stage1-2) individuals, 38.2% were 
hypertensives and among the CKD (stage 3a-5) patients 61.1% were 
hypertensives.Among the subjects with CKD (stage 1-2) 3.9 % had CVD and in the 







CKD stage 1-2 n(%) CKD stage3a-5 
Present Absent Total Present Absent Total 
DM 116(30) 271(70) 387(100) 63(55.8) 50(44.2) 113(100) 
HT 148(38.2) 239(61.8) 387(100) 69(61.1) 44(38.9) 113(100) 
CVD 15(3.9) 372(96.1) 387(100) 14(12.4) 99(87.6) 113(100) 
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Absent 271(84.4) 50(15.6) 
Total 387(77.4) 113(22.6) 
 
*pvalue < 0.05 is statistically significant 
 
Table 15, shows the association of diabetes with different stages of CKD. Among the 
179 (35.8%) diabetic patients, 116(64.8%) had CKD(stage1-2) and 63 (35.2%)had 
CKD(stage3a-5). Among the 321(64.2%) of study individuals without diabetes, 
271(84.4%) had CKD (stage1-2) and 50(15.6%) had CKD (stage3a-5).There was 
significant association between diabetes and different stages of CKD (p value 0.000). 
 














 Absent 239(84.5) 44(15.5) 
Total 387(77.4) 113(22.6) 
*p value < 0.05 is statistically significant 
Table 16, shows the association between hypertension and CKD. Hypertension was 
present in 217(43.4%) of patients. Among the hypertensive patients 148(68.2%) had 
CKD(stage1-2)  and 69(31.8%) had CKD(stage3a-5). Among the 283(56.6%) 
normotensive patients 239(84.5%) hadCKD(stage1-2) and 44(15.5%) had CKD (stage 
3a-5). There was significant association between hypertension and different stages of 




















 Absent 372(79) 99(21.0) 
Total 387(77.4) 113(22.6) 
*pvalue < 0.05 is statistically significant 
 
Table 17, shows the association between patients with CVD and different stages of 
CKD. Out of 29 (5.8%) patients who had Cardio vascular disease, 15(51.7%) had 
CKD(stage1-2) and 14(48.3%) had CKD(stage3a-5). Among the 471(94.2%) study 
individuals without CVD, 372(79%) hadCKD(stage1-2) and 99(21%) had CKD(stage 
3a-5).There was significant association between patients with CVD and different 















  The present study was conducted to assess the risk factors for renal 
dysfunction in a heterogeneous study population. The study was conducted to stress 
the need for early identification of risk factors causing CKD. The use of eGFR for 
CKD classification in this study will help in early diagnosis of CKD, because serum 
creatinine measurement alone will not determine the patients with stage 2 CKD. If 
CKD diagnosis is made early and treated, the progression of CKD can be prevented. 
  The prevalence of CKD (Stage 3a-5) based on the EPI eGFR (<60 
ml/min/1.73m
2
) in this study was 22.6%. The prevalence of different stages of CKD 
in this study were, stage1- 22.2%, stage2 - 55.2%, stage3a - 13.2%, stage3b - 3.8%, 
stage4 -4.2% and stage5-1.4%. In the Screening and Early Evaluation of Kidney 
disease (SEEK) study, Ajay.K.Singh et al
2
 have done a population based study, 
among 5588 urban participants and have observed the prevalence  as 17.2% (Stage 1-
5) and only 6% in CKD(stages3a-5), by using CKD-EPI formula for eGFR 
estimation. In another study by Narinder.P.Singh et al
233
. which had 5252 semi urban 
participants, the prevalence among CKD (Stage 3a-5) was 13.3%, eGFR was 
calculated using Cockcroft-Gault formula.A study done among the apparently healthy 
adult central government employees, among 3398 participants, in Agra by Varma et 
al.
234
the prevalence of CKD(stage1-3) was 13.12% (CKD-EPI). Sanjay Kumar 
Agarwal et al.
235
 used serum creatinine more than 1.8 mg/dl on two occasions, 8-12 
weeks apart as criteria for CKD diagnosis, and has found a prevalence of 
CKD(Stage3-5) as 0.785%. A US study done by Vassalotti et al,
236
 the Kidney Early 
Evaluation Programme(KEEP) the prevalence of CKD was 28.7%.Compared to other 
studies conducted among Indian population, the present study showed a high 
prevalence of CKD. All these four Indian studies were population based study and in 
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our study, more of diseased population is assessed and this may be attributed to the 
high prevalence of CKD. The very high prevalence of stage 3a-5 CKD, raises the 
possibility of CKD hot spot in the belt of rural and urban area of Trichy. To rule in 
and rule out the possible hot spot of CKD, a population based study should be 
performed in this geographical belt.  
  In this study 13% of the study population had overt proteinuria (Urine spot 
protein creatinine ratio more than 0.5), 26.6% had moderate proteinuria (UPCR 0.15 
to 0.5). There was significant association between the proteinuria and CKD stages (p 
value 0.000). Many studies have found association between proteinuria and CKD. 
Inaguma Daijo et al.
237
 in their recent study has found significant association between 
proteinuria and CKD and has identified proteinuria as a risk factor with CKD 
progressing to ESRD. KDIGO 2012
36
 guidelines recommend urinary ACR as a better 
marker of diagnosis and progression of CKD, mainly in diabetic and hypertensive 
people and urinary PCR comes in the next order of preference. In this study we have 
analysed urinary spot PCR. Tracy Ying et al.
238
 in a single centered prospective study 
of measuring proteinuria as the risk of progression of CKD has postulated that spot 
UPCR is equally good as the gold standard 24 hours proteinuria.
 
  In this study there were 94 patients with thyroid dysfunction. Among the 500 
study population, subclinical hypothyroidism was present among 10.2% of people, 
which was more than overt hypothyroidism (7. 6%).There were 5 (1%) hyperthyroid 
patients. There was no significant association between thyroid dysfunction and 
different stages of CKD in our study (p value0.202). In a large cross sectional study 
from a voluntary health examination program  Yi-Cheng Chang et al.,
239
 have 
documented a decrease in eGFR of 87.99, 83.46 and 72.22 ml/min/1.73 m
2
 for 
euthyroid, sub clinical and overt hypothyroidism patients respectively. Similarly, 
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Saroj Kathwada et al.
240
 had found that hypothyroidism is associated with CKD 
progression. Xiaolin Huang et al.
19
 in their prospective study had concluded that a 
high serum FT4 level is associated with increased risk of CKD and they have also 
found no association between T3 and TSH and incident CKD. In this study we had 
only 5 patients with hyperthyroidism and none of them had CKD(stage3a-5). Several 
studies have shown that there is increase in eGFR in hyperthyroidism. In 
hyperthyroidism an increase of 17-18% of eGFR has been noticed and this rise in 
GFR is due to increase in renal blood flow and activation of renin angiotensin 
aldosterone system.
118 
Hyperthyroidism causes CKD by increasing the renal blood 
flow leading to intra glomerular hypertension and increased filtration pressure. 
Associated proteinuria in hyperthyroidism also causes renal injury.
241
 
  In our study the relationship between dyslipidemia and different stages CKD 
was assessed, serum levels of total cholesterol, HDLc, TGLc and LDLc were 
analysed and their relationship with CKD was studied. Among the study population 
19.6% had hypercholesterolemia, 24.2% had high triglyceride level, 54.4% had low 
HDLc and 13.8% had high LDLc levels. There was significant association between 
CKD and high TGL levels (pvalue= 0.004) and low HDLc (p value=0.004). But there 
was no significant association between CKD and high levels of totalcholesterol (p 
value=0.563) and LDLc(pvalue=0.154 ).Saroj  Khatiwada et al
240
 in their cross 
sectional study, conducted among 360 CKD patients have stated that 
hypercholesterolemia, low HDLc, hypertriglyceridemia and undesirable LDL 
cholesterol were significantly associated with presence of cardiovascular disease in 
CKD. But did not find significant rise in dyslipidemia cases during CKD progression. 
Our study also did not show significant association for total cholesterol and LDLc and 
CKD. Zhongshang Yuan et al
102
 in a large scale multicentric cross-sectional study 
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(National community based program) has concluded that TG/HDL ratio was 
associated with renal dysfunction and also exhibited a significantly strong association 
between increase in serum creatinine and CKD in hypothyroidism and euthyroidism. 
  In this study, 38% the study subjects had normal BMI, 41.2% were overweight 
and 15.6% were obese. There were more participants in the overweight category. 
There was no significant association between obesity and CKD in our study (pvalue 
0.95). A study done by Zaman et al.,
242
has shown a negative association between BMI 
and CKD in a study done among Type 2 DM. Similarly, Narinder P Singh et al.
233
 has 
found an inverse association between BMI and renal impairment. The BMI assess 
both the central and peripheral fat, muscle mass and fluid. As it is the central obesity 
that determines the cardiovascular and the renal risk, BMI might not have accurately 
shown the association with CKD. A lot of studies have stated obesity as an important 
risk factor for CKD. Christiana Aryee et al.
144
 had stated that in their study higher 
anthropometric were recorded among hypertensive nephropathy patients.Andrzej 
Jaroszynski et al.
243
 had demonstrated that central obesity (waist circumference and 
waist hip ratio) showed higher discriminative ability for CKD than BMI. In this study 
we found a significant difference between the mean values of waist circumference 
between the CKD (stage1-2) and CKD (stage 3a-5) (p value=0.02). In early stages of 
obesity there will be increased GFR. The mechanism for early rise in GFR in obesity 
may be due to macula densa feedback mechanism, the visceral obesity causes 
compression of kidneys which may cause an increase in sodium reabsorption in loop 
of Henle hence less sodium in the macula densa and causes a tubulo glomerular 
feedback and increases renin secretion, increased blood flow and GFR. The 






  The prevalence of Diabetes mellitus among our study population was 35.8%, 
and among the CKD patients 47.8% had diabetics. There was significant association 
between diabetes and CKD stages (p value 0.000). Diabetes is the second most 
common risk factor for CKD in our study. In a study done by Wu Bingcao et al.
244
 the 
prevalence of CKD in T2DM was 38.3%, which is similar to that of our study.The 
study by Justin Gatwood et al,
245
also had reported a prevalence of 40%, which is 
nearly similar to our study .In a retrospective hospital based study done in Assam, 
Manjuri Sharma et al,
246
have identified diabetes mellitus(44.2%) as a leading cause of 
CKD. Sajith Kumar Soman et al,
247
 have concluded in their study that CKD was 
highly prevalent among diabetics and the duration of diabetes, urinary protein levels 
and RBS value had a strong association with CKD in diabetes. 
  The prevalence of Hypertension was 43.4% and the prevalence of 
hypertension among CKD (stage 3a-5), patients was 61.1% and there was significant 
association between hypertension and different stages of CKD (p value=0.000). In our 
study hypertension was the most common risk factor for CKD. A lot of studies have 
stated hypertension as a common risk factor for CKD. The SEEK study done by 
Ajay.K.Singh et al.
2
showed a high prevalence of hypertension(65%) and identified 
hypertension as one of the most common risk factor for CKD. Kayori Hayashi et al
5
, 
in their study of metabolic factors associated with CKD have found that hypertension 
was associated with rapid decline in eGFR and hence need to be monitored for 
prevention of occurrence of CKD. Narinder.P.Singh et al
233
. in a population based 
study have found a CKD prevalence of 17.1% among hypertensives and have stated 
that hypertension plays an important role as risk factor in CKD development. 
  In our study population Cardiovascular disease(CVD) was found in 29 (5.8%) 
patients. Among the CKD (stage 3a-5) patients in our study 12.4% had CVD. There 
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was a significant association between CVD and different stages of CKD (p 
value=0.001). Several studies have shown association between CKD and CVD. Luis 
.M.Ruilope et al
248
 in their HOT study  has stated that patients who had renal 
insufficiency as identified by a baseline creatinine of >1.5 mg/dl or eGFR< 60 
ml/min/1.73 m
2
 had an increased risk of CVD. In the HOPE randomized trial 
Johannes.F.E.Mann et al,
249
 have concluded that in patients with pre-existing vascular 
disease or diabetes combined with cardiovascular risk, mild renal insufficiency 
significantly increased the risk of CVD. Bruce. F. Culleton et al.
250
 in a community 
based cohort have found that mild renal insufficiency is common in the community 
and those with mild renal insufficiency were associated with high prevalence of CVD. 
This may be because many traditional CVD risk factors like hypertension, 


















  In this cross-sectional study among a heterogeneous adult population in a 
tertiary care centre, 500 adults of both sexes were evaluated for their renal status. The 
study showed a prevalence of Chronic Kidney Disease (stage 3a-5) (based on eGFR < 
60ml/min/1.73m
2
) to be 22.6% and the prevalence of CKD stage 2 was 55.2%. With 
increase in age there was a significant decrease in eGFR. In this study male sex had a 
higher prevalence of CKD (stage 3a-5), as the age increased. In this study 60.4% of 
the study subjects had normal proteinuria and 13% had overt proteinuria. There was 
significant association between proteinuria and different stages of CKD.  
  Sub clinical hypothyroidism was the prevalent (10.2%) thyroid dysfunction, 
among the study population. There was no significant association between thyroid 
dysfunction and different stages of CKD.On study of association between 
dyslipidemia and different stages of CKD, significant association was found between 
low HDLc and high TGL levels and different CKD stages, whereas increased levels 
of total cholesterol and high LDLc levels were not significantly associated with CKD. 
  Among the conventional risk factors like obesity, HT and DM, in the study of 
association of different BMI category and different stages of CKD, 41.2% of the 
study population were overweight. Obesity by BMI was not significantly associated 
with different CKD stages, but central obesity, by waist circumference, the mean 
values showed a significant difference between the different CKD stages (p value 
0.02). The prevalence of hypertension was high (43.4%) in the study population. 
Among the patients with CKD (stage 3a-5) 61.1% were hypertensives. The 
prevalence of diabetes mellitus among the study population was 35.8% and 47.8% of 
CKD (stage 3a-5) were diabetics. Hypertension was the most common risk factor for 
CKD in the study population. CKD was significantly associated with the common risk 
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factors like hypertension and diabetes. 
  On studying the association between CVD and different stages of CKD, 
12.4% of the CKD (stage 3a-5) had CVD. Cardiovascular disease was also 
significantly associated with different stages of CKD. 
  Based on the study done, it is suggested that estimated Glomerular Filtration 
Rate (eGFR) may be included in the laboratory reports of all patients with risk factors 
like Diabetes Mellitus, Hypertension and Obesity for early identification of renal 
dysfunction. Patients with Cardiovascular disease and dyslipidemia may be 





















 The prevalence of Chronic Kidney Disease was high in the study population. 
 The prevalence of CKD was more among males than females in our study 
population. 
 Hypertension, Diabetes mellitus, Cardiovascular disease and Proteinuria were 
associated significantly with different stages of CKD. 
 Hypertension was the most common risk factor among CKD patients.  
 There was significant association between high triglyceride levels and low 



















LIMITATION OF THE STUDY 
 
 As this was an observational study the progression pattern of CKD could not 
be assessed. 
 This study was conducted among hospital population which represents a 














1. Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for 
guidance, and a framework for moving forward. Kidney Int. 2014 Jan;85(1):49–61.  
 
2. Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, Almeida AF, 
Channakeshavamurthy A, Ballal HS, Gaccione P, Issacs R. Epidemiology and risk factors of 
chronic kidney disease in India–results from the SEEK (Screening and Early Evaluation of 
Kidney Disease) study. BMC nephrology. 2013 Dec;14(1):114. 
 
3. Coresh J, Hu J-R, Bello AK, Feldman HI, Fogo AB, Ganji MR, et al. Action plan for 
determining and monitoring the prevalence of chronic kidney disease. Kidney Int Suppl. 2017 
Oct 1;7(2):63–70.  
 
4. Raines N, González M, Wyatt C, Kurzrok M, Pool C, Lemma T, et al. Risk factors for 
reduced glomerular filtration rate in a Nicaraguan community affected by mesoamerican 
nephropathy. MEDICC Rev. 2014 Apr;16:16–22.  
 
5. Hayashi K, Takayama M, Abe T, Kanda T, Hirose H, Shimizu-Hirota R, et al. Investigation 
of Metabolic Factors Associated with eGFR Decline Over 1 Year in a Japanese Population 
without CKD. J Atheroscler Thromb. 2017 Aug 1;24(8):863–75.  
 
6. Adrogué HJ, Madias NE. Sodium and Potassium in the Pathogenesis of Hypertension. N Engl 
J Med. 2007 May 10;356(19):1966–78.  
 
7. Drenjančević-Perić I, Jelaković B, Lombard JH, Kunert MP, Kibel A, Gros M. High-Salt Diet 
and Hypertension: Focus on the Renin-Angiotensin System. Kidney Blood Press Res. 
2011;34(1):1–11.  
 
8. Zhou X, Matavelli L, Frohlich ED. Uric acid: Its relationship to renal hemodynamics and the 
renal renin-angiotensin system. Curr Hypertens Rep. 2006 Mar 1;8(2):120–4.  
 
9. Kang H-T, Shim J-Y, Lee Y-J, Lee J-E, Linton JA, Kim J-K, et al. Association between the 
Ratio of Triglycerides to High-Density Lipoprotein Cholesterol and Chronic Kidney Disease 
in Korean Adults: The 2005 Korean National Health and Nutrition Examination Survey. 
Kidney Blood Press Res. 2011;34(3):173–9.  
 
10. Ritz E, Wanner C. Lipid Changes and Statins in Chronic Renal Insufficiency. J Am Soc 
Nephrol. 2006 Dec 1;17(12 suppl 3):S226–30.  
 
11. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk 
factors in chronic kidney disease: overall burden and rates of treatment and control. Archives 
of internal medicine. 2006 Sep 25;166(17):1884-91. 
 
12. Kim J-Y, Kang H-T, Lee H-R, Lee Y-J, Shim J-Y. Comparison of Lipid-Related Ratios for 
Prediction of Chronic Kidney Disease Stage 3 or More in Korean Adults. J Korean Med Sci. 
2012;27(12):1524.  
 
13. Johnson ALICM, Stahl A, Zager RA. Triglyceride accumulation in injured renal tubular cells: 
Alterations in both synthetic and catabolic pathways. Kidney Int. 2005 Jun;67(6):2196–209. 
  
14. Baragetti A, Norata GD, Sarcina C, Rastelli F, Grigore L, Garlaschelli K, Uboldi P, Baragetti 
I, Pozzi C, Catapano AL. High density lipoprotein cholesterol levels are an independent 
predictor of the progression of chronic kidney disease. Journal of internal medicine. 2013 
Sep;274(3):252-62. 
 15. Sun K, Lin D, Li F, Huang C, Qi Y, Xue S, Tang J, Yang C, Li Y, Ren M, Yan L. Discordant 
associations of lipid parameters with albuminuria and chronic kidney disease: a population-
based study. Lipids in health and disease. 2015 Dec;14(1):152. 
 
16. Villabona C, Sahun M, Gómez N, Gómez JM, Soler J, Roca M, et al. Blood Volumes and 
Renal Function in Overt and Subclinical Primary Hypothyroidism. Am J Med Sci. 1999 Oct 
1;318(4):277–80.  
 
17. Hollander JGD, Wulkan RW, Mantel MJ, Berghout A. Correlation between severity of 
thyroid dysfunction and renal function. Clin Endocrinol (Oxf). 62(4):423–7.  
 
18. Zhang Y, Chang Y, Ryu S, Cho J, Lee W-Y, Rhee E-J, et al. Thyroid hormone levels and 
incident chronic kidney disease in euthyroid individuals: the Kangbuk Samsung Health Study. 
Int J Epidemiol. 2014 Oct 1;43(5):1624–32.  
 
19. Huang X, Ding L, Peng K, Lin L, Wang T, Zhao Z, Xu Y, Lu J, Chen Y, Wang W, Bi Y. 
Thyroid hormones associate with risk of incident chronic kidney disease and rapid decline in 
renal function: a prospective investigation. Journal of translational medicine. 2016 
Dec;14(1):336. 
 
20. Cooper DS, Biondi B. Subclinical thyroid disease. The Lancet. 2012 Mar 
24;379(9821):1142–54.  
 
21. Åsvold BO, Bjøro T, Vatten LJ. Association of thyroid function with estimated glomerular 
filtration rate in a population-based study: the HUNT study. Eur J Endocrinol. 2011 Jan 
1;164(1):101–5.  
 
22. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence 
study. Archives of internal medicine. 2000 Feb 28;160(4):526-34 
 
23. García-Trabanino R, Jarquín E, Wesseling C, Johnson RJ, González-Quiroz M, Weiss I, et al. 
Heat stress, dehydration, and kidney function in sugarcane cutters in El Salvador – A cross-
shift study of workers at risk of Mesoamerican nephropathy. Environ Res. 2015 Oct 
1;142:746–55.  
 
24. Soderland P, Lovekar S, Weiner DE, Brooks DR, Kaufman JS. Chronic Kidney Disease 
Associated With Environmental Toxins and Exposures. Adv Chronic Kidney Dis. 2010 May 
1;17(3):254–64.  
 
25. McClean M, Laws R, Rubio OR, Brooks D, Kaufman J, Weiner D, Nicholson S, Miller A, 
Makey C, Collins E, Ames J. Industrial hygiene/occupational health assessment: evaluating 
potential hazards associated with chemicals and work practices at the Ingenio San Antonio 
(Chichigalpa, Nicaragua). Boston, MA: Boston University School of Public Health. 2010. 
 
26. Ting SMS, Nair H, Ching I, Taheri S, Dasgupta I. Overweight, Obesity and Chronic Kidney 
Disease. Nephron Clin Pract. 2009;112(3):c121–7.  
 
27. Burton JO, Gray LJ, Webb DR, Davies MJ, Khunti K, Crasto W, et al. Association of 
anthropometric obesity measures with chronic kidney disease risk in a non-diabetic patient 
population. Nephrol Dial Transplant. 2012 May 1;27(5):1860–6.  
 
28. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk Factors for 
Chronic Kidney Disease: A Prospective Study of 23,534 Men and Women in Washington 
County, Maryland. J Am Soc Nephrol. 2003 Nov 1;14(11):2934–41.  
 29. Orth SR, Hallan SI. Smoking: A Risk Factor for Progression of Chronic Kidney Disease and 
for Cardiovascular Morbidity and Mortality in Renal Patients—Absence of Evidence or 
Evidence of Absence? Clin J Am Soc Nephrol. 2008 Jan 1;3(1):226–36.  
 
30. Hall JE. Guyton and Hall Textbook of Medical Physiology E-Book. Elsevier Health Sciences; 
2015. 1172 p.  
 
31. Delaney.P.Michael,Price.P.Christopher,Lamb.J.Edmund.Tietz Textbook of Clinical 
Chemistry and Molecular Diagnostics.5
th
 ed. Philadelphia.Elsevier.2012.48;Kidney 
Disease;p.1540-41. 
 
32. Rüster C, Wolf G. Renin-Angiotensin-Aldosterone System and Progression of Renal Disease. 
J Am Soc Nephrol. 2006 Nov 1;17(11):2985–91.  
 
33. Zatz R. Haemodynamically mediated glomerular injury: the end of a 15-year-old 
controversy? Curr Opin Nephrol Hypertens. 1996 Nov;5(6):468.  
 
34. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. 
Kidney Int. 1997 Jan;51(1):2–15.  
 
35. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic 
Kidney Disease.Kidney International Supplement.2013;3(1):5 
 
36. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US Commentary 
on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. 
Am J Kidney Dis. 2014 May;63(5):713–35.  
 
37. Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for 
guidance, and a framework for moving forward. Kidney Int. 2014 Jan;85(1):49–61.  
 
38. Myers GL. Recommendations for Improving Serum Creatinine Measurement: A Report from 
the Laboratory Working Group of the National Kidney Disease Education Program. Clin 
Chem. 2006 Jan 1;52(1):5–18.  
 
39. Levey AS, Coresh J, Bolton K, Culleton B, Harvey KS, Ikizler TA, Johnson CA, Kausz A, 
Kimmel PL, Kusek J, Levin A. K/DOQI clinical practice guidelines for chronic kidney 
disease: evaluation, classification, and stratification. American Journal of Kidney Diseases. 
2002;39(2 SUPPL. 1) 
 
40. Imai E, Matsuo S, Makino H, Watanabe T, Akizawa T, Nitta K, Iimuro S, Ohashi Y, Hishida 
A. Chronic Kidney Disease Japan Cohort study: baseline characteristics and factors 
associated with causative diseases and renal function. Clinical and experimental nephrology. 
2010 Dec 1;14(6):558-70. 
 
41. Luyckx VA, Tuttle KR, Garcia-Garcia G, Gharbi MB, Heerspink HJL, Johnson DW, et al. 
Reducing major risk factors for chronic kidney disease. Kidney Int Suppl. 2017 Oct;7(2):71–
87.  
 
42. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure 
patients. Kidney Int. 2005 Dec;68:S87–93.  
 
43. Senthilnathan G, Prabhakaran R. A Study of Evaluation of Thyroid Function Status In 
Patients With Chronic Kidney Disease. :4.  
 
44. Perrone RD, Madias NE, Levey AS. Serum Creatinine as an Index of Renal Function: New 
Insights into Old Concepts. :21.  
 
45. Florkowski CM, Chew-Harris JS. Methods of Estimating GFR – Different Equations 
Including CKD-EPI. Clin Biochem Rev. 2011 May;32(2):75–9.  
 
46. Cockcroft DW, Gault H. Prediction of Creatinine Clearance from Serum Creatinine. Nephron. 
1976;16(1):31–41.  
 
47. Levey AS. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum 
Creatinine: A New Prediction Equation. Ann Intern Med. 1999 Mar 16;130(6):461.  
 
48. Lin J, Knight EL, Hogan ML, Singh AK. A Comparison of Prediction Equations for 
Estimating Glomerular Filtration Rate in Adults without Kidney Disease. J Am Soc Nephrol. 
2003 Oct 1;14(10):2573–80.  
 
49. Levey AS, Stevens LA, Schmid CH, Zhang Y (Lucy), Castro AF, Feldman HI, et al. A New 
Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 2009 May 5;150(9):604.  
 
50. Roos JF, Doust J, Tett SE, Kirkpatrick CMJ. Diagnostic accuracy of cystatin C compared to 
serum creatinine for the estimation of renal dysfunction in adults and children—A meta-
analysis. Clin Biochem. 2007 Mar 1;40(5):383–91.  
 
51. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a 
marker of kidney function: A meta-analysis. Am J Kidney Dis. 2002 Aug 1;40(2):221–6.  
 
52. Schwartz GJ, Work DF. Measurement and Estimation of GFR in Children and Adolescents. 
Clin J Am Soc Nephrol. 2009 Nov 1;4(11):1832–43.  
 
53. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New 
Equations to Estimate GFR in Children with CKD. J Am Soc Nephrol JASN. 2009 
Mar;20(3):629–37.  
 
54. Price CP. Use of Protein:Creatinine Ratio Measurements on Random Urine Samples for 
Prediction of Significant Proteinuria: A Systematic Review. Clin Chem. 2005 Jul 
14;51(9):1577–86.  
 
55. Katayev A, Zebelman AM, Sharp TM, Samantha Flynn, Bernstein RK. Prevalence of isolated 
non-albumin proteinuria in the US population tested for both, urine total protein and urine 
albumin: An unexpected discovery. Clin Biochem. 2017 Apr 1;50(6):262–9.  
 
56. Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein 
components in disease. Can Med Assoc J. 2007 Aug 14;177(4):361–8.  
 
57. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of Single Voided Urine Samples to 
Estimate Quantitative Proteinuria. N Engl J Med. 1983 Dec 22;309(25):1543–6.  
 
58. Jong PE de, Curhan GC. Screening, Monitoring, and Treatment of Albuminuria: Public 
Health Perspectives. J Am Soc Nephrol. 2006 Aug 1;17(8):2120–6.  
 
59. Cieciura T, Urbanowicz A, Perkowska-Ptasinska A, Nowacka-Cieciura E, Tronina O, 
Majchrzak J, et al. Tubular and Glomerular Proteinuria in Diagnosing Chronic Allograft 
Nephropathy With Relevance to the Degree of Urinary Albumin Excretion. Transplant Proc. 
2005 Mar 1;37(2):987–90.  
 
60. Halimi J-M, Matthias B, Al‐Najjar A, Laouad I, Chatelet V, Marlière J-F, et al. Respective 
Predictive Role of Urinary Albumin Excretion and Nonalbumin Proteinuria on Graft Loss and 
Death in Renal Transplant Recipients. Am J Transplant. 7(12):2775–81.  
 
61. Kim JH, Oh SY, Kim EH, Lee MJ, Jeon YK, Kim BH, et al. Addition of nonalbumin 
proteinuria to albuminuria improves prediction of type 2 diabetic nephropathy progression. 
Diabetol Metab Syndr. 2017 Sep 6;9:68.  
 
62. Brunskill NJ. Albumin handling by proximal tubular cells: mechanisms and mediators. 
Nephrology Dialysis Transplantation. 2000 Dec 1;15(90006):39-40 
 
63. Eddy AA, Giachelli CM, McCulloch  with the technical assistance of L, Liu E. Renal 
expression of genes that promote interstitial inflammation and fibrosis in rats with protein-
overload proteinuria. Kidney Int. 1995 Jun 1;47(6):1546–57.  
 
64. Powers.C.Alvin.Harrison’s Principles of Internal Medicine 19th ed.( Vol.2).United States of 
America. Mc Graw Hill education.2015.419; Diabetes Mellitus Complication;p.2424  
 
65. Ziyadeh FN. The Extracellular Matrix in Diabetic Nephropathy. Am J Kidney Dis. 1993 Nov 
1;22(5):736–44.  
 
66. Ziyadeh FN. Mediators of hyperglycemia and the pathogenesis of matrix accumulation in 
diabetic renal disease. Miner Electrolyte Metab. 1995;21(4–5):292–302.  
 
67. Bleyer AJ, Fumo P, Snipes ER, Goldfarb S, Simmons DA, Ziyadeh FN. Polyol pathway 
mediates high glucose-induced collagen synthesis in proximal tubule. Kidney Int. 1994 
Mar;45(3):659–66.  
 
68. Goldfarb S, Ziyadeh FN, Kern EFO, Simmons DA. Effects of Polyol-Pathway Inhibition and 
Dietary myo-Inositol on Glomerular Hemodynamic Function in Experimental Diabetes 
Mellitus in Rats. Diabetes. 1991 Apr 1;40(4):465–71.  
 
69. Studer RK, Craven PA, DeRubertis FR. Role for Protein Kinase C in the Mediation of 
Increased Fibronectin Accumulation by Mesangial Cells Grown in High-Glucose Medium. 
Diabetes. 1993 Jan 1;42(1):118–26.  
 
70. Fumo P, Kuncio GS, Ziyadeh FN. PKC and high glucose stimulate collagen alpha 1 (IV) 
transcriptional activity in a reporter mesangial cell line. Am J Physiol-Ren Physiol. 1994 Oct 
1;267(4):F632–8.  
 
71. Cohen MP, Sharma K, Jin Y, Hud E, Wu VY, Tomaszewski J, et al. Prevention of diabetic 
nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy. J 
Clin Invest. 1995 May 1;95(5):2338–45.  
 
72. Brownlee M M. Advanced Protein Glycosylation in Diabetes and Aging. Annu Rev Med. 
1995;46(1):223–34.  
 
73. Sharma K, Ziyadeh FN. Hyperglycemia and Diabetic Kidney Disease: The Case for 
Transforming Growth Factor–β as a Key Mediator. Diabetes. 1995 Oct 1;44(10):1139–46.  
 
74. Border WA, Ruoslahtit E, ofNephrology D. Transforming Growth Factor-,B in Disease: The 
Dark Side of Tissue Repair. :7.  
 
75. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, et al. Cellular events in the 
evolution of experimental diabetic nephropathy. Kidney Int. 1995 Mar;47(3):935–44.  
 76. Inaba T, Ishibashi S, Gotoda T, Kawamura M, Morino N, Nojima Y, et al. Enhanced 
Expression of Platelet-Derived Growth Factor-β Receptor by High Glucose Involvement of 
Platelet-Derived Growth Factor in Diabetic Angiopathy. Diabetes. 1996 Apr 1;45(4):507–12.  
 
77. Hammerman MR. `The growth hormone–insulin-like growth factor axis in kidney re-
revisited. Nephrol Dial Transplant. 1999 Aug 1;14(8):1853–60.  
 
78. Flyvbjerg A, Orskov H. Kidney tissue insulin-like growth factor I and initial renal growth in 
diabetic rats: Relation to severity of diabetes. Eur J Endocrinol. 1990 Mar 1;122(3):374–8.  
 
79. Liu Y, Tolbert EM, Sun AM, Dworkin LD. In vivo and in vitro evidence for increased 
expression of HGF receptor in kidney of diabetic rat. Am J Physiol-Ren Physiol. 1996 
Dec;271(6):F1202–10.  
 
80. Wolf G, Mueller E, Stahl RA, Ziyadeh FN. Angiotensin II-induced hypertrophy of cultured 
murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. 
The Journal of clinical investigation. 1993 Sep 1;92(3):1366-72. 
 
81. Kennefick TM, Anderson S. Role of angiotensin II in diabetic nephropathy. Semin Nephrol. 
1997 Sep;17(5):441–7.  
 
82. Nakamura T, Ebihara I, Tomino Y, Koide H. Alteration of growth-related proto-oncogene 
expression in diabetic glomeruli by a specific endothelin receptor A antagonist. Nephrology 
Dialysis Transplantation. 1996 Aug 1;11(8):1528-31.  
 
83. Craven PA, Patterson MC, DeRubertis FR. Role of Enhanced Arachidonate Availability 
Through Phospholipase A2 Pathway in Mediation of Increased Prostaglandin Synthesis by 
Glomeruli From Diabetic Rats. Diabetes. 1988 Apr 1;37(4):429–35.  
 
84. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int. 1999 
Aug 1;56(2):393–405.  
 
85. Reusch JEB. Diabetes, microvascular complications, and cardiovascular complications: what 
is it about glucose? J Clin Invest. 2003 Oct 1;112(7):986–8.  
 
86. Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R. Activation of 
mitogen-activated protein kinase cascade in diabetic glomeruli and mesangial cells 
cultured under high glucose conditions. Kidney Int Suppl. 1997 Sep;60:S66-69. 
 
87. Haneda M, Araki S, Togawa M, Sugimoto T, Motohide I, Kikkawa R. Mitogen-Activated 
Protein Kinase Cascade Is Activated in Glomeruli of Diabetic Rats and Glomerular Mesangial 
Cells Cultured Under High Glucose Conditions. Diabetes. 1997 May 1;46(5):847–53.  
 
88. Simm A, Münch G, Seif F, Schenk O, Heidland A, Richter H, et al. Advanced glycation 
endproducts stimulate the MAP-kinase pathway in tubulus cell line LLC-PK1. FEBS Lett. 
410(2–3):481–4.  
 
89. Nagata S. Apoptosis by Death Factor. Cell. 1997 Feb 7;88(3):355–65.  
 
90. Reed JC. Bcl-2 and the regulation of programmed cell death. The Journal of cell biology. 
1994 Jan;124(1-2):1-6. 
 
91. Ortiz A, Ziyadeh FN, Neilson EG. Expression of apoptosis-regulatory genes in renal proximal 
tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys. J Investig 
Med Off Publ Am Fed Clin Res. 1997 Feb;45(2):50–6.  
 
92. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential 
consequences. Am J Physiol-Ren Physiol. 2006 Feb;290(2):F262–72.  
 
93. Stefanovic V, Milojkovic M. Treatment of Dyslipidemia in Chronic Kidney Disease. Int J 
Artif Organs. 2004 Oct 1;27(10):821–7. 
 
94. Attman P, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositional 
abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant. 1998 Nov 
1;13(11):2833–41.  
 
95. Kronenberg F, Kuen E, Ritz E, Junker R, König P, Kraatz G, et al. Lipoprotein(a) Serum 
Concentrations and Apolipoprotein(a) Phenotypes in Mild and Moderate Renal Failure. J Am 
Soc Nephrol. 2000 Jan 1;11(1):105–15.  
 
96. Weintraub M, Burstein A, Rassin T, Liron M, Ringel Y, Cabili S, et al. Severe defect in 
clearing postprandial chylomicron remnants in dialysis patients. Kidney Int. 1992 
Nov;42(5):1247–52.  
 
97. Attman P-O, Samuelsson O, Alaupovic P. Lipoprotein Metabolism and Renal Failure. Am J 
Kidney Dis. 1993 Jun 1;21(6):573–92.  
 
98. Heuck CC, Liersch M, Ritz E, Stegmeier K, Wirth A, Mehls O. Hyperlipoproteinemia in 
experimental chronic renal insufficiency in the rat. Kidney Int. 1978 Aug;14(2):142–50.  
 
99. Majumdar A. Lipid abnormalities in renal disease. 2000;93:5.  
 
100. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. Impaired metabolism of high 
density lipoprotein in uremic patients. Kidney Int. 1992 Jun;41(6):1653–61.  
 
101. Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG. Abnormalities in hepatic lipase in 
chronic renal failure: role of excess parathyroid hormone. J Clin Invest. 1996 May 
15;97(10):2167–73.  
 
102. Yuan Z, Zhao M, Zhang B, Zhang H, Zhang X, Guan Q, Ning G, Gao L, Xue F, Zhao J. 
Thyroid function modifies the association between ratio of triglyceride to high-density 
lipoprotein cholesterol and renal function: a multicenter cross-sectional study. Scientific 
reports. 2015 Jul 16;5:11052. 
 
103. Fujisawa M, Haramaki R, Miyazaki H, Imaizumi T, Okuda S. Role of Lipoprotein (a) and 
TGF-β1 in Atherosclerosis of Hemodialysis Patients. J Am Soc Nephrol. 2000 Oct 
1;11(10):1889–95.  
 
104. Moorhead JF, El-Nahas M, Chan MK, Varghese Z. LIPID NEPHROTOXICITY IN 
CHRONIC PROGRESSIVE GLOMERULAR AND TUBULO-INTERSTITIAL DISEASE. 
The Lancet. 1982 Dec 11;320(8311):1309–11.  
 
105. Abrass CK. Cellular Lipid Metabolism and the Role of Lipids in Progressive Renal Disease. 
Am J Nephrol. 2004;24(1):46–53.  
 
106. Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA, et al. Early Mechanisms 
of Renal Injury in Hypercholesterolemic or Hypertriglyceridemic Rats. J Am Soc Nephrol. 
2000 Apr 1;11(4):669–83.  
 
107. Sun L, Halaihel N, Zhang W, Shimomura I, Horton JD, Rogers T, Levi M. Role of SREBP-1 
in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. Journal of 
Biological Chemistry. 2002 Mar 1. 
 
108. Jiang T, Wang Z, Proctor G, Moskowitz S, Liebman SE, Rogers T, et al. Diet-induced 
Obesity in C57BL/6J Mice Causes Increased Renal Lipid Accumulation and 
Glomerulosclerosis via a Sterol Regulatory Element-binding Protein-1c-dependent Pathway. J 
Biol Chem. 2005 Sep 16;280(37):32317–25.  
 
109. van Hoek I, Daminet S. Interactions between thyroid and kidney function in pathological 
conditions of these organ systems: A review. Gen Comp Endocrinol. 2009 Feb 1;160(3):205–
15.  
 
110. Iglesias P, Díez JJ. Thyroid dysfunction and kidney disease. Eur J Endocrinol. 2009 Apr 
1;160(4):503–15.  
 
111. Kumar J, Gordillo R, Kaskel FJ, Druschel CM, Woroniecki RP. Increased Prevalence of 
Renal and Urinary Tract Anomalies in Children with Congenital Hypothyroidism. J Pediatr. 
2009 Feb 1;154(2):263–6.  
 
112. Canavan JP, Holt J, Easton J, Smith K, Goldspink DF. Thyroid‐induced changes in the 
growth of the Liver, Kidney, and Diaphragm of Neonatal Rats. Journal of cellular physiology. 
1994 Oct;161(1):49-54. 
 
113. Lin H-H, Tang M-J. Thyroid hormone upregulates Na,K-ATPase α and β mRNA in primary 
cultures of proximal tubule cells. Life Sci. 1997 Jan 3;60(6):375–82.  
 
114. Katz AI, Lindheimer MD. Renal Sodium- and Potassium-Activated Adenosine 
Triphosphatase and Sodium Reabsorption in the Hypothyroid Rat. J Clin Invest. 1973 Apr 
1;52(4):796–804.  
 
115. Vaamonde CA, Sebastianelli MJ, Vaamonde LS, Pellegrini EL, Watts RS, Klingler EL, et al. 
Impaired renal tubular reabsorption of sodium in hypothyroid man. Transl Res. 1975 Mar 
1;85(3):451–66.  
 
116. Pracyk JB, Slotkin TA. Thyroid hormone differentially regulates development of beta-
adrenergic receptors, adenylate cyclase and ornithine decarboxylase in rat heart and kidney. J 
Dev Physiol. 1991 Oct;16(4):251–61.  
 
117. Segarra AB, Ramírez M, Banegas I, Hermoso F, Vargas F, Vives F, et al. Influence of 
Thyroid Disorders on Kidney Angiotensinase Activity. Horm Metab Res. 2006 Jan;38(1):48–
52.  
 
118. Haro JM, Sabio JM, Vargas F. Renal β-adrenoceptors in thyroxine-treated rats. J Endocrinol 
Invest. 1992 Sep 1;15(8):605–8.  
 
119. Baum M, Dwarakanath V, Alpern RJ, Moe OW. Effects of thyroid hormone on the neonatal 
renal cortical Na+/H+ antiporter. Kidney Int. 1998 May;53(5):1254–8.  
 
120. Prisant LM, Gujral JS, Mulloy AL. Hyperthyroidism: a secondary cause of isolated systolic 
hypertension. J Clin Hypertens Greenwich Conn. 2006 Aug;8(8):596–9.  
 121. Basu G, Mohapatra A. Interactions between thyroid disorders and kidney disease. Indian J 
Endocrinol Metab. 2012;16(2):204–13.  
 
122. Kreisman SH, Hennessey JV. Consistent reversible elevations of serum creatinine levels in 
severe hypothyroidism. Archives of internal medicine. 1999 Jan 11;159(1):79-82. 
 
123. Mooraki A, Broumand B, Neekdoost F, Amirmokri P, Bastani B. Reversible acute renal 
failure associated with hypothyroidism: Report of four cases with a brief review of literature. 
Nephrology. 8(2):57–60.  
 
124. Karanikas G, Schütz M, Szabo M, Becherer A, Wiesner K, Dudczak R, et al. Isotopic Renal 
Function Studies in Severe Hypothyroidism and after Thyroid Hormone Replacement 
Therapy. Am J Nephrol. 2004;24(1):41–5.  
 
125. Al‐Fifi S, Girardin C, Sharma A, Rodd C. Moderate renal failure in association with 
prolonged acquired hypothyroidism in children. Acta Pædiatrica. 2007 Jan 2;88(7):715–7.  
 
126. Åsvold BO, Bjøro T, Vatten LJ. Association of thyroid function with estimated glomerular 
filtration rate in a population-based study: the HUNT study. Eur J Endocrinol. 2011 Jan 
1;164(1):101–5.  
 
127. Woodward A, McCann S, Al-Jubouri M. The relationship between estimated glomerular 
filtration rate and thyroid function: an observational study. Ann Clin Biochem. 2008 Sep 
1;45(5):515–7.  
 
128. Van MW, Lobatto S. Treatment of severe hypothyroidism in a patient with progressive renal 
failure leads to significant improvement of renal function. Clin Nephrol. 2007 Jun;67(6):391–
3.  
 
129. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks 
of death, cardiovascular events, and hospitalization. New England Journal of Medicine. 2004 
Sep 23;351(13):1296-305. 
 
130. Basu G, Mohapatra A. Interactions between thyroid disorders and kidney disease. Indian J 
Endocrinol Metab. 2012;16(2):204.  
 
131. Schmid C, Brändle M, Zwimpfer C, Zapf J, Wiesli P. Effect of Thyroxine Replacement on 
Creatinine, Insulin-Like Growth Factor 1, Acid-Labile Subunit, and Vascular Endothelial 
Growth Factor. Clin Chem. 2004 Jan 1;50(1):228–31.  
 
132. Lo JC, Chertow GM, Go AS, Hsu C-Y. Increased prevalence of subclinical and clinical 
hypothyroidism in persons with chronic kidney disease. Kidney Int. 2005 Mar;67(3):1047–
52.  
 
133. Song SH, Kwak IS, Lee DW, Kang YH, Seong EY, Park JS. The prevalence of low 
triiodothyronine according to the stage of chronic kidney disease in subjects with a normal 
thyroid-stimulating hormone. Nephrol Dial Transplant. 2009 May 1;24(5):1534–8.  
 
134. Wiederkehr MR, Kalogiros J, Krapf R. Correction of metabolic acidosis improves thyroid and 
growth hormone axes in haemodialysis patients. Nephrol Dial Transplant. 2004 May 
1;19(5):1190–7.  
 
135. Zoccali C, Tripepi G, Cutrupi S, Pizzini P, Mallamaci F. Low Triiodothyronine: A New Facet 
of Inflammation in End-Stage Renal Disease. J Am Soc Nephrol. 2005 Sep 1;16(9):2789–95.  
 136. Kaptein EM. Thyroid Hormone Metabolism and Thyroid Diseases in Chronic Renal Failure. 
2018;17(1):19.  
 
137. Hall JE, Henegar JR, Dwyer TM, Liu J, Silva AA da, Kuo JJ, et al. Is obesity a major cause 
of chronic kidney disease? Adv Chronic Kidney Dis. 2004 Jan 1;11(1):41–54.  
 
138. Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyrén O. Obesity and Risk for 
Chronic Renal Failure. J Am Soc Nephrol. 2006 Jun 1;17(6):1695–702.  
 
139. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of 
development of end-stage renal disease in a screened cohort. Kidney Int. 2004 May 
1;65(5):1870–6.  
 
140. Hsu C, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body Mass Index and Risk for End-
Stage Renal Disease. Ann Intern Med. 2006 Jan 3;144(1):21.  
 
141. Bonnet F, Deprele C, Sassolas A, Moulin P, Alamartine E, Berthezène F, et al. Excessive 
body weight as a new independent risk factor for clinical and pathological progression in 
primary IgA nephritis. Am J Kidney Dis. 2001 Apr 1;37(4):720–7.  
 
142. Gonzalez E, Gutierrez E, Morales E, Hernandez E, Andres A, Bello I, et al. Factors 
influencing the progression of renal damage in patients with unilateral renal agenesis and 
remnant kidney. Kidney Int. 2005 Jul 1;68(1):263–70.  
 
143. Praga M, Hernández E, Herrero JC, Morales E, Revilla Y, Díaz-González R, et al. Influence 
of obesity on the appearance of proteinuria and renal insufficiency after unilateral 
nephrectomy. Kidney Int. 2000 Nov 1;58(5):2111–8.  
 
144. Aryee C, Owiredu WK, Osei-Yeboah J, Owusu-Dabo E, Laing EF, Owusu IK. An Analysis 
of Anthropometric Indicators and Modifiable Lifestyle Parameters Associated with 
Hypertensive Nephropathy. International journal of hypertension. 2016;2016. 
 
145. Ram R, Goswami DN, Bhattacharya SK, Bhattacharya K, Saha BK, Saha J, et al. An 
epidemiological study on risk factors of diabetes mellitus among patients attending a medical 
college hospital in Kolkata, West Bengal. J Indian Med Assoc. 2006 Aug;104(8):428–30.  
 
146. Srivastava T. Nondiabetic consequences of obesity on kidney. Pediatr Nephrol. 2006 Apr 
1;21(4):463–70.  
 
147. De Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL. Obesity and target organ damage: the 
kidney. International journal of obesity. 2002 Nov 28;26(S4):S21.  
 
148. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and Structural Changes 
in the Kidney in the Early Stages of Obesity. J Am Soc Nephrol. 2001 Jun 1;12(6):1211–7.  
 
149. Wahba IM, Mak RH. Obesity and Obesity-Initiated Metabolic Syndrome: Mechanistic Links 
to Chronic Kidney Disease. Clin J Am Soc Nephrol. 2007 May 1;2(3):550–62.  
 
150. Hall JE, Brands MW, Dixon WN, Smith MJ. Obesity-induced hypertension. Renal function 
and systemic hemodynamics. Hypertension. 1993 Sep 1;22(3):292–9.  
 
151. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis. 2002 Jan 
1;39(1):1–11.  
152. Hall JE. Louis K. Dahl Memorial Lecture. Renal and cardiovascular mechanisms of 
hypertension in obesity. Hypertension. 1994 Mar 1;23(3):381–94.  
 
153. Hall JE. Mechanisms of Abnormal Renal Sodium Handling in Obesity Hypertension. 2018;7.  
 
154. Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of Obesity-
Associated Cardiovascular and Renal Disease. Am J Med Sci. 2002 Sep 1;324(3):127–37.  
 
155. Landsberg L, Krieger DR. Obesity, Metabolism, and the Sympathetic Nervous System. Am J 
Hypertens. 1989 Mar 1;2(3_Pt_2):125S-132S.  
 
156. Ferrannini E, Haffner SM, Stern MP. Essential hypertension: an insulin-resistant state. J 
Cardiovasc Pharmacol. 1990;15 Suppl 5:S18-25.  
 
157. Robles RG, Villa E, Santirso R, Martinez J, Ruilope LM, Carmen C, et al. Effects of 
Captopril on Sympathetic Activity, Lipid and Carbohydrate Metabolism in a Model of 
Obesity-Induced Hypertension in Dogs. Am J Hypertens. 1993 Dec 1;6(12):1009–15.  
 
158. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to 
lipotoxicity. Trends Endocrinol Metab. 2010 Jun 1;21(6):345–52.  
 
159. Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC, Investigators  for the C and RE (CARE) 
T. Effect of Pravastatin on Loss of Renal Function in People with Moderate Chronic Renal 
Insufficiency and Cardiovascular Disease. J Am Soc Nephrol. 2003 Jun 1;14(6):1605–13.  
 
160. Wisse BE. The Inflammatory Syndrome: The Role of Adipose Tissue Cytokines in Metabolic 
Disorders Linked to Obesity. J Am Soc Nephrol. 2004 Nov 1;15(11):2792–800.  
 
161. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic Syndrome: A 
Comprehensive Perspective Based on Interactions Between Obesity, Diabetes, and 
Inflammation. Circulation. 2005 Mar 22;111(11):1448–54.  
 
162. Wu Y, Liu Z, Xiang Z, Zeng C, Chen Z, Ma X, et al. Obesity-Related Glomerulopathy: 
Insights from Gene Expression Profiles of the Glomeruli Derived from Renal Biopsy 
Samples. Endocrinology. 2006 Jan;147(1):44–50.  
 
163. Sharma K, Considine RV. The Ob protein (leptin) and the kidney. Kidney Int. 1998 
Jun;53(6):1483–7.  
 
164. Briley LP, Szczech LA. Leptin and Renal Disease. Semin Dial. 19(1):54–9.  
 
165. Gal CS-L, Raufaste D, Brossard G, Pouzet B, Marty E, Maffrand J-P, et al. Characterization 
and localization of leptin receptors in the rat kidney. FEBS Lett. 404(2–3):185–91.  
 
166. Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, et al. Leptin stimulates 
proliferation and TGF-β expression in renal glomerular endothelial cells: Potential role in 
glomerulosclerosis1. Kidney Int. 1999 Sep 1;56(3):860–72.  
 
167. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, et al. Plasma Leptin 
and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study 
(WOSCOPS). Circulation. 2001 Dec 18;104(25):3052–6.  
 
168. Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij 
L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular 
disease. Circulation. 2003;108:2154-69. 
 169. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, Salem DN, Levey 
AS, Sarnak MJ. Kidney disease as a risk factor for recurrent cardiovascular disease and 
mortality1. American Journal of Kidney Diseases. 2004 Aug 1;44(2):198-206.  
 
170. Bleyer AJ, Shemanski LR, Burke GL, Hansen KJ, Appel RG. Tobacco, hypertension, and 
vascular disease: Risk factors for renal functional decline in an older population. Kidney Int. 
2000 May 1;57(5):2072–9.  
 
171. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D. Predictors of New-Onset 
Kidney Disease in a Community-Based Population. JAMA. 2004 Feb 18;291(7):844–50.  
 
172. Brosius FC, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, et al. 
Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular 
Disease: A Science Advisory From the American Heart Association Kidney and 
Cardiovascular Disease Council; the Councils on High Blood Pressure Research, 
Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of 
Care and Outcomes Research Interdisciplinary Working Group: Developed in Collaboration 
With the National Kidney Foundation. Circulation. 2006 Sep 5;114(10):1083–7.  
 
173. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity 
in chronic kidney disease: Pathogenesis, clinical relevance, and treatment. Kidney Int. 2004 
May 1;65(5):1568–76.  
 
174. Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, et al. Renalase is a novel, soluble 
monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005 
May 2;115(5):1275–80.  
 
175. Amann K, Tenyi GMT-M, Simonoviciene A, Koch A, Orth S, Ritz E. Remodeling of 
Resistance Arteries in Renal Failure: Effect of Endothelin Receptor Blockade. J Am Soc 
Nephrol. 2001 Oct 1;12(10):2040–50.  
 
176. Mallamaci F, Tripepi G, Maas R, Malatino L, Böger R, Zoccali C. Analysis of the 
Relationship between Norepinephrine and Asymmetric Dimethyl Arginine Levels among 
Patients with End-Stage Renal Disease. J Am Soc Nephrol. 2004 Feb 1;15(2):435–41.  
 
177. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation Between Serum Phosphate Level 
and Cardiovascular Event Rate in People With Coronary Disease. Circulation. 2005 Oct 
25;112(17):2627–33.  
 
178. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, et al. Cardiovascular 
disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global 
Outcomes (KDIGO). Kidney Int. 2011 Sep;80(6):572–86.  
 
179. Merkin SS, Diez Roux AV, Coresh J, Fried LF, Jackson SA, Powe NR. Individual and 
neighborhood socioeconomic status and progressive chronic kidney disease in an elderly 
population: The Cardiovascular Health Study. Soc Sci Med. 2007 Aug 1;65(4):809–21.  
 
180. Vart P, Gansevoort RT, Coresh J, Reijneveld SA, Bültmann U. Socioeconomic Measures and 
CKD in the United States and The Netherlands. Clin J Am Soc Nephrol. 2013 Jun 
27;CJN.12521212.  
181. Nuyts GD, D’Haese PC, Elseviers MM, de Broe ME, Van Vlem E, Thys J, et al. New 
occupational risk factors for chronic renal failure. The Lancet. 1995 Jul 1;346(8966):7–11.  
 
182. Stengel B, Cénée S, Limasset J-C, Protois J-C, Marcelli A, Brochard P, et al. Organic Solvent 
Exposure May Increase the Risk of Glomerular Nephropathies with Chronic Renal Failure. 
Int J Epidemiol. 1995 Apr 1;24(2):427–34.  
 
183. Wedeen RP. Occupational and environmental renal disease. Semin Nephrol. 1997 
Jan;17(1):46–53.  
 
184. Torres C, Aragón A, González M, López I, Jakobsson K, Elinder C-G, et al. Decreased 
Kidney Function of Unknown Cause in Nicaragua: A Community-Based Survey. Am J 
Kidney Dis. 2010 Mar 1;55(3):485–96.  
 
185. Schrier RW. Renal, Metabolic, and Circulatory Responses to Heat and Exercise: Studies in 
Military Recruits During Summer Training, with Implications for Acute Renal Failure. Ann 
Intern Med. 1970 Aug 1;73(2):213.  
 
186. Brikowski TH, Lotan Y, Pearle MS. Climate-related increase in the prevalence of urolithiasis 
in the United States. Proc Natl Acad Sci. 2008 Jul 15;105(28):9841–6.  
 
187. Wijkström J, Leiva R, Elinder C-G, Leiva S, Trujillo Z, Trujillo L, et al. Clinical and 
Pathological Characterization of Mesoamerican Nephropathy: A New Kidney Disease in 
Central America. Am J Kidney Dis. 2013 Nov 1;62(5):908–18.  
 
188. Roncal Jimenez CA, Ishimoto T, Lanaspa MA, Rivard CJ, Nakagawa T, Ejaz AA, et al. 
Fructokinase activity mediates dehydration-induced renal injury. Kidney Int. 2014 
Aug;86(2):294–302.  
 
189. Cirillo P, Gersch MS, Mu W, Scherer PM, Kim KM, Gesualdo L, et al. Ketohexokinase-
Dependent Metabolism of Fructose Induces Proinflammatory Mediators in Proximal Tubular 
Cells. J Am Soc Nephrol. 2009 Mar 1;20(3):545–53.  
 
190. Glushakova O, Kosugi T, Roncal C, Mu W, Heinig M, Cirillo P, et al. Fructose Induces the 
Inflammatory Molecule ICAM-1 in Endothelial Cells. J Am Soc Nephrol. 2008 Sep 
1;19(9):1712–20.  
 
191. Wu M-S,Yang C-W, Pan M-J, Chang C-T, Chen Y-C. Reduced renal Na+-K+-Cl- co-
transporter activity and inhibited NKCC2 mRNA expression by Leptospira shermani: from 
bed-side to bench. Nephrol Dial Transplant. 2004 Oct 1;19(10):2472–9.  
 
192. Abdulkader RCRM, Silva MV. The kidney in leptospirosis. Pediatr Nephrol. 2008 Dec 
1;23(12):2111.  
 
193. Romieu I, Palazuelos E, Hernandez Avila M, Rios C, Muñoz I, Jimenez C, et al. Sources of 
lead exposure in Mexico City. Environ Health Perspect. 1994 Apr;102(4):384–9.  
 
194. Sabolić I. Common Mechanisms in Nephropathy Induced by Toxic Metals. Nephron Physiol. 
2006;104(3):p107–14.  
 
195. Xia J, Wang L, Ma Z, Zhong L, Wang Y, Gao Y, et al. Cigarette smoking and chronic kidney 
disease in the general population: a systematic review and meta-analysis of prospective cohort 
studies. Nephrol Dial Transplant. 2017 Mar 1;32(3):475–87.  
196. Orth SR. Cigarette smoking: an important renal risk factor–far beyond carcinogenesis. 
Tobacco induced diseases. 2003 Jun;1(2):137. 
 
197. Orth SR. Effects of Smoking on Systemic and Intrarenal Hemodynamics: Influence on Renal 
Function. J Am Soc Nephrol. 2004 Jan 1;15(1 suppl):S58–63.  
 198. Orth SR. Smoking and the Kidney. J Am Soc Nephrol. 2002 Jun 1;13(6):1663–72.  
 
199. Baggio B, Budakovic A, Perissinotto E, Maggi S, Cantaro S, Enzi G, et al. Atherosclerotic 
risk factors and renal function in the elderly: The role of hyperfibrinogenaemia and smoking. 
Results from the Italian Longitudinal Study on Ageing (ILSA). Nephrol Dial Transplant Off 
Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2005 Feb 1;20:114–23.  
 
200. Jaimes EA, Tian R-X, Raij L. Nicotine: the link between cigarette smoking and the 
progression of renal injury? Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H76-82.  
 
201. Dasgupta P, Chellappan SP. Nicotine-mediated cell proliferation and angiogenesis: new 
twists to an old story. Cell Cycle Georget Tex. 2006 Oct;5(20):2324–8.  
 
202. Grassi G, Seravalle G, Calhoun DA, Bolla GB, Giannattasio C, Marabini M, et al. 
Mechanisms responsible for sympathetic activation by cigarette smoking in humans. 
Circulation. 1994 Jul 1;90(1):248–53.  
 
203. Hansen KW, Pedersen MM, Christiansen JS, Mogensen CE. Night Blood Pressure and 
Cigarette Smoking: Disparate Association in Healthy Subjects and Diabetic Patients. Blood 
Press. 1994 Jan 1;3(6):381–8.  
 
204. Davidson MB, Hix JK, Vidt DG, Brotman DJ. Association of Impaired Diurnal Blood 
Pressure Variation With a Subsequent Decline in Glomerular Filtration Rate. Arch Intern 
Med. 2006 Apr 24;166(8):846–52.  
 
205. Ritz E, Benck U, Franek E, Keller C, Seyfarth M, Clorius J. Effects of smoking on renal 
hemodynamics in healthy volunteers and in patients with glomerular disease. J Am Soc 
Nephrol. 1998 Oct 1;9(10):1798–804.  
 
206. Main J. How Important Is Atheromatous Renal Artery Stenosis as a Cause of End-Stage 
Renal Disease? Semin Dial. 14(3):143–5.  
 
207. Auerbach O, Carter HW, Garfinkel L, Hammond EC. Cigarette Smoking and Coronary 
Artery Disease: A Macroscopic and Microscopic Study. Chest. 1976 Dec 1;70(6):697–705.  
 
208. Bos WJW, Demircan MM, Weening JJ, Krediet RT, Wal VD, C A. Renal vascular changes in 
renal disease independent of hypertension. Nephrol Dial Transplant. 2001 Mar 1;16(3):537–
41.  
 
209. Markowitz GS, Lin J, Valeri AM, Avila C, Nasr SH, D’Agati VD. Idiopathic nodular 
glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking. 
Hum Pathol. 2002 Aug 1;33(8):826–35.  
 
210. World Health Organization. Substance Abuse Dept, World Health Organization. Department 
of Mental Health, Substance Abuse, World Health Organization. Global status report: alcohol 
policy. World Health Organization; 2004 Jul 23. 
 
211. Thiel DHV, Gavaler JS, Little JM, Lester R. Alcohol: Its effect on the kidney. Metab - Clin 
Exp. 1977 Aug 1;26(8):857–66.  
 
212. Keller CK, Andrassy K, Waldherr R, Ritz E. Postinfectious glomerulonephritis—is there a 
link to alcoholism? QJM Int J Med. 1994 Feb 1;87(2):97–102.  
 
213. Pablo NC, Churg J, Needle MA, Ganesharajah M. Renal Papillary Necrosis: Relapsing Form 
Associated With Alcoholism. Am J Kidney Dis. 1986 Jan 1;7(1):88–94.  
 
214. Muthukumar T, Jha V, Wanchoo A, Bambery P, Sakhuja V. Acute Renal Failure Due to 
Nontraumatic Rhabdomyolysis Following Binge Drinking. Ren Fail. 1999 Jan;21(5):545–9.  
 
215. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Brabec BA, O’Corragain OA, 
Edmonds PJ, et al. High alcohol consumption and the risk of renal damage: a systematic 
review and meta-analysis. QJM Int J Med. 2015 Jul 1;108(7):539–48.  
 
216. Tanasescu M, Hu FB, Willett WC, Stampfer MJ, Rimm EB. Alcohol consumption and risk of 
coronary heart disease among men with type 2 diabetes mellitus. J Am Coll Cardiol. 2001 
Dec 1;38(7):1836–42.  
 
217. Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, Van Denburgh M, et al. 
Moderate Alcohol Intake, Increased Levels of High-Density Lipoprotein and Its Subfractions, 
and Decreased Risk of Myocardial Infarction. J Occup Environ Med. 1994 May;36(5):504.  
 
218. Rodrigo R, Rivera G, Orellana M, Araya J, Bosco C. Rat kidney antioxidant response to long-
term exposure to flavonol rich red wine. Life Sci. 2002 Nov 1;71(24):2881–95.  
 
219. Shigematsu S, Ishida S, Hara M, Takahashi N, Yoshimatsu H, Sakata T, et al. Resveratrol, a 
red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses 
induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic Biol Med. 
2003 Apr 1;34(7):810–7.  
 
220. Hippisley-Cox J, Coupland C. Predicting the risk of Chronic Kidney Disease in Men and 
Women in England and Wales: prospective derivation and external validation of the 
QKidney® Scores. BMC family practice. 2010 Dec;11(1):49. 
 
221. Rule AD, Bergstralh EJ, Melton LJ, Li X, Weaver AL, Lieske JC. Kidney Stones and the 
Risk for Chronic Kidney Disease. Clin J Am Soc Nephrol. 2009 Apr 1;4(4):804–11.  
 
222. Jungers P, Joly D, Barbey F, Choukroun G, Daudon M. ESRD caused by nephrolithiasis: 
Prevalence, mechanisms, and prevention. Am J Kidney Dis. 2004 Nov 1;44(5):799–805.  
 
223. Saucier NA, Sinha MK, Liang KV, Krambeck AE, Weaver AL, Bergstralh EJ, et al. Risk 
Factors for CKD in Persons With Kidney Stones: A Case-Control Study in Olmsted County, 
Minnesota. Am J Kidney Dis. 2010 Jan 1;55(1):61–8.  
 
224. Evan AP, Lingeman JE, Coe FL, Shao Y, Parks JH, Bledsoe SB, et al. Crystal-associated 
nephropathy in patients with brushite nephrolithiasis. Kidney Int. 2005 Feb;67(2):576–91.  
 
225. Klahr S. New Insights Into the Consequences and Mechanisms of Renal Impairment in 
Obstructive Nephropathy. Am J Kidney Dis. 1991 Dec;18(6):689–99.  
 
226. Hwang SJ, Haas M, Harris HW, Silva P, Yalla S, Sullivan MR, Otuechere G, Kashgarian M, 
Zeidel ML. Transport defects of rabbit medullary thick ascending limb cells in obstructive 
nephropathy. The Journal of clinical investigation. 1993 Jan 1;91(1):21-8. 
 
227. Ophascharoensuk V, Giachelli CM, Gordon K, Hughes J, Pichler R, Brown P, et al. 
Obstructive uropathy in the mouse: Role of osteopontin in interstitial fibrosis and apoptosis. 
Kidney Int. 1999 Aug;56(2):571–80.  
 
228. Larsson PA, Cano M, Grenabo L, Brorson J-E, Hedelin H, Pettersson S, et al. Morphological 
Lesions of the Rat Urinary Tract Induced by Inoculation of Mycoplasmas and Other Urinary 
Tract Pathogens. Urol Int. 1989;44(4):210–7.  
 
229. Johnson RJ, Kivlighn SD, Kim Y-G, Suga S, Fogo AB. Reappraisal of the pathogenesis and 
consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. 
Am J Kidney Dis. 1999 Feb 1;33(2):225–34.  
 
230. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh 
Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment 
of High Blood Pressure. Hypertension. 2003 Dec 1;42(6):1206–52.  
 
231. Lim JU, Lee JH, Kim JS, Hwang YI, Kim T-H, Lim SY, et al. Comparison of World Health 
Organization and Asia-Pacific body mass index classifications in COPD patients. Int J Chron 
Obstruct Pulmon Dis. 2017 Aug 21;12:2465–75.  
 
232. American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 
2017 Jan;40(Supplement 1):S11–24.  
 
233. Singh NP, Ingle GK, Saini VK, Jami A, Beniwal P, Lal M, Meena GS. Prevalence of low 
glomerular filtration rate, proteinuria and associated risk factors in North India using 
Cockcroft-Gault and Modification of Diet in Renal Disease equation: an observational, cross-
sectional study. BMC nephrology. 2009 Dec;10(1):4 
 
234. Varma PP, Raman DK, Ramakrishnan TS, Singh P, Varma A. Prevalence of early stages of 
chronic kidney disease in apparently healthy central government employees in India. Nephrol 
Dial Transplant. 2010 Sep;25(9):3011–7.  
 
235. 235.  Agarwal SK, Dash SC, Irshad M, Raju S, Singh R, Pandey RM. Prevalence of 
chronic renal failure in adults in Delhi, India. Nephrol Dial Transplant. 2005 Aug 
1;20(8):1638–42.  
 
236. Vassalotti JA, Li S, Chen S-C, Collins AJ. Screening Populations at Increased Risk of CKD: 
The Kidney Early Evaluation Program (KEEP) and the Public Health Problem. Am J Kidney 
Dis. 2009 Mar 1;53(3, Supplement 3):S107–14.  
 
237. Inaguma D, Imai E, Takeuchi A, Ohashi Y, Watanabe T, et al. Risk factors for CKD 
progression in Japanese patients: findings from the Chronic Kidney Disease Japan Cohort 
(CKD-JAC) study. Clin Exp Nephrol. 2017 Jun;21(3):446–56.  
 
238. Ying T, Clayton P, Naresh C, Chadban S. Predictive value of spot versus 24-hour measures of 
proteinuria for death, end-stage kidney disease or chronic kidney disease progression. BMC 
nephrology. 2018 Dec;19(1):55. 
 
239. Chang YC, Chang CH, Yeh YC, Chuang LM, Tu YK. Subclinical and overt hypothyroidism 
is associated with reduced glomerular filtration rate and proteinuria: a large cross-sectional 
population study. Scientific reports. 2018 Feb 1;8(1):2031. 
 
240. Khatiwada S, Rajendra KC, Gautam S, Lamsal M, Baral N. Thyroid dysfunction and 
dyslipidemia in chronic kidney disease patients. BMC Endocrine disorders. 2015 
Dec;15(1):65 
 
241. Vargas F, Moreno JM, Rodríguez-Gómez I, Wangensteen R, Osuna A, Álvarez-Guerra M, et 
al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol. 2006 Feb 
1;154(2):197–212.  
 242. Zaman SB, Hossain N, Rahman M. Associations between Body Mass Index and Chronic 
Kidney Disease in Type 2 Diabetes Mellitus Patients: Findings from the Northeast of 
Thailand. :9.  
 
243. Jaroszynski A, Dereziński T, Jaroszyńska A, Zapolski T, Wąsikowska B, Wysokiński A, et al. 
Association of anthropometric measures of obesity and chronic kidney disease in elderly 
women. Ann Agric Environ Med. 2016 Sep 27;23(4):636–40.  
 
244. Wu B, Bell K, Stanford A, Kern DM, Tunceli O, Vupputuri S, et al. Understanding CKD 
among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 
2007–2012. BMJ Open Diabetes Res Care. 2016 Apr;4(1):e000154.  
 
245. Gatwood J, Chisholm-Burns M, Davis R, Thomas F, Potukuchi P, Hung A, et al. Evidence of 
chronic kidney disease in veterans with incident diabetes mellitus. Reboldi G, editor. PLOS 
ONE. 2018 Feb 9;13(2):e0192712.  
 
246. Sharma M, Doley P, Das HJ. Etiological profile of chronic kidney disease: A single-center 
retrospective hospital-based study. Saudi J Kidney Dis Transplant. 2018 Mar 1;29(2):409.  
 
247. Soman SK, Areekal B, Varghese RG, John S, Gopan RS, Jacob QM, et al. Chronic kidney 
disease-prevalence and determinants among type 2 diabetes mellitus patients attending a 
primary care setting in central Kerala. Int J Community Med Public Health. 2018 Jun 
22;5(7):2776–81.  
 
248. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal Function 
and Intensive Lowering of Blood Pressure in Hypertensive Participants of the Hypertension 
Optimal Treatment (HOT) Study. J Am Soc Nephrol. 2001 Feb 1;12(2):218–25.  
 
249. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S, for the HOPE Investigators. Renal 
Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The 
HOPE Randomized Trial. Ann Intern Med. 2001 Apr 17;134(8):629.  
 
250. Culleton BF, Larson MG, Wilson PWF, Evans JC, Parfrey PS, Levy D. Cardiovascular 
disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 




































































































































































































































































































1 55 M 1.53 51 80 21.79 140 90 68 Y Y N N N N N N N N N Y N Y N N 68 110 5.9 26 1.1 186 220 40 143 37 0.99 7.77 3.3 0.16 75.2
2 75 F 1.5 60 96 26.67 120 80 84 N N Y N N N N N N N N Y N N N N 250 294 8.1 41 0.9 73 114 35 65 15 2.56 1.44 2.78 0.52 62.5
3 57 F 1.52 55 91 23.81 160 100 76 N N N N N N N N N N N Y N N N N 144 177 7.3 26 0.9 192 161 44 89 38 2.03 1.24 3.15 0.76 71
4 65 F 1.5 49 78 21.78 120 60 68 N N N N N N N N N Y N N N N N N 100 26 1 102 219 37 144 20 1.07 7.77 1.97 1.81 59.1
5 50 M 1.59 51 79 20.17 140 80 72 N Y Y N N N N N N N N Y N N Y N 196 348 8.8 33 1.2 286 219 40 130 57 2.75 5.56 3.4 0.1 70.1
6 35 M 1.6 70.5 92 27.54 120 70 76 N N N N N N N N N N N Y N N N N 81 112 16 1.2 124 184 33 121 25 1.79 1.46 3.94 0.01 76.8
7 68 F 1.49 53 87 23.87 140 70 78 N N Y Y N N N N N Y N N N N N N 157 225 6.8 19 0.9 129 87 24 46 26 0.15 2.06 3.78 0.11 65.7
8 64 M 1.6 56 86 21.88 100 60 80 y N Y N N N N N N N N Y N N Y N 52 85 220 8.2 57 2.3 96 113 22 73 19 0.71 1.46 2.47 3.79 28.9
9 35 M 1.84 88 98 25.99 120 80 82 N N N N N N N N N Y Y N N N Y N 86 142 28 1.7 81 140 33 82 16 3.5 1.22 3.97 0.09 51.1
10 56 M 1.71 66.8 93 22.84 130 90 88 N Y N N N N N N N N N Y Y N Y N 116 144 19 1.2 132 129 25 76 26 3.57 1.26 3.45 0.04 67.2
11 55 M 1.76 63.4 86 20.47 130 80 82 N N N N N N N N N N N Y N Y Y N 74 193 31 1.1 57 121 35 69 11 4.02 1.26 3.27 0.05 75.2
12 49 F 1.56 78.8 113 32.38 110 80 86 N N Y N N N N N N N N Y N N N N 109 194 27 1.09 152 176 42 101 30 0.89 1.18 2.98 0.04 59.6
13 52 M 1.63 75 100 28.23 120 80 78 N N N N N N N N N N N y N N N N 113 243 6.6 18 0.9 218 175 33 101 44 2.75 1.26 2.8 0.07 97.9
14 47 M 1.58 68 92 27.24 130 80 86 N N N N N N N N N Y Y N N Y Y N 113 45 2.7 128 143 39 77 26 5.02 3.81 2.26 4.5 26.9
15 43 M 1.62 61 84 23.24 120 70 84 Y N N N N N N N N N N Y N N N N 92 111 26 1.08 77 147 42 84 15 1.69 1.18 3.42 0.01 83.6
16 35 F 1.56 77.5 84 31.85 120 80 76 N N N N N N N N N N N Y N N N N 80 102 22 0.95 54 153 47 84 11 1.69 1.3 3.08 0.01 77.6
17 39 M 1.62 59.3 74 22.60 90 60 84 N N N N N N N N N N N Y N N N N 78 112 27 1.13 107 163 43 94 21 2.75 1.26 2.8 0.01 81.4
18 44 F 1.49 59.2 82 26.67 110 80 76 N N N N N N N N N N N Y N N N N 76 119 13 0.96 47 89 25 53 9 18.88 0.75 3.02 0.01 71.9
19 59 M 1.6 53 90 20.70 110 70 86 Y N N N N N N N N y N N Y N Y N 127 41 0.8 54 45 56 26 11 1.03 1.48 2.5 0.03 97.8
20 22 M 1.68 74 90 26.22 110 70 74 N N N N N N N N N N N Y N N N N 79 15 1.2 53 125 46 64 11 0.01 1.25 2.61 0.02 85.3
21 53 M 1.65 63 95 23.14 130 90 86 N Y N N Y N N N N N N y N Y N N 212 295 179 9.8 31 1.1 81 131 30 88 16 0.71 1.96 2.47 0.92 16.2
22 43 F 1.52 53 86 22.94 120 60 78 N N N N N N N N N N N Y N N N N 73 88 15 1.05 56 157 48 90 11 2.73 1.19 2.87 0.07 65
23 45 F 1.56 51 86 20.96 110 70 68 N N N N N N N N N N N Y N N N N 120 80 33 1.2 115 175 40 108 23 5.77 1.08 3.24 0.18 54.5
24 60 F 1.64 77 110 28.63 120 80 76 N Y Y N N N N N N N N Y N N N N 125 184 18 1.2 86 184 38 119 17 2.36 1.3 2.71 0.08 59.7
25 50 M 1.72 77 98 26.03 120 70 82 N N N N N N N N N N N Y N Y Y N 101 79 18 1.26 495 201 39 101 99 1.21 1.24 3.36 0.06 66.1
26 60 M 1.69 77 97 26.96 130 80 84 N Y N N N N N N N N N Y N N N N 80 135 26 1.3 147 198 46 118 29 4.1 1.04 2.65 0.09 59.3
27 65 M 1.64 61 70 22.68 130 60 84 N N N N N N N N N Y Y N N N N N 99 121 16 1.29 80 161 36 102 16 4.17 1.27 3.13 0.02 57.8
28 52 M 1.65 70 86 25.71 140 90 66 N N Y N N N N N N N N Y N Y Y N 170 9.3 16 0.9 156 191 49 106 31 1.46 1.17 2.02 0.65 97.9
29 60 F 1.52 58 106 25.10 130 80 72 N Y Y N N N N N N N N Y N N N N 84 254 6.5 18 0.8 114 82 20 44 23 2.58 1.24 2.3 1.1 80.1
30 60 M 1.57 74 113 30.02 140 70 70 N Y N N N N N N N N N Y N N N N 75 96 42 1.5 89 117 28 74 18 3.3 0.96 4.46 0.6 49.9
31 33 F 1.54 55 84 23.19 110 70 76 N N N N N N N N N Y N N N N N N 98 20 0.4 80 158 42 103 14 2.53 1.22 3.23 1.04 136.9
32 40 F 1.48 51 88 23.28 120 80 80 N N N N N N N N N N N Y N N N N 146 15 1 49 111 31 64 16 4.79 1.42 2.89 0.1 70.4
33 75 M 1.7 54 83 18.69 130 80 76 N N Y N N N N N N N N Y N N N N 124 175 232 7.6 22 1.4 150 192 43 116 30 3.75 1.31 2.05 1.73 48.8
34 48 M 1.73 68 93 22.72 120 70 74 N N Y N N N N N N N N Y N Y Y N 235 425 7.6 22 1.2 162 224 36 78 27 1.86 1.25 2.32 0.08 71.1
35 40 M 1.61 50 73 19.29 120 80 78 N N N N N N N N N Y N N N N N N 85 32 1.5 165 184 38 105 33 2.89 1.17 2.58 0.8 57.4
36 52 M 1.72 51 78 17.24 120 70 86 N N N N N N N N N N N Y N Y Y n 95 21 1.2 78 155 42 94 16 2.9 1.45 3.16 1.12 69.1
37 39 M 1.53 66 90 28.19 110 70 82 N N Y N N Y N N N Y Y N N Y Y N 331 420 9.2 29 1.4 128 97 32 50 26 0.04 1.86 3.66 0.09 62.8
38 51 M 1.69 75 76 26.26 110 80 84 N N N N N N Y N N N N Y N N N Y 97 214 6.2 23 1.5 436 195 31 100 87 1.41 1.15 3.43 0.05 50.9
39 53 F 1.5 79.7 85 35.42 140 80 84 N N N N N N N N N N N Y N N N N 88 109 24 1.1 94 147 28 93 19 1.28 1.08 3.06 0.1 57.3
40 52 M 1.71 67 80 22.91 100 70 88 N N Y N N N N N N Y N N N N Y N 170 314 8.2 26 1.43 88 127 33 75 18 2.57 1.25 3.05 0.09 55.9
41 58 M 1.63 65 80 24.46 130 80 84 N N N N N N N Y N Y N N N N N N 91 142 19 1.4 88 147 29 94 18 1.11 1.02 2.36 0.43 55
42 52 M 1.72 68 76 22.99 130 80 68 N N N N N N N N N N N Y N N N N 90 116 28 1.13 72 196 45 122 14 1.08 1.18 3.37 0.06 74.3
43 50 F 1.45 56 103 26.63 110 70 76 N N Y N N N N N N N N Y N N N N 324 414 8.6 17 0.92 113 185 39 120 23 2.39 1.29 3.19 0.93 72.6
44 52 M 1.54 78 107 32.89 110 70 88 N N N N N N N N N N N Y N N N N 101 153 21 1.38 95 139 38 79 19 4.09 1.25 3.34 0.07 58.4
45 31 F 1.44 62 62 29.90 120 80 78 N Y N N N N N N N N N Y N N N N 98 20 1 113 205 41 122 23 47.04 0.71 2.34 0.09 75
46 24 M 1.63 44 63 16.56 110 80 86 N N N N N N N N N N N Y N N N N 112 2.83 15 1.1 116 128 21 81 23 1.04 1.69 2.22 0.12 93.5
47 20 M 1.495 41.5 73 18.57 130 80 80 N N N N N N N N N N N Y N N N N 74 16 1 69 171 37 93 14 2.33 1.86 3.66 0.12 107.9
48 26 F 1.46 65 102 30.49 110 70 74 N N N N N N N N N N N Y N N N N 76 18 0.92 68 182 42 108 42 4.78 1.1 2.74 0.09 85.9
49 32 F 1.5 57 83 25.33 110 80 78 N N N Y N N N N N N N Y N N N N 86 24 0.9 84 118 37 64 17 47.64 0.71 2.34 0.05 84.6
50 56 F 1.44 49 94 23.63 180 110 80 N Y N N N N N N N N N Y N N N N 84 16 1 85 181 43 101 17 1.58 1.48 2.88 0.23 62.9



































































































































































































































































































52 29 F 1.5 68.6 92 30.49 110 80 84 N N N N N N N N N Y N N N N N N 98 113 18 0.88 43 121 38 72 9 1 1.55 2.89 0.08 90
53 26 F 1.57 92.5 124 37.53 110 80 86 N N N N N N N N N N N Y N N N N 86 124 19 0.78 102 133 35 79 20 9.41 1.07 3.21 0.08 104.9
54 61 M 1.56 63 93 25.89 170 80 84 N Y N N N N N Y N N N Y N N N N 88 140 37 1.3 97 138 44 75 19 2.12 1.31 3.06 0.06 58.9
55 61 M 1.66 62 91 22.50 120 80 84 N N N N N N N N N N N Y N N N N 93 109 25 1.18 77 169 40 104 15 1.69 1.4 3.23 0.14 66.2
56 60 M 1.61 54.6 78 21.06 140 100 84 N Y N N N N N N N N N Y N N Y N 99 131 34 2.04 98 138 42 79 20 0.9 1.75 3.28 0.3 34.4
57 41 M 1.65 73.7 90 27.07 130 90 84 N N N N N N N N N N N Y N N Y N 95 85 25 1.4 98 167 50 92 20 2.36 1.25 2.89 0.04 62
58 27 M 1.66 49.3 67 17.89 110 80 78 N N N N N N N N N N N Y N Y Y N 95 132 17 1.09 49 161 60 84 10 1.46 1.33 3.41 0.07 92.5
59 62 M 1.68 65 88 23.03 110 60 84 N N N N N N N N N N N Y N N N N 94 143 30 1.2 65 160 39 97 13 0.6 1.18 2.57 0.08 64.4
60 57 F 1.61 71.5 90 27.58 100 80 76 N N Y N N N N N N N N Y N N N N 115 239 7.2 20 0.9 122 197 45 113 24 2.48 1.13 3.13 0.12 71
61 49 F 1.61 61.5 100 23.73 120 80 84 N N Y N N N N N N N N Y N N N N 359 439 8.8 16 0.96 65 141 44 75 32 2.61 1.28 4.29 0.09 69.4
62 69 M 1.72 74 96 25.01 130 80 76 N N N N N N N N N N N Y N N N N 97 154 33 1.2 134 159 29 96 27 2.33 1.07 4.29 0.01 61.3
63 62 F 1.45 61.8 92 29.39 140 90 80 N Y N N N N N N N N N Y N N N N 83 124 19 0.8 151 189 35 115 30 3.36 1.37 3.27 0.12 79
64 28 M 1.66 78.7 95 28.56 110 70 84 N N N N N N N N N N N Y N Y N N 92 115 15 1.2 100 193 64 100 20 2.42 1.47 3.95 0.09 81.8
65 37 M 1.72 80.6 80 27.24 110 80 84 N N Y N N N N N N N N Y N N N N 392 588 10.1 39 1.5 306 237 42 137 61 1.49 1.39 2.81 0.1 58.6
66 61 M 1.72 80.6 96 27.24 110 80 84 N Y N N N N N N N N N Y N Y N N 87 102 25 1.4 90 170 32 103 18 5.86 1.22 3.2 0.01 53.8
67 75 F 1.58 58 100 23.23 190 100 80 N N Y Y Y N Y N N N N Y N N N Y 153 249 7.7 20 1 240 205 33 116 48 2.52 1.32 1.42 0.57 62.1
68 22 F 1.54 57 85 24.03 110 80 90 N N N N N N N N N N N Y N N N N 90 16 0.9 98 181 46 76 20 1.33 1.54 3.78 0.09 90.8
69 43 F 1.48 49 84 22.37 110 70 72 N N N N N N N N N N N Y N N N N 95 25 0.9 81 198 41 121 16 3.17 0.98 3.77 0.08 78.3
70 20 F 1.42 31 60 15.37 100 70 68 N N N N N N N N N N N Y N N N N 101 25 0.9 79 115 31 63 16 3 1.27 3.58 0.12 92
71 70 F 1.51 49 86 21.49 110 70 72 N Y Y N N N N N N N N Y N N N N 139 305 >500 12.8 30 1.6 87 115 37 61 17 3.9 1.03 2.31 0.003 32.3
72 70 M 1.72 80 98 27.04 120 80 84 N Y N Y N N N N N N N Y N N N N 103 138 20 1.3 217 214 36 128 43 4.51 1.27 2.69 0.08 55.3
73 40 F 1.55 80 109 33.30 130 90 86 N N N Y N N N N N N N Y N N N N 88 142 15 0.9 114 157 43 85 23 4.32 1.17 2.91 0.07 80
74 52 M 1.57 66 98 26.78 130 70 86 N Y Y N N N N Y N N N Y N N Y N 98 172 6.9 15 1 105 109 29 57 21 6.55 1.59 2.03 0.26 86.2
75 40 M 1.69 57.2 78 20.03 110 80 86 N N N N N N N N N N N Y N N N N 84 129 16 1.1 186 210 49 121 37 0.82 1.31 2.81 0.14 83.5
76 55 M 1.65 119 134 43.71 150 80 80 N N N Y N N N N N N N Y N N N N 211 271 8.1 27 1.9 120 239 54 144 24 1.36 1.53 1.69 0.3 29.2
77 65 F 1.43 41 80 20.05 130 100 86 N Y Y N N N N N N N N Y N N N N 79 22 1 73 154 55 81 15 1.34 1.58 2.14 0.17 59.1
78 55 M 1.68 86 96 30.47 110 80 74 N N Y N Y N N N N N N Y N Y Y N 161 215 6.7 22 1.1 180 189 29 116 36 6.79 1.23 3.04 0.08 75.2
79 45 F 1.53 51 94 21.79 120 70 80 N N N N N N N N N Y Y N N N N N 77 16 1 116 209 55 118 23 2.9 1 3.71 0.07 68
80 58 M 1.66 84 111 30.48 140 90 84 N N N N N N N N N Y N N N Y Y N 115 95 15 1.04 86 177 46 99 17 2.48 1.27 2.17 0.08 78.8
81 37 F 1.65 78 102 28.65 120 80 84 N N N N N N N N N N N Y N N N N 109 128 16 0.98 72 139 40 78 14 2.34 1.04 2.62 0.04 73.7
82 36 M 1.725 57.8 81 19.42 100 60 80 N N N N N N N N N Y N N N N N N 90 116 16 1 60 141 33 87 12 1.22 1.21 3.14 0.1 96.4
83 25 M 1.65 70 78 25.71 130 80 76 N N N N N N N N N N N Y N N N Y 89 99 16 1.22 116 181 43 109 23 3.51 1.19 2.13 0.05 81.9
84 55 F 1.47 47 82 21.75 100 60 78 N N N Y N N N N N N N Y N N N N 90 129 30 1.2 253 201 43 110 51 100 0.13 0.29 0.07 50.8
85 33 F 1.63 48 76 18.07 100 80 78 N N Y N N N N N N N N Y N N N N 91 119 18 0.87 73 162 46 91 15 1.8 1.2 2.9 0.06 87.5
86 40 F 1.55 72 106 29.97 120 80 76 N N N N N N N N N N N y N N N Y 82 106 18 1.01 85 158 39 92 17 12.87 0.8 2.85 0.12 69.1
87 35 F 1.5 52.5 85 23.33 110 80 80 N N N N N N N N N N N y N N N N 91 85 19 0.97 106 173 43 105 21 3.48 1.16 3.23 0.1 75.7
88 38 F 1.48 50 86 22.83 110 70 80 N N N N N N N N N N N Y N N N N 116 15 0.97 106 173 43 105 21 1.91 1.61 3.25 0.07 74.1
89 50 F 1.55 78 78 32.47 130 90 78 N Y N N N N N N N N N Y N N N N 86 127 21 1 88 172 38 108 18 2.93 1.07 3.39 0.1 65.6
90 48 F 1.44 48 101 23.15 110 80 66 N Y N N N N N N N N N Y N N N N 132 170 8.8 18 1.2 137 260 53 162 27 0.8 1.51 2.24 0.13 53.4
91 53 F 1.55 68 86 28.30 130 90 80 N Y N N N N N N N N N Y N N N N 93 153 25 1.14 206 204 40 118 41 3.61 1.42 2.95 0.18 54.9
92 48 F 1.53 65 94 27.77 120 80 76 N N Y N N N N N N N N Y N N N N 162 172 8.2 15 0.9 131 174 47 100 26 1.96 1.36 2.61 0.04 75.6
93 54 M 1.65 93 113 34.16 160 100 84 N N N N N N N N N N N Y N N Y N 91 113 19 1.23 101 175 43 103 20 1.87 1.05 2.97 0.06 66.1
94 45 F 1.55 63 93 26.22 130 80 96 N N N N N N N N N N N Y N N N N 124 152 6.48 16 0.96 135 165 27 105 27 5.6 1.36 3.26 0.1 71.4
95 27 M 1.75 72.5 75 23.67 110 80 82 N N N N N N N N N N N Y N Y Y N 93 105 18 1.13 233 212 38 124 47 1.22 1.21 3.14 0.06 88.6
96 20 F 1.5 56 86 24.89 90 60 82 N N N N N N N N N N N Y N N N N 74 15 0.89 46 105 34 61 9 2.75 1.09 3.42 0.25 93.3
97 40 M 1.6 68 94 26.56 130 80 76 N N N N N N N N N N N Y N N Y N 91 124 4.95 22 1.01 92 148 39 87 18 3.3 1.07 3.71 0.16 92.6
98 63 M 1.6 65 101 25.39 130 80 86 N Y Y N N N N N N Y N N N N N N 101 169 5.71 39 1.09 273 123 22 63 55 2.03 1.09 2.81 0.1 54
99 41 M 1.6 54 80 21.09 180 80 66 N N N N N N N N N N N Y N N Y N 117 129 15 1.17 126 101 36 54 25 3.57 0.99 3.74 0.19 77
100 59 F 1.6 66 87 25.78 140 80 86 N Y Y Y N N N N N N N Y N N N N 116 156 7.1 15 1.06 244 253 47 151 49 2.62 1.31 2.62 0.1 57.4
101 47 F 1.53 74 105 31.61 120 80 66 N N N Y N N N N N N N Y N N N N 96 22 0.1 88 190 58 108 18 4.68 1.33 2.81 0.06 195.7



































































































































































































































































































103 32 F 1.58 32 64 12.82 90 60 82 N N N N N N N N N Y N N N N Y N 119 16 0.7 94 61 17 32 19 1.06 0.98 2 0.53 114.6
104 39 M 1.79 70 89 21.85 120 80 76 N N Y N N N N N N N N Y N Y Y N 250 366 460 8.6 15 1.2 267 177 35 106 53 1.58 1.38 3.09 0.08 75.7
105 60 M 1.62 68 90 25.91 150 90 82 N Y Y N N N N N N N N Y N N Y N 134 198 8.6 23 1.3 69 160 34 99 14 1.9 1.4 2.2 0.11 59.3
106 43 M 1.64 76 94 28.26 110 80 84 N N Y N N N N N N N N Y N N Y N 94 89 20 1.24 106 117 25 74 21 0.83 1.49 2.88 0.1 70.8
107 65 M 1.68 62.3 94 22.07 130 80 72 N N N N N N N N N Y N N N Y Y N 96 181 6.8 68 2.4 82 137 41 78 16 3.31 1.27 2.77 0.1 27.3
108 37 M 1.75 75 91 24.49 120 80 76 N N N N N N N N N N N Y N Y N N 97 140 29 1.29 161 214 46 135 32 5.26 1.09 3.42 0.07 70.4
109 69 F 1.53 68 115 29.05 150 80 68 N Y Y N Y N N N N N N y N N N N 181 270 8.5 18 1.04 157 211 37 138 31 2.64 1.14 2.58 0.12 54.8
110 20 F 1.5 65 100 28.89 100 80 68 N N N N N N N N N N N y N N n N 84 14 0.98 130 129 28 80 26 1.4 1.12 2.77 0.09 83
111 65 F 1.47 30 75 13.88 110 80 76 N N N N N N N N N Y N N N N N N 252 6.5 15 0.97 82 114 36 62 16 2.64 1.29 2.56 0.26 61.3
112 55 F 1.42 58 88 28.76 110 80 88 N Y Y N N N N N N Y N N N N N N 149 8.5 31 1.7 172 121 24 73 34 9.55 1.52 3.06 0.15 33.4
113 70 F 1.37 38 89 20.25 160 80 74 N Y N N N N N N N N N Y N N N N 112 6.6 17 0.9 64 74 39 33 13 2.61 0.92 3.48 0.39 64.8
114 47 F 1.51 55 95 24.12 130 80 70 N N N N N N N N N N N Y N N N N 87 20 0.9 174 198 55 114 35 2.24 1.16 3.06 0.07 76.1
115 36 F 1.44 40 88 19.29 120 60 88 N N N N N N N N N N N Y N N N N 103 15 1 65 125 38 74 13 1.28 1.23 2.8 0.19 72.4
116 49 F 1.45 39 76 18.55 90 60 80 N N N N N N N N N N N Y N N N N 168 5.9 21 0.9 80 193 44 123 16 4.16 1.14 2.43 0.14 75.1
117 30 M 1.68 60 78 21.26 110 80 78 N N N N N N N N N N N Y N N N N 90 100 17 1.34 47 126 36 77 9 2.05 1.48 3.37 0.09 70.6
118 40 F 1.58 40 76 16.02 110 80 76 N N N N N N N N N N N Y N N N N 77 101 18 1.17 70 149 33 94 14 3.06 1.02 3.06 0.05 58.2
119 50 M 1.64 70 88 26.03 120 80 84 N N Y N N N N N N N N Y N N Y N 125 341 8.5 18 1.3 238 177 47 97 48 1.54 1.49 3.6 0.05 63.6
120 37 F 1.55 40 70 16.65 120 70 78 N N N N N N N N N N N Y N N N N 83 137 15 1.01 139 148 30 90 28 5.07 1.16 3.02 0.15 71.1
121 23 F 1.45 55 92 26.16 90 60 78 N N N N N N N N N N N Y N N N N 98 23 0.8 46 140 49 78 9 4.4 1.32 3.17 0.03 103.9
122 50 M 1.66 74 86 26.85 120 80 64 N N Y N Y N N N N N N Y N N Y N 102 211 8.5 42 2.85 118 137 30 81 24 3.04 1.07 1.25 0.35 24.6
123 43 M 1.7 65 85 22.49 110 80 86 N N Y N N N N N N N N Y N Y N N 180 375 8.69 21 0.9 114 228 52 139 23 2.05 1.02 1.53 0.09 104.2
124 57 F 1.5 65 98 28.89 120 80 84 N N N N N N N N N N N Y N N N N 101 88 17 0.83 268 224 47 128 54 2.93 0.77 5.09 0.16 78.3
125 62 M 1.54 58 76 24.46 150 90 88 N N Y N N N N N N N N Y N N N N 163 202 9.11 36 1.67 127 168 40 101 25 2.52 1.12 1.78 3.47 43.2
126 26 F 1.51 46 87 20.17 100 70 80 N N N N N N N N N N N Y N N N N 102 15 0.7 54 135 45 79 11 3.18 1.02 2.92 0.32 119.6
127 50 F 1.55 64 114 26.64 140 80 82 N Y N N N N N N N N N Y N N N N 104 5.4 26 2.2 167 250 59 144 33 12.34 1.47 2.48 0.19 25.3
128 35 F 1.53 52 92 22.21 110 80 70 Y N N N N N N N N N N Y N N N N 151 4.9 16 0.6 134 339 67 200 27 16.75 1.04 2.13 6.9 118.1
129 68 M 1.72 76 104 25.69 120 80 76 N N N N N N N N N N N Y N N N N 136 6.63 25 1.33 123 211 33 137 25 6.63 0.88 3.2 0.11 54.5
130 40 F 1.52 60 102 25.97 120 70 72 N N N N N N N N N N N Y N N N N 99 6.75 29 1.1 83 190 41 122 17 3.39 1.07 3.05 0.12 62.8
131 58 F 1.6 70 106 27.34 110 70 68 N N N N N N N N N N N Y N N N N 78 6.08 20 0.9 295 202 41 114 59 7.91 1.04 2.33 0.08 70.5
132 34 M 1.7 76 102 26.30 130 80 76 N N N N N N N N N N N Y N N N N 90 113 15 1.31 156 133 37 95 31 17.63 1.25 3.15 0.05 70.4
133 42 M 1.6 64 88 25.00 130 80 82 N N N N N N N N N N N Y N N N N 90 106 22 0.99 197 156 27 95 39 2.51 1.25 1.07 0.05 93.6
134 52 M 1.72 76 95 25.69 120 80 88 N N N N N N N N N N N Y N N N N 92 45 1.68 77 185 37 114 15 0.33 1.19 2.86 0.14 46
135 60 M 1.58 56 74 22.43 120 80 80 N Y N N N N N N N N N Y N N y N 97 45 2.7 272 215 44 109 54 1.52 1.49 3.02 0.15 24.5
136 50 M 1.6 70 92 27.34 120 80 76 N N Y N N N N N N Y N N N N N N 230 364 7.3 15 0.9 110 142 34 85 22 2.97 0.93 2.91 0.14 99.2
137 63 M 1.62 83 107 31.63 140 90 72 N N Y N N N N N N N N Y N N y N 104 170 7.25 36 1 71 126 38 71 14 4.25 1.3 2.27 0.03 79.7
138 46 M 1.65 65 96 23.88 110 80 78 N N Y N N N N N N Y N N N N Y N 193 289 7.9 22 1.01 146 148 31 87 29 2.23 0.98 3.36 0.26 88.8
139 42 M 1.6 67 86 26.17 110 80 88 N N Y N N N N N N N N Y N N Y N 108 202 8.2 41 2.44 110 149 40 86 22 1.53 1.55 2.95 1.77 31.4
140 43 M 1.45 54 90 25.68 110 70 76 N N N Y N N N N N N N Y N N N N 103 114 15 0.84 111 122 24 72 22 6.91 0.83 2.75 0.11 85.1
141 56 M 1.52 60 93 25.97 110 60 88 N Y Y N N N N N N N N y N N N N 186 10.6 28 1.21 177 198 32 98 25 4.34 1.02 2.62 0.16 66.5
142 52 F 1.63 99.6 120 37.49 130 90 86 N Y Y N N N N N N N N Y N N N N 166 8.2 15 1 196 250 38 101 42 4.67 1.24 2.9 0.23 64.7
143 39 F 1.56 63 99 25.89 100 70 99 N N N N N N N N N N N Y N N N N 108 15 0.8 135 94 13 58 27 3.12 1.11 2.43 0.19 92.9
144 50 F 1.68 74 112 26.22 140 100 78 N N N N N N N N N Y N N N N N N 90 99 129 15 0.9 71 185 39 117 14 2.59 1.32 1.49 0.13 74.6
145 46 M 1.68 76 88 26.93 120 80 76 N N Y N N N N N N N N Y N N N N 135 159 7.6 29 1 132 150 49 77 26 2.43 1.1 3.4 0.11 89.9
146 49 M 1.65 68 98 24.98 140 70 82 N N N N N N N N N N N Y N N Y N 99 123 30 1.17 55 126 33 78 11 2.43 1.1 3.4 0.08 72.8
147 47 M 1.58 72 103 28.84 130 80 76 N N N N N N N N N N N Y N Y Y N 135 71 29 1.16 132 150 49 77 26 1.12 0.86 3.08 0.32 74.6
148 47 F 1.5 46 65 20.44 120 90 86 N N N N N N N N N N N Y N N N N 103 161 24 1.04 115 120 32 78 18 4.02 1.44 2.7 0.08 63.9
149 38 M 1.67 60 84 21.51 120 80 76 Y N N N N N N Y N N N Y N N Y N 104 15 1.08 462 158 34 87 92 1.49 1.09 2.91 0.07 86.6
150 30 F 1.6 62 82 24.22 110 70 68 N N N N N N N N N N N Y N N N N 145 200 7.18 23 1.17 155 217 42 135 31 2.37 0.98 3.02 0.07 62.5
151 42 M 1.65 76 98 27.92 110 70 72 N Y N N N N N N N Y Y N N N Y N 108 102 22 1.38 107 144 34 89 21 1.77 1.35 3.53 0.09 62.9
152 50 F 1.6 80 108 31.25 140 90 82 N N N N N N N N N N N y N N N N 168 192 6.5 32 1 143 170 43 95 43 29 1.08 1.79 0.19 65.6



































































































































































































































































































154 40 M 1.64 88 108 32.72 150 80 86 N N N N N N N N N N N Y N N N N 98 27 1.1 175 128 29 66 35 3.47 1.49 3.77 0.07 83.5
155 50 M 1.46 75 102 35.18 120 80 88 N Y Y Y N N N N N N N Y N N N N 130 170 311 11.5 69 1.6 189 141 24 85 38 150 0.3 10 0.53 49.5
156 26 M 1.66 76 94 27.58 120 80 90 N N N N N N N N N N N Y Y N Y N 116 31 1.3 121 178 32 89 24 1.71 1.5 2.53 0.12 75.3
157 32 r 1.69 54 82 18.91 100 60 80 N N N N N N N N N N N Y N N N N 94 130 19 1 135 185 40 88 25 1.95 1.78 3.36 0.09 99.1
158 71 F 1.58 62 99 24.84 130 80 82 N N N N N N N N N N N Y N N N N 96 132 27 1.05 182 171 29 109 36 2.41 1.09 3.12 0.05 53.4
159 39 M 1.7 78 106 26.99 120 70 78 N N N N N N N N N Y N N N N N N 106 111 29 1.34 98 171 35 112 20 2.75 1.02 1.32 0.13 66.3
160 38 F 1.48 51 96 23.28 110 80 78 N N N N N N N N N N N Y N N N N 84 125 5.9 15 0.94 107 202 45 113 21 2.25 1.1 3.4 0.07 77
161 33 F 1.54 66 86 27.83 130 80 78 N N N N N N N N N N N Y N N N N 129 17 0.79 72 140 34 87 14 0.66 1.2 2.93 0.08 98.4
162 55 F 1.54 72 108 30.36 140 90 78 N Y N N N N N N N N N Y N N N N 134 6.8 26 0.95 67 129 36 75 13 1.52 1.19 3.11 0.1 67.4
163 45 F 1.54 68 98 28.67 100 60 80 N N N N N N N N N N N Y N N N N 146 23 0.82 44 148 44 85 9 1.82 1.24 3.31 0.09 86.4
164 65 M 1.72 62 106 20.96 130 80 68 N N Y N N N N N N N N Y N N N N 98 4.5 27 1.2 95 152 47 86 19 1.52 1.29 3.28 0.09 63.1
165 48 M 1.55 56 86 23.31 120 80 88 N N Y N N N N N N N N Y N Y Y N 101 8.75 22 1.14 175 191 58 93 35 10.62 1.13 3.17 0.13 75.6
166 55 F 1.62 60 86 22.86 100 60 88 N N Y N N N N N N N N Y N N N N 220 232 484 9.61 85 2.7 196 159 28 99 39 1.25 1.17 1.21 10.69 19.1
167 55 F 1.59 58 115 22.94 130 70 78 N N Y N N N N N N N N Y N N N N 359 382 9.2 15 0.8 108 129 35 74 22 3.27 1.38 1.5 1.3 83
168 21 F 1.55 59 92 24.56 130 70 88 Y N N N N N N N N N N Y N N N N 88 115 15 84 94 16 63 17 1.94 0.67 2.67 4 3
169 31 F 1.75 75 96 24.49 120 80 80 Y N N N N N N N N N N Y N N N N 71 91 26 0.95 95 188 43 113 19 1.37 1.11 2.97 0.89 79.8
170 45 M 1.65 62 98 22.77 120 80 68 N N N N N N N N N N N Y N N Y N 163 302 7.2 27 1.18 104 187 42 123 21 3.58 1.33 3.69 0.09 74.1
171 25 M 1.65 68 82 24.98 120 70 66 N N N N N N N N N N N Y N N N N 63 128 26 1.28 128 121 29 68 26 4.74 1.43 3.89 0.27 77.3
172 22 F 1.52 48 70 20.78 110 70 76 N N N N N N N N N N N Y N N N N 61 16 0.79 73 150 55 78 15 2.47 1.02 3.13 0.16 106.3
173 58 M 1.58 65 76 26.04 130 90 78 N Y Y N N N N N N N N Y N N N N 87 160 41 2.27 303 181 30 110 61 1.33 1.02 4.03 0.67 30.7
174 55 F 1.45 55 97 26.16 110 80 76 N N N Y N N N N N N N Y N N N N 87 135 19 1.01 126 190 40 76 22 2.35 1.27 2.43 0.14 65.8
175 55 F 152 62 84 0.00 110 82 78 N N N N N N N N N N N Y N N N N 176 133 7.5 16 0.89 142 210 49 124 28 2.45 1.22 3.14 0.19 73
176 29 F 1.5 54 84 24.00 120 70 68 N N N N N N N N N N N Y N N N N 75 16 1 70 197 47 122 14 2.22 0.95 2.83 0.05 76.1
177 40 F 1.48 60 86 27.39 120 80 76 N N N N N N N N N N N Y N N N N 72 108 22 0.89 94 199 47 127 19 2.81 1.09 2.05 0.07 81.1
178 57 M 1.62 83 114 31.63 140 90 82 N N N N N N N N N Y Y N N N N Y 102 18 1.08 225 144 28 82 45 3.32 1.11 3.47 0.09 75.8
179 51 F 1.54 86 114 36.26 130 80 80 N N N N N N N N N N N Y N N N N 64 19 1.02 90 133 37 84 18 2.92 1.05 2.83 0.14 63.6
180 37 F 1.58 96 121 38.46 130 90 76 N N N N N N N N N N N Y N N N N 164 162 6.8 20 0.93 77 175 39 110 15 0.78 1.25 2.65 0.09 78.5
181 44 M 1.7 91.5 106 31.66 120 90 84 N N N N N N N N N N N Y N Y N N 91 109 24 1.56 169 196 39 121 34 2.25 1.05 3.7 0.05 53.2
182 64 M 1.56 75 111 30.82 150 100 86 N N Y N N N N N N Y N N N N N N 91 148 18 1.17 128 215 46 130 26 4.24 1.1 3.17 0.09 65.5
183 43 M 1.65 68 102 24.98 170 100 84 N Y Y N N N N N N N N Y N N Y N 74 127 21 1.24 114 148 29 95 23 2.29 1.58 3.59 0.14 70.8
184 49 M 1.62 76 108 28.96 110 70 78 N N Y N N N N N N N N Y N N N N 218 350 8.5 19 0.93 163 236 55 140 33 0.84 1.17 3.39 1.36 96.1
185 28 F 1.56 62 96 25.48 110 70 68 N N N N N N N N N N N Y N N N N 84 22 0.87 78 174 38 108 16 1.2 1.11 2.91 0.08 90.7
186 48 F 1.62 78.5 100 29.91 110 60 76 N N  N N N N N N N N N Y N N N N 79 16 0.85 40 157 45 99 8 0.76 1.21 2.9 0.07 81
187 49 M 1.69 80.8 106 28.29 100 60 82 N N N N N N N N N Y Y N N Y Y N 146 42 2.05 293 113 25 59 59 2.59 1 3.99 0.23 36.9
188 72 F 1.4 55 102 28.06 150 80 72 N Y N N N N N N N Y N N N N N N 120 21 1.2 82 183 44 111 16 2.87 1.17 2.7 0.26 45.1
189 55 F 1.48 40 86 18.26 180 90 68 N Y N N N N N N N N N Y N N N N 151 8.5 49 1.3 187 186 42 113 37 2.29 1.23 2.74 0.09 46.1
190 60 F 1.55 50 90 20.81 140 70 66 N Y N N N N N N N N N Y N N N N 79 6.06 27 0.92 75 154 50 89 15 0.62 1.03 2.83 0.29 67.7
191 50 F 1.48 56 91 25.57 110 70 82 N N N N N N N N N N N Y N N N N 84 109 4.8 21 0.9 62 172 54 96 12 2.54 1.37 3.11 0.09 74.6
192 20 F 1.61 40 73 15.43 120 70 80 N N N N N N N N N N N Y N N N N 112 31 0.8 108 162 48 82 21 0.28 1.92 3.09 0.19 106.1
193 39 F 1.68 60 90 21.26 120 80 76 N N N N N N N N N N N Y N N N N 112 15 1 181 151 29 88 36 2.47 1.09 2.66 0.21 70.6
194 64 M 1.66 56 90 20.32 90 60 70 N N N N Y N Y N N Y Y N N Y N N 72 155 28 1.24 77 101 29 62 15 1.96 1.28 3 0.97 61.1
195 59 F 1.46 44.2 90 20.74 110 70 68 N N N N N N N N N N N Y N N N N 91 154 22 0.87 112 151 42 93 22 2.54 1.14 3.44 0.19 72.9
196 69 F 1.62 78 106 29.72 100 70 86 Y Y Y N N N N N N N N Y N N N N 148 8.5 104 2.4 142 101 36 60 28 1.72 1.52 1.78 1.3 19.9
197 53 M 1.7 70.5 96 24.39 110 70 82 N Y Y N N N N N N N N Y N N N N 77 221 7.2 19 1.1 265 206 38 119 53 4.43 1.37 2.74 0.11 76.2
198 52 M 1.61 60 88 23.15 110 80 76 N N N N N N N N N N N Y N Y N N 74 93 18 1.04 51 105 32 60 10 3.94 1.13 3.24 0.1 82.2
199 68 M 1.67 67 97 24.02 140 90 78 N N Y N N N N N N N N Y Y N N N 162 193 7.2 23 1.08 242 161 33 94 48 1.83 1.51 2.79 0.12 70.2
200 55 M 1.7 90 110 31.14 170 100 84 N Y Y N N N N N N N N Y N N N N 179 227 8.2 27 1.52 190 195 37 120 38 2.12 1.14 3.33 0.28 50.8
201 51 M 1.67 76 103 27.25 110 80 78 N N N N N N N N N N N Y N N N N 94 138 27 1.16 125 206 35 138 25 1.52 1.38 3.48 0.06 72.5
202 37 F 1.565 64 102 26.13 110 60 84 N N N N N N N N N N N Y N N N N 78 89 30 0.86 137 219 51 125 27 5.33 0.92 3.42 0.1 86.3
203 27 M 1.69 71 89 24.86 100 60 76 N N N N N N N N N N N Y N N N N 79 91 21 0.97 63 115 28 69 1.1 1.75 1.22 3.31 0.08 106.5



































































































































































































































































































205 50 M 1.64 85 111 31.60 130 80 88 N N N N N N N N N y Y N N N N N 100 28 1.6 99 180 43 110 20 6.73 1.12 2.88 0.2 49.5
206 65 M 1.6 75 110 29.30 150 90 76 N Y N N N N N N N Y Y N N Y Y N 140 359 7.5 31 1.4 88 207 58 120 18 4.1 1.1 3.17 0.07 52.4
207 43 M 1.68 65.9 96 23.35 140 80 72 N N N N N N N N N  N N Y N N Y N 92 18 0.93 79 139 30 87 16 1.58 1.53 3.23 0.19 100.2
208 37 F 1.48 60 94 27.39 120 80 88 N N N N N N N N N N N Y N N N N 127 17 0.87 116 172 43 101 23 2.41 1.15 3.54 0.3 85.1
209 53 M 1.72 78 110 26.37 140 80 78 N N N N N N N N N N N Y N N N N 92 31 1.13 67 168 39 106 13 2.99 1.12 3.3 0.06 73.8
210 33 M 1.72 68 96 22.99 120 80 84 N N N N N N N N N N N Y N N N N 105 18 0.94 102 147 31 90 20 2.55 1.19 3.88 0.05 106.1
211 41 F 1.53 81 109 34.60 120 80 82 N N N N N N N N N N N Y N N N N 101 16 0.8 72 184 37 122 14 3.49 1.09 2.98 0.04 91.6
212 50 M 1.64 55 76 20.45 140 80 78 N Y Y N N N N N N N N Y N N Y N 112 258 7.6 104 5.5 64 154 38 30 13 2.26 1.12 1.91 9.05 11.1
213 34 M 1.63 59.5 84 22.39 110 70 88 N N N N N N N N N N N Y Y Y Y N 91 16 0.9 237 616 91 369 47 1.43 1.43 3.46 1.28 111
214 73 M 1.65 62.5 106 22.96 120 70 70 N Y N N N N N N N N N Y N N N N 115 15 1.2 115 147 21 94 23 2.45 1.24 2.65 0.21 59.6
215 60 M 1.665 54.5 89 19.66 130 80 70 N N N N N N N N N Y N N N Y Y N 100 198 7.8 19 1.1 100 142 27 95 20 2.76 1.18 3.14 0.69 72.6
216 73 F 1.48 55 83 25.11 110 70 66 N N N N N N N N N N N Y N N N N 78 30 0.93 53 177 57 101 11 3.42 1.26 2.94 0.14 61
217 45 F 1.58 63.5 95 25.44 120 80 76 N N N Y N N N N N N N Y N N N Y 100 21 0.93 69 135 39 81 14 0.84 1.62 3.14 0.05 74.2
218 45 M 1.635 66.5 98 24.88 120 80 78 N N Y N N N N N N N N Y N N N N 139 162 7 19 1.17 240 119 26 64 48 1.55 1.14 3.01 0.11 74.8
219 20 M 1.6 66.5 86 25.98 120 80 62 N N N N N N N N N N N Y N N N N 71 17 1.06 102 105 35 58 20 3.29 1.59 3.73 0.09 100.5
220 28 M 1.635 64 90 23.94 110 80 78 N N N N N N N N N N N Y N N N N 105 41 0.92 43 108 41 55 9 1.07 1.55 4.04 0.11 112.8
221 43 M 1.58 68 104 27.24 120 80 76 N N N N N N N N N N N Y N N N N 97 18 1.03 89 140 38 83 18 2.45 1.13 3.46 0.07 88.6
222 61 M 1.7 74 108 25.61 130 80 82 N Y Y N N N N N N N N Y N N N N 151 6.8 21 1.3 78 221 73 128 16 3.94 1.44 2.73 0.14 58.9
223 32 M 1.705 74.2 102 25.52 120 80 78 N N N N N N N N N N N Y N N Y N 101 16 0.81 310 271 48 171 62 2.13 0.97 2.26 0.19 117.6
224 40 M 1.605 67.5 102 26.20 120 80 80 N N N N N N N N N N N Y N Y N N 93 20 1.12 271 181 30 112 54 3.76 1.26 3.36 0.08 81.7
225 65 F 1.52 74 104 32.03 120 60 80 N N Y N N N N N N N N Y N N N N 105 235 6.43 17 0.79 83 171 40 106 17 6.68 0.9 2.78 0.08 78.6
226 43 M 1.7 76 107 26.30 120 80 76 N N N N N N N N N N N Y N N N N 114 194 6.5 22 1.37 123 193 35 123 25 2.29 1.17 3.53 0.05 62.7
227 57 M 1.62 56 76 21.34 110 80 78 N N Y N N N N N N N N Y N N N N 266 320 9 28 0.98 48 106 44 57 10 2.92 1.31 3.01 0.11 85.2
228 35 F 1.6 62 84 24.22 120 80 72 N N Y N N N N N N N N Y N N N N 230 278 7.6 14 0.81 79 148 52 80 16 2.41 1.18 2.68 0.12 94.1
229 39 F 1.55 66 90 27.47 120 80 76 N N N N N N N N N N N Y N N N N 129 27 0.96 172 168 37 104 34 1.08 1.65 3.94 0.05 74.5
230 31 F 1.53 68 115 29.05 120 80 76 N N N N N N N N N N N Y N N N N 101 108 24 0.82 73 169 43 103 15 2.39 1.17 4.1 0.06 95.3
231 45 F 1.57 79.6 90 32.29 150 100 78 N Y N N N N N N N N N Y N N N N 96 110 22 0.8 117 280 61 180 23 2.62 1.24 3.31 0.1 89
232 44 F 1.49 66.4 96 29.91 100 70 72 N N N Y N N N N N N N Y N N N N 127 143 30 0.9 126 190 40 76 22 29.3 0.81 2.41 0.2 77.8
233 57 F 1.58 73.8 100 29.56 120 80 80 N N Y N N N N N N N N Y N N N N 142 202 7.18 22 0.89 149 226 39 145 30 1.87 1.42 2.71 0.03 71.9
234 63 F 1.56 66.8 107 27.45 110 70 76 N N Y N N N N N N N N Y N N N N 187 280 8.39 17 0.95 194 241 42 156 39 2.76 1.13 2.73 0.13 63.7
235 58 M 1.7 92.1 118 31.87 130 90 68 N Y Y N N N N N N Y N N N N N N 231 272 9.22 26 0.94 170 216 48 131 34 1.26 1.41 3.48 0.13 89
236 29 M 1.66 70.9 93 25.73 140 90 76 N N N N N N N Y N N N Y N N Y N 88 94 18 1.13 64 152 38 96 13 1.45 1.46 4.66 0.06 87.3
237 47 F 1.47 65.6 109 30.36 120 80 78 N N N N N N N N N N N Y N N N N 94 92 24 1.02 65 162 41 98 13 12 1.41 2.95 0.09 65.2
238 57 M 1.675 77.1 98 27.48 130 90 84 N N N N N N N N N N N Y N N Y N 103 129 21 1.04 227 184 32 106 45 3.02 1.24 3.7 0.14 79.3
239 68 M 1.65 65.1 95 23.91 110 70 76 N N Y N N N N N N Y N N N N N N 214 364 38 0.92 131 178 43 106 26 1.74 1.06 3.67 0.21 85.2
240 40 F 1.6 70.7 103 27.62 100 70 86 N N N N N N N N N Y Y N N N N N 106 111 25 0.98 126 177 35 108 25 2.42 1.36 3.38 0.13 72.2
241 42 F 1.6 78.7 100 30.74 126 80 88 N N N N N N N N N N N Y N N N N 107 77 18 0.95 89 180 58 99 18 5.21 1.04 3.17 0.32 73.9
242 50 M 1.68 73.2 93 25.94 110 80 80 N Y Y N Y N N N N N N Y N Y Y N 274 439 7.42 24 1.14 151 191 45 111 30 1.93 1.28 3.71 0.08 74.6
243 20 F 1.42 40 72 19.84 130 80 76 N N N N N N N N N N N Y N N N N 96 31 1 83 103 29 64 17 2.24 1.16 3.06 0.6 81
244 46 F 1.515 44 79 19.17 150 90 80 N Y N N N N N N N N N Y N N N N 80 123 37 1 333 278 43 160 67 2.47 1.08 2.34 0.11 67.5
245 46 F 1.5 64 82 28.44 100 70 78 N N N N N N N N N N N Y N N N N 305 540 10.5 24 0.9 85 117 30 67 17 2.46 1 3.23 0.12 76.7
246 52 F 1.5 65 101 28.89 140 100 76 N Y Y N N Y N N N N N Y N N N N 225 217 10.1 37 1.5 266 282 52 175 53 3.19 1.21 2.02 0.5 39.6
247 70 F 1.46 58 108 27.21 110 60 76 N Y N N N N N N N N N Y N N N N 201 8.5 41 1 241 210 36 127 48 2.38 1.05 4.44 0.23 57
248 48 F 1.5 68 101 30.22 140 80 82 N N N Y N N N N N N N Y N N N N 87 22 0.9 153 184 37 111 31 3.81 1.31 2.8 0.4 75.6
249 20 F 1.45 42 74 19.98 120 80 78 N N N N N N N N Y N N Y N N N N 100 20 0.8 87 130 35 76 17 3.89 1.4 3.62 0.1 106.1
250 40 M 1.7 85 98 29.41 120 80 86 N N Y N N N N N N N N Y N N Y N 310 430 8.6 24 1.12 97 179 43 108 19 1.19 1.14 3.11 0.21 81.7
251 48 F 1.47 72 107 33.32 140 80 80 N N N Y N N N N N N N Y N N N N 95 17 0.8 80 169 45 101 16 2.01 0.87 3.62 0.17 87.2
252 50 M 1.55 52 76 21.64 110 80 88 N N N N N N N N N Y N N N Y Y N 64 107 15 1 195 142 26 83 39 2.39 1.21 3.56 0.16 86.2
253 76 M 1.55 60 91 24.97 120 80 76 N N N N N N N N N N N Y N N N N 92 141 28 1 190 154 29 92 38 18.93 0.799 3.33 0.22 72.8
254 57 M 1.58 76 104 30.44 170 110 68 N N N N N N N N N N N Y N N N N 88 134 37 1.7 237 190 35 115 47 1.41 1.21 2.83 1.29 43.8



































































































































































































































































































256 42 M 1.67 84.2 100 30.19 120 80 76 N N N N N N N N N Y N N N N N N 7.2 17 1.1 169 196 39 123 84 1.66 1.6 3.21 0.12 82.4
257 35 F 1.51 62.8 94 27.54 110 80 76 N N N N N N N N N N N Y N N N N 86 26 0.8 172 257 50 163 34 1.12 1.06 3.38 0.12 95.5
258 65 M 1.59 68.1 106 26.94 120 70 82 N N N N N N N N N Y N Y N N Y N 227 336 7.5 17 1 192 157 34 91 38 1.02 1.3 2.84 0.15 78.6
259 52 M 1.64 73.1 94 27.18 140 100 78 N N N N N N N N N N N Y N N Y N 112 152 15 1 65 172 41 108 13 4.51 1.46 3.09 0.01 86.2
260 46 M 1.64 61.6 88 22.90 170 100 72 N N N N N N N N N N N Y N Y Y N 85 141 21 1 124 200 41 124 25 1.59 1.08 3.39 0.16 89.9
261 52 M 1.61 50 80 19.29 100 70 78 N N N N N N N N N N N Y N N N N 91 192 23 0.7 105 143 33 88 21 1.09 0.98 3.16 0.28 108.5
262 23 M 1.695 59.6 83 20.74 120 80 84 N N N N N N N N N N N Y N Y Y N 95 116 15 1 63 135 60 66 13 3.16 1.27 2.6 0.1 105.6
263 73 M 1.67 71.4 101 25.60 140 70 80 N Y N N N N N N N Y Y N N N N N 105 144 25 1.1 62 157 47 92 12 2.79 1.43 3.49 0.1 66.2
264 28 F 1.59 60.1 79 23.77 120 80 86 N N N N N N N N N N N Y N N N N 92 107 18 0.8 55 148 40 91 11 2.76 1.16 3.14 0.09 100.3
265 49 M 1.71 73.2 91 25.03 120 86 78 N Y Y N N N N N N N N Y N N N N 134 233 7.8 26 1.23 240 203 43 116 48 2.93 1.22 3.49 0.08 68.5
266 31 M 1.69 73 90 25.56 120 80 84 N N N N N N N N N N N Y N N N N 111 220 5.8 26 1.08 59 226 49 145 12 3.93 1.04 2.71 0.09 91
267 56 M 1.64 70.3 96 26.14 120 90 82 N Y Y N N N N N Y Y N N N Y Y N 123 303 8.3 27 1.81 510 147 28 78 102 4.7 1.04 2.9 0.44 40.9
268 29 F 1.649 49 75 18.02 110 80 76 N N N N N N N N N N N Y N N N N 99 24 0.9 126 175 35 84 15 2.16 1.78 3.1 0.08 86.4
269 67 F 1.5 62 106 27.56 160 90 76 N Y Y N N N N N N N N Y N N N N 249 346 7.3 23 1.2 191 118 38 59 38 1.91 1.8 3.64 0.15 46.7
270 54 M 1.62 96 88 36.58 120 80 78 N N N N N N N N N Y N N N N N N 93 165 32 1.1 132 237 52 143 26 5.42 1.32 4.22 0.1 75.7
271 60 F 1.56 60 98 24.65 110 70 86 N N N  N N N N N N N N Y N N N N 105 114 30 0.9 108 219 53 137 22 9.07 1.03 3.03 0.09 69.5
272 33 M 1.72 76 92 25.69 110 80 76 N N N N N N N N N N N Y N N N N 89 112 28 1.13 177 162 30 102 35 1.81 1.1 3.78 0.06 84.9
273 37 M 1.68 74 88 26.22 120 60 74 N N N N N N N N N N N Y N N N N 93 101 16 1.32 49 108 39 63 10 8.37 1.02 2.84 0.1 68.4
274 31 M 1.6 46 75 17.97 110 80 72 N N N N N N N N N N N Y N N N N 129 33 1.12 80 142 32 85 16 9.787 1.12 3.46 0.26 87.1
275 56 M 1.65 76 105 27.92 120 80 72 N Y Y N N N N N N N N Y N N N N 124 181 7.2 25 1.64 84 183 37 111 17 1.79 1.18 4.9 0.07 46.1
276 44 M 1.62 70 93 26.67 130 80 68 N N Y N N N N N N N N Y N N N N 98 191 7.5 38 1.27 96 203 41 121 19 13.86 0.71 3.72 0.07 68.3
277 47 F 1.41 56 94 28.17 80 60 76 N N N Y N N N N N N N Y N N N N 94 21 0.94 135 106 25 55 27 25.97 0.79 3.57 0.36 72.2
278 50 F 1.58 65 89 26.04 120 90 70 N N N N N N N N N N N Y N N N N ` 87 21 0.91 95 169 38 98 19 2.95 1.35 3.92 0.003 73.6
279 45 F 1.65 65 103 23.88 120 80 78 N N Y Y N N N N N N N Y N N N N 144 253 7.4 17 0.75 147 270 40 175 29 4.38 0.92 2.75 0.002 96.3
280 67 F 1.53 62 100 26.49 120 90 68 N Y N N N N N N N N N Y N N N N 95 139 4.51 20 0.92 141 223 49 130 28 1.2 1.17 4.03 0.004 64.4
281 31 M 1.67 71 86 25.46 120 80 74 N N N N N N N N N N N Y N Y Y N 107 126 14 1.08 184 144 23 84 37 0.74 1.58 3.74 0.002 91
282 50 M 1.7 108 110 37.37 120 80 88 N N N N N N N N N N N Y N N Y N 207 193 8.4 24 1.05 176 188 29 113 35 3.58 1.1 3.35 0.001 82.4
283 27 M 1.65 68.5 84 25.16 120 60 78 N N N N N N N N N N N Y Y N N N 147 16 0.86 381 257 33 154 76 0.89 1.15 3.55 0.07 113.9
284 52 F 1.5 58 94 25.78 110 80 78 N N N N N N N N N N N Y N N N N 93 106 160 15 1 126 162 35 111 26 3.24 0.96 3.32 0.09 64.7
285 37 F 1.4 49 83 25.00 110 70 76 N N N N N Y N N N N N Y N N N N 115 15 0.8 88 182 54 95 18 3.88 1.52 3.28 0.002 94.2
286 39 F 1.64 93 106 34.58 140 80 76 N N Y N N N N N N N N Y N N N N 272 350 9 22 0.9 78 137 35 90 16 1.28 1.39 3.64 0.005 80.5
287 68 F 1.65 80 106 29.38 120 80 78 N Y N N N N N N N N N Y N N N N 130 20 1 216 182 38 104 43 1.57 1.08 2.08 0.12 57.8
288 50 F 1.52 49.5 84 21.42 140 90 82 N Y Y N N N N N N N N Y N N N N 396 575 9.8 15 0.8 110 278 61 178 22 3.36 1.35 3.39 0.02 86
289 28 F 1.595 51 82 20.05 100 80 76 N N N N N N N N N N N Y N N N N 92 15 0.2 68 121 31 65 14 12.82 0.8 3.4 0.1 78.1
290 55 F 1.562 74 99 30.33 120 70 82 N N N N N N N N N Y N Y N N N N 120 24 1 85 179 43 103 17 3.43 1.04 3.17 0.13 70.4
291 50 F 1.6 65.5 95 25.59 140 90 76 N N N N N N N N N N N Y N N N N 99 27 0.9 244 231 42 128 49 0.6 1.24 3.68 0.1 74.6
292 50 F 1.59 80 106 31.64 160 100 78 N Y N N N N N N N Y N N N N N N 118 78 7.5 91 129 41 76 18 3.94 1.04 2.98 1.95 5.7
293 43 F 1.64 48 77 17.85 120 60 82 N N N N N N N N N N N Y N N N N 105 21 0.9 56 150 37 86 11 2.23 1.35 3.52 0.1 78.3
294 60 F 1.7 54 79 18.69 110 70 80 N N N N N N N N N Y N N N N N N 106 29 1 103 188 56 109 21 1.02 1.3 2.84 0.09 61.2
295 50 F 1.56 60 96 24.65 130 80 82 N N N N N N N N N N N Y N N N N 82 17 0.9 107 202 48 113 21 6.66 1.13 3.37 0.13 74.6
296 50 F 1.58 65 98 26.04 110 80 78 N N N N N N N N N N N Y N N N N 77 81 22 0.8 123 226 47 141 25 16.02 0.97 3.05 0.2 86
297 53 M 1.68 79.5 98 28.17 130 80 78 N N N N N N N Y N Y N N N N N N 103 190 49 1.56 214 123 15 76 43 2.2 1.53 3.3 0.5 50
298 65 F 1.62 74 100 28.20 120 80 76 N N N N N N N N N N N Y N N N N 100 146 17 1 143 169 48 90 29 1.65 1.31 4.29 0.09 59.1
299 30 M 1.6 65 88 25.39 110 70 76 N N N N N N N N N N N Y N Y Y N 93 96 27 1.11 85 161 36 92 17 1.83 1.31 4.29 0.02 88.6
300 32 M 1.605 76.2 97 29.58 110 70 82 N N N N N N N N N N N Y N N N N 88 126 19 0.97 81 152 35 91 16 3.67 1.21 3.75 0.05 102.9
301 60 F 1.51 48 83 21.05 110 70 78 N N N N N N N N N N N Y N N N N 91 83 16 0.84 126 203 51 107 25 11.36 0.8 3.38 0.77 75.5
302 52 M 1.6 65 92 25.39 130 80 78 N Y N N N N N N N N N Y N N N N 108 108 25 1.16 81 198 40 115 16 0.99 1.06 3.23 0.12 72
303 44 F 1.59 90 104 35.60 120 80 78 N N N Y N N N N N N N Y N N N N 89 126 22 1.01 105 189 40 117 21 1.63 1.44 3.3 0.13 67.6
304 51 M 1.6 70 76 27.34 170 100 74 N Y N N N N N N N Y Y N N N N N 106 163 24 1.03 124 129 30 70 25 3.1 1.33 2.95 0.2 83.7
305 50 F 1.44 52 72 25.08 160 100 72 N Y Y N N N N N N N N Y N N N N 223 348 8.8 32 1.23 158 277 65 159 32 1.67 1.34 3.21 0.59 51.1



































































































































































































































































































307 63 M 1.6 72 84 28.13 150 80 86 N N N N N N N N N Y N N N N Y N 74 133 36 1 78 183 47 103 16 3.7 1.22 3.52 0.12 79.7
308 46 M 1.608 64 94 24.75 120 70 76 N N Y N N N N N N N N Y N Y N N 266 269 10.1 23 1 215 213 35 129 43 2.55 1.11 3.57 0.24 89.9
309 45 M 1.58 64 82 25.64 110 80 76 N N N N N N N N Y Y N N N N N N 95 26 1.1 141 194 44 115 28 4.47 1.06 4.03 0.09 80.6
310 44 M 1.56 84 107 34.52 130 40 82 N Y Y N Y N N N N N N Y N Y Y N 104 151 37 1.8 215 133 26 86 43 8.16 1.55 3.47 0.21 44.8
311 65 M 1.65 76 102 27.92 120 80 76 N N N N N N N N N Y N N N N N N 95 113 24 0.98 105 179 46 100 21 176 1.08 3.19 0.28 80.6
312 29 M 1.72 76.5 86 25.86 110 70 78 N N N N N N N N N N N Y N N N N 102 116 20 1.1 106 166 38 96 21 0.85 1.38 4.29 0.15 90.2
313 45 M 1.56 41.5 77 17.05 100 60 78 N N N N N N N N N Y Y N N N N N 145 35 1.5 72 92 44 49 14 4.47 1.06 4.03 2.14 55.4
314 47 M 1.7 63.5 85 21.97 150 100 68 N N N N N N N N Y N N Y N N N N 84 21 1.1 150 156 33 95 30 3.7 1.22 3.55 0.1 79.5
315 52 M 1.68 59.5 94 21.08 150 90 80 N N Y N N N N N N Y Y N N N Y N 169 562 8.6 27 1.8 106 125 51 56 21 4.03 1.26 4.17 1.3 42.3
316 70 M 1.58 55 85 22.03 110 70 90 N N N N N N N N N Y N N N Y N N 83 5.8 45 2.9 80 115 33 66 16 3.33 1.03 2.41 1.3 21
317 43 M 1.575 45 79 18.14 110 70 90 N Y N N N N N N Y N N Y N Y Y N 100 26 1 76 127 36 76 15 1.61 1.21 1.76 0.07 91.8
318 51 F 1.6 74 101 28.91 120 80 76 N N N N N N N N N N N Y N N N N 82 88 25 0.7 79 185 53 115 18 2.27 1.27 3.55 0.26 101
319 48 F 1.62 65 102 24.77 110 70 78 N N N N N N N N N N N Y N N N N 88 92 22 1.16 126 166 34 115 25 0.68 1.18 3.2 0.13 55.4
320 59 M 1.72 76 99 25.69 120 80 72 N N N N N N N N N N N Y N N N N 79 152 23 1.4 82 72 46 31 12 2.99 1.25 3.37 1.27 54.6
321 55 M 1.68 62 97.5 21.97 110 80 78 N N Y N N N N N N N N Y N Y N N 213 361 8.2 22 1.02 229 141 30 83 46 1.74 1.38 3.17 0.29 82.4
322 53 F 1.5 43.8 79 19.47 140 80 78 N N Y N N N N N N N N N Y N N N 138 281 5.1 38 18 81 94 35 52 16 3.55 1.41 3.34 1.82 31.6
323 60 M 1.46 57.4 96 26.93 180 100 86 Y N N N N N N N N N N Y N N N N 118 32 1.9 74 103 85 65 15 4.3 1.23 3.02 0.4 37.5
324 45 F 1.51 59.6 87 26.14 130 90 76 N Y N N N N N N N N N Y N N N N 91 114 21 0.9 346 268 54 156 69 4.07 0.96 1.94 8.9 77.2
325 33 M 1.615 75.1 94 28.79 110 80 72 N N N N N N N Y N N N Y N Y N N 83 130 25 1.8 100 123 43 74 20 2.08 1.24 3.19 0.1 48.4
326 48 M 1.565 65.8 95 26.87 100 60 88 N N N N N N N N N N N Y N N N N 106 129 59 2.2 132 170 49 95 26 2.47 1.37 2.99 0.25 34.2
327 55 F 1.412 33.5 68 16.80 130 80 78 N N N N N N N N N Y N N N N N N 111 107 4.1 29 1.3 159 134 34 81 32 7.17 0.93 3.02 0.58 46.1
328 42 M 1.65 66 99.5 24.24 110 70 76 N N N N N N N N N N N Y N N N N 61 87 21 1.33 223 166 32 103 45 1.29 1.38 3.11 0.87 65.5
329 42 M 1.64 76 98 28.26 120 80 76 N N N N N N N N N Y N N N N N N 62 72 18 1.05 113 151 36 101 23 1.53 1.3 3.16 0.08 87.1
330 45 F 1.56 59.5 92 24.45 120 80 78 N N N N N N N N N N N Y N N N N 71 117 14 0.81 69 161 50 97 14 3.57 1.07 3.5 0.17 87.7
331 33 F 1.58 100 112 40.06 120 80 76 N N N Y N N N N N N N Y N N N N 71 105 17 0.86 120 213 48 140 24 0.03 1.82 4.92 0.12 88.8
332 36 M 1.595 57.5 88 22.60 120 80 76 N N N N N N N N N N N Y N N N N 70 100 18 1.15 165 160 39 99 33 2.43 1.27 2.7 0.02 81.4
333 39 M 1.72 74 98 25.01 120 80 76 N N N N N N N N N N N Y N Y Y N 93 113 23 0.97 51 141 42 95 10 16.19 0.95 2.86 0.06 97.9
334 62 M 1.63 70 95 26.35 120 70 84 N N N N N N N N N Y N N N N N N 81 112 17 1.19 89 132 40 89 15 0.91 1.24 2.71 0.09 65.1
335 52 F 1.51 62 103 27.19 130 80 78 N Y Y N N N N N N N N Y N N N N 264 764 9.5 34 0.94 587 358 60 192 117 1.29 1.38 2.72 0.32 69.7
336 70 M 1.57 58 83 23.53 120 70 78 N N N N N N N N N N N Y N N N N 85 125 28 1.5 120 129 28 83 24 2.12 1.11 2.28 0.1 46.5
337 47 F 1.52 67 101 29.00 120 80 78 N N N Y N N N N N N N Y N N N N 98 21 0.73 124 154 36 99 25 6.65 1.53 3.02 0.13 98.1
338 56 M 1.65 78 102 28.65 110 70 88 N N N N N N N N N N N Y N Y N N 196 26 0.95 124 175 41 113 25 4.85 1.19 2.62 0.08 89.1
339 43 F 1.62 60 98 22.86 110 80 82 N N N N N N N N N N N Y N N N N 76 68 24 0.8 63 146 44 90 13 3.48 1.53 2.92 0.08 90.3
340 38 F 1.57 73.2 96 29.70 140 90 76 N N N N N N N N N Y N N N N N N 93 17 0.78 47 148 46 93 9 1.05 1.35 2.98 0.09 96.4
341 46 M 1.74 62.5 80 20.64 100 50 70 N N N N N N N N N N N Y N N N N 72 69 4.3 17 0.98 33 123 49 77 7 1.57 1.27 2.55 0.13 92.1
342 39 M 1.625 74.9 103 28.36 110 60 88 N Y N N N N N N Y N N Y N N Y N 67 86 5.15 22 1.1 72 100 24 75 14 0.51 1.65 2.56 0.11 84.1
343 51 M 1.72 80 102 27.04 120 70 78 N N Y N N N N N N N N Y N N N N 100 205 7.5 25 0.89 80 169 40 112 16 9.04 1.12 2.56 0.11 99
344 50 M 1.77 78.6 98 25.09 140 90 82 N Y N N N N N N N Y N N N N N N 80 67 3.87 18 0.98 159 134 34 81 32 3.27 1.51 3 0.2 89.5
345 47 F 1.58 70 99 28.04 110 70 78 N N N N N N N N N N N Y N N N N 122 178 23 0.92 104 140 32 99 21 1.89 1.16 2.4 0.09 74.1
346 49 M 1.72 76 98 25.69 110 70 76 N N N N N N N N N Y N N N N N N 79 135 24 1.12 48 122 30 90 10 2.7 1.32 3 0.06 76.7
347 50 F 1.62 15.2 103 5.79 110 70 76 N N N N N N N N N N N Y N N N N 102 117 15 0.77 221 257 68 159 44 3.62 1.36 2.2 0.15 90
348 55 M 1.72 68 90 22.99 110 60 78 N N Y N N N N N N Y Y N N N Y N 67 199 259 6.6 34 1.6 202 170 35 103 40 3.43 1.25 2.62 0.16 47.8
349 75 M 1.6 53 93 20.70 150 80 82 N Y Y N N N N N N N N Y N N N N 102 210 5.9 28 1.3 80 126 29 87 16 4.49 1.19 2.5 1.54 53.4
350 44 M 1.67 73 104 26.18 120 80 80 N N Y N N N N N N N N Y N Y y N 255 349 8.1 21 0.8 124 208 47 140 25 2.1 0.92 2.85 0.18 108.6
351 62 M 1.53 70 113 29.90 130 80 76 N Y Y N Y N N N N N N Y N Y Y N 96 7.2 64 3.2 116 144 32 89 23 3.33 1.03 2.41 2.6 19.7
352 60 M 1.44 46 80 22.18 130 70 74 N Y Y N N N N N N N N Y N N N N 148 220 6 53 2 184 128 21 73 37 3.82 1.03 2.78 1.75 35.2
353 60 M 1.62 76 105 28.96 160 100 80 N N N N N N N N N N N Y N Y N N 76 107 164 4.8 40 1.1 169 186 40 124 34 0.62 1.46 2.04 0.2 72.6
354 61 M 1.62 72 98 27.43 100 70 96 N N N N N N N N N Y N N N N N N 127 37 1.1 100 137 24 94 20 1.2 1.43 2.77 0.23 72.1
355 52 M 1.59 59.5 100 23.54 140 80 78 N Y Y Y N N N N N Y N N N N Y N 150 316 8.5 83 3.2 224 164 33 96 45 16.07 0.59 2.9 3.3 21.1
356 55 M 1.65 84.5 115 31.04 110 80 80 N Y Y N N N N N N Y N N N N N 250 7.2 20 1 224 203 50 123 45 6.96 1.26 1.26 0.17 84.4



































































































































































































































































































358 38 M 1.61 62.8 95 24.23 180 70 80 N N N Y N N N N N N N Y N N Y N 84 123 33 1.72 259 143 31 83 52 100 0.53 1.94 0.19 49.3
359 27 M 1.7 70 88 24.22 100 70 78 N N N N N N N N N N N Y N N N N 86 101 14 1.24 115 137 32 94 23 4.55 1.48 3.71 0.16 79.2
360 65 M 1.59 59.1 88 23.38 110 70 80 N N N N N N N N N N N Y N N N N 80 113 24 1.04 155 131 27 89 31 3.14 1.24 2.89 0.07 75
361 51 F 1.525 63.2 102 27.18 110 70 80 N N N N N N N N N N N Y N N N N 90 162 15 0.79 177 141 38 85 35 3.12 1.02 3.09 0.17 86.7
362 39 M 1.6 58.2 94 22.73 200 120 80 Y Y Y N N N N N N N N Y N N N N 163 292 7.8 21 1.19 120 215 46 155 24 2.51 1.37 2.76 4.05 76.5
363 21 M 1.64 49 78 18.22 100 70 78 N N N N N N N N N N N Y N N Y N 74 73 15 0.94 82 122 44 72 16 1.11 1.78 4.5 0.13 115.4
364 55 M 1.65 61 90 22.41 150 100 78 N Y Y N N N N N N Y N N N N N N 172 288 6.9 73 3.2 118 177 29 127 24 1.89 1.31 2.1 8.8 20.7
365 33 M 1.7 90.1 94 31.18 120 90 76 N N N N N N N N N N N Y N N N N 78 144 22 1 85 204 52 138 17 6.26 1.12 3.97 0.06 98.5
366 54 F 1.53 70.6 104 30.16 130 90 80 N N N Y  N N N N N N N Y N N N N 70 89 15 1 115 226 48 157 23 7.99 1.08 2.93 0.07 63.8
367 45 F 1.55 58 98 24.14 110 70 88 N N N N N N N N N N N Y N N N N 58 30 0.9 87 223 64 136 17 1.19 1.16 2.91 0.05 77.2
368 40 F 1.52 55 90 23.81 170 100 70 N N N N N N N N N N N Y N N N N 73 81 4.4 21 0.6 59 133 54 75 12 1.43 1.49 3.52 0.13 114
369 42 F 1.5 52.5 85 23.33 110 70 78 N N N N N N N N N N N Y N N N N 85 19 1 74 169 54 106 15 1.41 1.2 2.92 0.05 69.4
370 21 F 1.585 41 68 16.32 100 70 78 N N N N N N N N N N N Y N N N N 69 16 0.6 72 124 28 75 14 0.38 1.56 1.86 0.8 130.3
371 43 F 1.67 82.5 103 29.58 110 70 78 N N N N N N N N N N N Y N N N N 114 169 27 0.9 163 216 54 138 33 2.87 1.13 2.11 0.12 78.3
372 60 F 1.538 36.5 73 15.43 100 70 80 N N N N N N N N N N N Y N N N N 83 19 0.6 161 178 32 121 32 4.41 1.08 2.76 0.21 99.1
373 39 M 1.62 69.6 93 26.52 100 70 84 N N N N N N N N N N N Y N N Y N 69 110 25 1.35 105 174 38 114 21 1.24 1.21 3.02 0.11 65.7
374 42 M 1.838 78.2 94 23.15 110 80 84 N N Y N N N N N N N N Y N N Y N 91 129 27 1.06 109 126 32 74 22 1.24 1.24 3.02 0.15 86.1
375 65 M 1.68 65 96 23.03 110 60 78 N N N N N N N N N N N Y N N N N 91 129 19 0.9 68 203 52 131 14 3.02 1.06 2.78 0.1 89.3
376 50 M 1.602 80.3 102 31.29 110 80 84 N N Y N N N N N N N N Y N N Y N 151 95 6.8 21 1.12 85 143 47 85 17 2.3 1.44 3.81 0.14 76.2
377 50 M 1.67 73.6 101 26.39 90 60 78 N N Y N N N N N N N N Y N N Y N 206 175 7.8 20 1.12 187 179 34 117 37 0.93 1.17 3.25 0.08 76.2
378 50 M 1.62 78.2 102 29.80 110 70 78 N N Y N N N N N N N N Y N N N N 115 251 7.2 26 1.01 152 128 32 81 30 3.7 1.2 3.22 0.13 86.3
379 52 M 1.725 88.6 110 29.78 120 80 78 N N N N N N N N N N N Y N N N N 84 21 1.2 97 214 40 143 19 4.03 1.27 3.43 0.2 69.1
380 55 M 1.56 75 108 30.82 130 80 78 N N N N N N N N N N N Y N N N N 88 137 24 0.1 76 156 37 102 15 1.22 1.38 4.01 0.19 95.8
381 38 M 1.695 73.8 98 25.69 120 90 84 N N N N N N N N N N N Y N N N N 85 168 17 1.08 140 214 46 136 28 4.94 1.28 3.9 0.15 86.6
382 53 M 1.565 63.8 92 26.05 130 80 88 N N N N N N N N N N N Y N N Y N 89 110 15 0.8 81 149 52 81 16 2.4 0.98 3.8 0.09 102
383 72 M 1.65 80 104 29.38 120 80 80 N Y N N N N N N N Y N N N N Y N 85 96 22 1.24 95 166 37 111 19 3.61 1.11 3.7 0.11 60.1
384 53 M 1.592 56.3 88 22.21 100 80 84 N N N N N N N N N N N Y N N Y N 80 115 25 1 79 188 45 125 16 2.73 1.11 4.43 0.13 85.5
385 50 M 1.625 62 92 23.48 110 70 84 N N N N N N N N N N N Y N N Y N 67 123 38 1.31 92 190 53 127 18 1.82 1.29 3.62 0.1 63
386 34 F 1.65 68 86 24.98 100 70 80 N N N N N N N N N N N Y N N N N 64 95 18 0.82 48 119 40 70 10 3.7 1.23 4.24 0.1 93.4
387 52 F 1.59 68 102 26.90 110 70 76 N N N N N N N N N N N Y N N N 103 150 39 0.98 77 133 45 80 15 3.24 1.35 3.53 0.1 66.3
388 61 F 1.41 76 108 38.23 120 90 80 N Y Y Y N N N N N N N Y N N N N 94 191 9.9 45 1.2 179 151 40 92 36 5.45 1.59 0.93 3.48 48.7
389 45 M 1.54 74 102 31.20 120 80 80 N N Y N N N N N N N N Y N N N N 240 398 7.4 20 0.97 298 189 36 116 60 1.95 1.21 3.54 0.26 93.9
390 32 M 1.68 72.6 84 25.72 120 80 74 N N N N N N N N N N N Y N N N N 78 150 23 1.01 155 200 44 130 31 1.94 1.06 4.05 0.07 98
391 79 M 1.635 68 88 25.44 190 90 72 N N N N N N N N N Y N N N N N N 106 31 1.2 62 157 29 101 12 1.03 1.16 4.07 5.08 57.2
392 60 M 1.675 55 79 19.60 120 90 78 N Y N Y N N N N N Y N N N N N N 111 208 11.3 92 190 53 127 18 2.74 1.33 1.61 4.28 4.3
393 63 M 1.54 50 72 21.08 100 60 76 N N N N N N N N N Y N N N N N N 90 49 0.9 67 110 32 67 13 3.12 1.35 2.79 0.2 90.6
394 40 M 1.6 59 86 23.05 110 80 84 N N N N N N N N Y N N Y N Y Y N 65 28 1.1 63 127 45 65 13 0.708 1.91 3.1 0.16 83.5
395 59 F 1.54 54 78 22.77 120 90 76 N Y N N Y N N N N N N Y N N N N 86 4.9 22 0.6 153 134 37 79 31 3.19 1.11 1.94 0.2 99.8
396 55 M 1.65 67 104 24.61 180 110 76 N Y Y N N N N N N N  N Y N N N N 114 160 284 7.31 33 1.4 190 139 29 88 38 2.44 1.34 2.27 0.31 56.2
397 61 M 1.58 56 76 22.43 170 100 78 N Y N N Y N Y N N N N Y N N N N 91 27 1.1 84 163 39 111 17 3.28 1.22 2.5 0.01 72.1
398 56 M 1.6 72 105 28.13 130 80 80 N Y Y N Y N N N N N N Y N Y Y N 218 134 195 7.2 27 1.1 115 67 22 60 23 5.02 1.15 3.42 0.32 74.6
399 74 M 1.62 54 78 20.58 120 80 76 N N N N Y N N N N Y Y N N Y N N 80 4.4 66 1.4 109 143 36 96 22 3.76 1.91 3.34 0.04 49.1
400 50 M 1.73 58 78 19.38 120 70 78 N N N N Y N N N N N N Y Y Y N N 77 4.98 15 1.2 93 122 30 66 19 3.11 0.94 3.56 0.22 70.1
401 69 M 1.52 64 102 27.70 100 60 78 N Y Y N Y N N N N N N Y N N N N 124 5.88 76 2.76 122 135 29 108 24 2.5 1.27 3.06 0.26 22.4
402 36 M 1.65 76.3 95 28.03 130 90 86 N N N N N N N N Y N N Y N N N N 110 26 1.1 103 162 41 95 21 2.27 1.27 3.55 0.06 85.9
403 57 M 1.65 63 94 23.14 120 84 84 N N N N N N N N N N N Y N N N N 79 107 16 1.16 110 114 31 86 22 1.68 1.31 3.51 0.12 6.95
404 38 M 1.67 71.3 93 25.57 180 110 80 N Y N N N N N N N N N Y N Y Y N 88 108 20 1.38 232 130 37 88 46 2.78 1.34 3.51 0.27 64.4
405 55 M 1.65 72.7 96 26.70 120 80 78 N N N N N N N N N N N Y N N N N 81 90 18 1.25 115 124 50 79 23 3.73 1.39 3.54 0.09 64.4
406 58 F 1.46 68 94 31.90 120 80 80 N N N N N N N N N N N Y N N N N 79 74 16 0.88 207 165 48 116 41 3.1 0.95 2.93 0.06 83.3
407 50 F 1.595 65.1 104 25.59 130 80 88 N N N N N N N N N N N Y N N N N 88 120 18 0.87 251 117 29 77 50 2.92 1.11 3.26 0.05 77.7



































































































































































































































































































409 68 M 1.57 52 78 21.10 130 80 84 N N N N Y N N Y N Y N N N N N N 81 4.35 36 1.31 103 105 30 57 21 3.25 2.33 2.95 0.1 55.5
410 50 M 1.65 53 84 19.47 150 90 74 N N Y N Y N N N N Y Y N N Y Y N 186 288 8.6 27 1.4 330 182 42 110 66 9.72 1.43 2.99 0.87 63
411 62 F 1.58 48 94 19.23 140 100 78 N Y Y N Y N N N N N N Y N N N N 257 420 254 8.69 17 0.92 214 138 37 71 43 2.96 1.02 2.24 0.1 66.7
412 58 M 1.7 71 88 24.57 120 70 84 N N Y N N N N N N Y N N N N N N 255 260 7.7 18 1.24 118 123 28 73 24 2.57 1.53 2.86 0.14 63.7
413 63 M 1.623 78.6 96 29.84 140 90 82 N Y N N N N N N N Y N N N N N N 169 175 6.1 17 1.09 106 177 35 108 21 8.34 1.05 3.18 0.15 71.9
414 70 M 1.68 75.2 94 26.64 110 70 82 N Y Y N N N N N N N N Y N N N N 188 424 7.2 19 1.17 136 172 33 104 27 1.85 1.56 2.99 0.25 62.8
415 52 M 1.57 75.2 109 30.51 110 80 76 N N Y N N N N N N N N Y N N N N 123 217 6.3 28 1.12 77 195 43 120 15 1.78 1.44 3.72 0.07 75.1
416 40 F 1.53 80 115 34.17 120 80 76 N N Y Y N N N N N N N Y N N N N 416 508 10.4 16 0.9 128 203 32 130 26 9.22 1.38 2.57 0.16 80
417 50 F 1.55 57 88 23.73 100 70 68 N Y Y N Y N N N N N N Y N Y Y N 104 7.6 17 0.92 68 108 24 64 14 3.05 1.25 2.51 0.06 96.6
418 50 F 1.53 53 95 22.64 130 70 70 N N N N N Y N N N N N Y N N N N 75 121 19 0.9 85 160 31 100 18 2.94 1.09 2.44 0.39 74.6
419 31 M 1.62 44 74 16.77 110 70 60 N N N N N Y N N N N N Y N Y Y N 104 32 1.1 46 81 23 48 9 1.69 1.5 2.84 0.27 89
420 68 M 1.56 48 82 19.72 110 80 82 N N N N Y N Y N N N N Y N N N N 91 5.1 33 1.3 147 90 25 55 29 62 0.8 3.51 0.16 56.1
421 42 M 1.74 70.5 102 23.29 110 80 84 N N N N N N N N N N N Y N N N N 83 121 23 1.4 49 134 44 80 10 2.57 1.58 2.9 0.06 61.5
422 59 F 1.57 65 106 26.37 160 100 78 N Y Y N Y N N N N N N Y N N N N 392 398 8.74 22 1 202 178 26 110 40 0.58 2.09 3.31 0.52 23.8
423 74 M 1.6 66 85 25.78 110 90 80 N N N N Y N N N N N N Y N Y Y N 74 21 1 162 124 31 72 32 1.21 1.27 3.37 0.05 97.8
424 70 F 1.54 75 110 31.62 110 70 80 N N Y N N N N N N N N Y N N N N 116 133 6.2 36 1.4 150 209 38 123 30 0.38 1.57 1.71 3.4 38
425 39 F 1.69 58 84 20.31 110 70 86 N N N N N N N N N N N Y N N N N 125 40 0.9 198 177 15 102 40 2.53 1.05 2.9 0.35 80.5
426 43 F 1.663 64 91 23.14 100 70 78 N N N N N N N N N N N Y N N N N 77 21 0.9 76 191 37 115 15 2.17 1.36 3.48 0.09 78.3
427 67 M 1.72 78 91 26.37 130 90 78 N Y Y N Y N N N Y N N Y N N N N 171 320 293 5.7 29 1.1 157 142 21 97 24 5.65 1.21 2.31 0.62 68.1
428 45 M 1.38 47.5 85 24.94 110 80 82 N N Y N N N N N N N N Y N N N N 89 223 7.2 117 3.4 85 161 36 92 17 7.61 1.4 2.75 0.62 20.6
429 35 M 1.45 43 75 20.45 100 60 86 N N N N N Y N N N Y N N N N N N 88 18 1.1 67 82 21 46 13 2.91 1.68 3.18 0.22 86.5
430 49 M 1.72 55 76 18.59 100 60 82 N N N N N N N N N Y N N N N Y N 152 93 5.8 17 1.19 67 89 28 44 13 2.83 1.31 3.07 0.05 71.3
431 42 F 1.6 85 104 33.20 120 80 84 N N N N N N N N N N N Y N N N N 83 137 29 0.78 60 125 36 69 12 0.02 4.66 10.13 0.17 93.8
432 55 M 1.56 44 87 18.08 120 80 72 N N N N N N N N N N N Y N N N N 187 467 8.1 81 3.3 110 125 27 75 22 0.694 1.79 1.67 1.18 19.9
433 55 M 1.69 57 86 19.96 120 80 82 N Y N N N N N N N N N Y N N N N 62 23 1.3 143 169 48 90 29 2.71 1.14 3.51 0.31 61.4
434 40 M 1.83 75 90 22.40 150 100 72 N Y N N N N N N Y N N Y N Y Y N 113 22 0.9 87 140 38 88 17 0.948 1.43 1.79 0.14 106.5
435 62 M 1.65 88 102 32.32 160 100 70 N Y Y N Y N N N N N N Y N N N N 104 143 7.3 145 137 93 86 37 38 19 1.3 1.92 1.07 0.42 3.4
436 75 M 1.58 70 87 28.04 130 70 78 N Y Y N N N N N N N N Y N N N N 230 335 9.1 36 2.2 211 137 29 87 42 1.05 1.27 2.02 4.7 27.7
437 45 M 1.61 90 119 34.72 110 70 80 N N N N N N N N N Y N N N N N N 97 27 1.1 158 277 65 159 32 3.52 1.09 3.12 0.16 80.6
438 40 F 1.53 68.2 91 29.13 110 80 86 N N N N N N N N N N N Y N N N N 97 4.72 19 0.88 159 147 32 87 32 3.37 1.2 2.63 0.08 82.2
439 67 F 1.49 64.1 95 28.87 120 70 76 N N N N N N N N Y N N Y N N N N 82 31 0.87 62 200 53 118 12 1.11 1.58 2.69 0.07 68.9
440 27 F 1.49 64.1 95 28.87 90 50 86 N N N N N N N N N N N Y N N N N 89 97 16 0.96 63 151 36 92 13 3.52 1.21 2.69 0.07 81.1
441 50 M 1.755 83.1 105 26.98 160 110 78 N N N N N N N N N N N Y N Y N N 75 86 31 1.08 276 181 27 105 55 3.11 1.56 2.72 0.14 79.6
442 55 M 1.642 66.2 93 24.55 140 80 62 N N N N N N N N N N N Y N Y Y N 87 112 21 1.2 154 197 46 118 31 2.6 1.22 2.89 0.11 67.7
443 40 M 1.67 77.3 97 27.72 110 80 72 N N N N N N N N N N N Y N N Y N 77 110 19 1.23 97 169 31 109 19 5.56 1.48 2.68 0.04 73
444 40 F 1.49 66 98 29.73 150 100 78 N N Y N N N N N N N N Y N N N N 178 258 6.5 15 0.8 271 173 29 98 54 0.18 3.82 9.14 0.2 92.2
445 36 F 1.55 65 98 27.06 130 70 78 N N N N N N N N Y N N Y N N N N 83 15 0.8 88 139 27 84 18 2.64 1.48 2.57 0.09 94.8
446 62 F 1.4 78 127 39.80 130 80 76 N Y Y N N N N N N N N Y N N N N 96 176 39 1.8 157 93 27 47 31 3.77 1.5 2.3 2.39 29.6
447 31 M 1.642 61.9 85 22.96 110 70 76 N N N N N N N N N N N Y N N N N 85 112 16 1.02 121 202 46 122 24 3.55 1.36 1.02 0.24 97.5
448 58 M 1.58 72.5 98 29.04 120 80 76 N N N N N N N N N N N Y N N N N 91 120 18 1.09 126 132 27 86 25 3.59 1.16 3.2 0.3 74.4
449 25 F 1.58 83.6 104 33.49 100 70 90 N N N N N N N N N N N Y N N N N 83 71 17 0.9 65 156 42 96 13 2.6 1.2 2.35 0.13 88.9
450 72 M 1.64 75.8 106 28.18 120 80 82 N N N N N N N N N N N Y N N N N 108 122 28 1.18 110 149 35 91 22 3.66 1.15 3.09 0.34 64.5
451 37 F 1.54 63.9 95 26.94 100 70 78 N N N N N N N N N N N Y N N N N 67 92 16 1.01 154 216 42 133 31 4.25 1.1 2.84 0.09 71.1
452 53 M 1.708 77.9 101 26.70 110 80 80 N N N N N N N N N N N Y N N Y N 82 84 35 0.97 89 122 46 72 18 0.02 1.19 3.93 0.09 88.8
453 48 F 1.572 79.4 101 32.13 120 70 76 N N N N N N N N N N N Y N N N N 88 100 15 0.72 100 139 42 83 20 2.21 1.17 3.4 0.12 99
454 43 M 1.68 63.5 86 22.50 90 50 76 N N N N N N N N N N N Y N N N N 80 93 18 1.17 132 164 33 103 26 2.52 1.38 3.42 0.15 75.9
455 63 M 1.65 77.4 104 28.43 150 100 86 N Y N N N N N N N Y Y N N N N N 101 124 28 1.24 147 217 40 143 29 4.1 0.88 3.33 0.13 61.5
456 53 F 1.55 98.3 114 40.92 130 80 82 N Y N N N N N N N N N Y N N N N 85 115 24 1.03 118 161 41 97 24 1.33 1.27 3.16 0.08 62
457 84 M 1.72 45 88 15.21 130 90 82 N N N N Y N N N N Y N N N N N N 89 5.51 83 2.4 181 87 32 47 36 2.24 1.55 6.39 0.32 23.9
458 63 M 1.75 70 100 22.86 180 110 78 N Y N N Y N N N N N Y N N Y Y N 96 5.2 30 1.34 380 190 46 115 76 17.75 0.5 2.17 0.04 56



































































































































































































































































































460 38 M 1.6 58 88 22.66 100 80 100 N N N N Y N N N N N N Y N Y N N 131 41 1.2 160 171 24 103 33 3.5 1.4 2.66 0.18 76.2
461 60 F 1.58 68 98.5 27.24 110 70 72 N N N N Y N N N N N N Y N N N N 87 94 134 5.35 20 1.3 287 132 36 74 57 33.32 0.93 2.53 0.13 44.6
462 62 F 1.5 47 76 20.89 150 90 86 N Y Y Y N N N N N N N Y N N N N 147 34 0.8 249 138 51 80 50 2.1 1.91 2.46 0.21 79
463 51 M 1.67 69.5 100 24.92 120 80 82 N N Y N N N N N N N N Y N N N N 214 238 7.39 28 0.9 150 218 47 138 30 1.83 1.35 3.09 0.08 98.5
464 47 M 1.672 75.1 92 26.86 120 80 84 N N N N N N N N N N N Y N N N N 235 299 7.4 36 1.1 145 188 36 120 29 6.48 1.27 3.26 0.58 79.5
465 42 M 1.625 72.2 99 27.34 120 80 82 N N Y N N N N N N N N Y N N N N 179 333 7.85 21 1.1 146 197 39 132 29 2.32 1.38 3.38 0.25 82.4
466 56 M 1.645 83.3 104 30.78 140 90 88 N Y N N N N N Y N N N Y N N N N 102 138 17 1.2 144 169 37 98 29 0.81 1.03 3.04 0.1 67.2
467 54 F 1.56 87.4 110 35.91 140 90 86 N N Y N N N N N N N N Y N N N N 235 304 8.11 24 0.94 189 227 40 130 38 1.98 0.96 2.9 0.27 68.8
468 73 M 1.655 78 92 28.48 120 80 76 N N N N N N N N N Y N N N N N N 89 120 33 1.3 136 212 53 102 27 2.03 1.37 3.14 0.2 54.1
469 63 F 1.61 80 110 30.86 150 70 88 N Y Y Y N N N N N N N Y N N N N 163 178 7.2 34 1.19 164 256 52 167 33 2.65 1.37 2.36 0.28 48.5
470 55 M 1.8 80 92.5 24.69 136 90 82 N N N N N N N N N Y N N N N N N 102 109 21 0.75 135 175 31 114 21 6 1.05 3.25 1.36 103.3
471 27 M 1.724 58.5 78 19.68 110 80 76 N N N N N N N N N N N Y N N N N 88 88 23 0.66 57 130 35 79 11 1.89 1.43 4.12 0.09 132.5
472 52 M 1.68 57.4 83 20.34 150 90 84 Y N Y N N N N N N N N Y Y N N N 272 361 9.44 19 0.7 82 175 33 113 16 3.11 1.29 2.59 0.33 108.5
473 60 F 1.575 75.7 107 30.52 110 60 80 N Y N N N N N N N Y N N N N N N 87 118 25 0.77 74 206 61 124 15 1.05 1.37 3.35 0.24 83.9
474 60 F 1.49 85 106 38.29 110 70 88 N N N N N N N N N N N Y N N N N 108 114 15 0.49 84 154 40 92 17 3.76 1.05 3.12 0.1 105.9
475 60 F 1.555 63 97 26.05 130 80 78 N Y N N N N N N N N N Y N N N N 107 142 18 0.64 103 227 43 150 21 5.54 1.08 2.83 0.07 97
476 29 M 1.57 73 95 29.62 130 80 84 N N N N N N N N N N N Y N N N N 78 97 19 0.71 115 169 41 105 23 1.41 1.17 3.48 0.07 126.8
477 48 F 1.605 86.3 107 33.50 150 90 78 N N N N N N N N N N N Y N N N N 190 128 5.21 15 0.58 78 169 47 97 16 5.03 1.12 3.05 0.08 109
478 57 M 1.69 89 110 31.16 160 110 82 N N N N N N N N N N N Y N N Y N 123 172 5.02 19 0.83 161 181 39 113 32 2.59 1.27 3.6 0.22 97.7
479 51 F 1.453 49.4 91 23.40 110 70 82 N N Y N N N N N N N N Y N N N N 141 185 7.7 17 0.52 165 173 42 105 33 3.07 1.24 3.68 0.06 110.6
480 28 M 1.78 71.6 89 22.60 120 80 68 N N N N N N N N N N N Y N N N N 84 87 19 0.79 59 132 42 77 12 2.43 1.26 3.55 0.07 122.2
481 44 M 1.68 101 114 35.79 140 100 78 N Y Y N N N N N N N N Y N Y Y N 212 129 5.9 28 0.7 161 207 46 133 11 2.78 1.19 3.08 0.14 114.8
482 35 M 1.662 52.9 68 19.15 120 80 86 N N N N N N N N N N N Y N Y Y N 80 94 16 0.67 87 181 30 126 17 1.01 1.16 3.37 0.16 124.5
483 55 F 1.48 97.6 119 44.56 140 90 76 N Y Y N N N N N N N N Y N N N N 129 152 7 15 0.62 84 149 47 84 17 1.92 1.01 3.15 0.12 99
484 41 M 1.668 68 97 24.44 120 90 78 Y N N N N N N N N N N Y N N N N 96 108 21 0.94 81 135 34 88 16 1.59 1.06 3.17 0.3 100.3
485 52 M 1.69 74 88 25.91 120 80 78 N N N N N N N N N N N Y N N N N 82 85 25 0.9 125 197 27 150 25 1.89 1.06 3.04 0.19 97.9
486 36 M 1.8 83 94 25.62 130 80 66 N N N N N N N N N N N Y N N N N 79 76 25 0.7 126 185 39 129 25 1.88 1.04 3.65 0.28 121.4
487 42 F 1.615 65.4 95 25.07 100 70 78 N N N N N N N N N N N Y N N N N 72 137 15 0.5 141 203 30 149 28 4.49 0.94 2.66 0.02 119.4
488 52 M 1.68 75.2 99 26.64 120 70 84 N N N N N N N N N N N Y N Y Y N 84 169 5.7 21 0.7 356 257 41 171 71 7.47 1.13 3.23 0.15 108.5
489 45 M 1.668 88.4 109 31.77 110 70 80 N N N N N N N N N N N Y N N N N 83 129 15 0.7 134 208 28 154 27 1.64 1.2 2.79 0.09 114
490 45 M 1.77 74.1 99 23.65 140 70 82 N N Y N N N N N N N N Y N Y N N 243 444 8.64 21 0.7 66 102 33 57 13 2.05 1.53 3.04 0.06 114
491 40 F 1.537 77.5 96 32.81 110 80 76 N N N N N N N N N N N Y N N N N 94 133 16 0.6 197 193 30 132 39 2.84 1.67 3.49 0.16 109.3
492 35 M 1.653 77.6 104 28.40 140 100 76 N N Y N N N N Y N N N Y N N Y N 329 461 8.83 24 0.9 288 217 39 148 58 1.79 1.41 3.31 0.09 110.3
493 39 M 1.55 90.9 118 37.84 120 70 80 N N N N N N N N N N N Y N N Y N 72 121 18 0.6 124 213 40 156 25 1.51 1.37 3.48 0.1 126.7
494 33 M 1.65 57.1 82 20.97 110 80 82 N N N N N N N N N N N Y N N N N      103 16 0.7 69 187 36 136 14 1.51 1.39 3.48 0.1 124
495 61 F 1.5 56.8 97 25.24 120 80 86 N N N N N N N N N N N Y N N N N 86 113 24 0.5 120 197 36 143 24 4.02 1.25 3.45 0.22 104.5
496 68 M 1.62 66.1 98 25.19 140 80 78 N Y Y Y N N N N N N N Y N N N N 114 7.4 17 1.2 196 150 36 91 34 3.37 1.78 2.75 0.05 61.8
497 41 F 1.49 68.1 98 25.18 120 80 82 N Y Y Y N N N N N N N Y N N N N 95 208 6.2 15 0.5 333 154 36 64 67 3.53 1.12 3.05 0.05 120.2
498 43 F 1.565 49.4 86 20.17 100 70 86 N Y N N N N N N N N N Y N Y N N 57 226 6.4 23 0.5 102 173 34 122 20 0.963 1.19 2.96 0.05 118.5
499 32 M 1.7 86.9 98 30.07 140 90 84 Y N Y N N N N N N N N Y N N N N 107 225 7.8 24 0.5 260 197 38 111 52 1.33 1.26 3.66 0.1 143.4



































































































































































































































































































CASE RECORD FORM 
 
Serial No:                                                                              Hospital No  OP/ IP 
Name of the Subject: 




Location:  urban/ semi urban/ rural 
 
Height:                             Weight:                     BMI:                     Waist circumference 
 
B.P                                                Pulse rate:  
Provisional Diagnosis: 
 










Personal History:Occupation; Farmer / Non farmer: 
If Farmer exposure to Agro-Chemicals: 

























Other relevant Investigation if any: 
TEST RESULT 
Blood Sugar          Fasting       (mg/dl)  
                              Post Prandial(mg/dl)  
                              Randoma(mg/dl)  
Blood Urea(mg/dl)  
Serum Creatinine(mg/dl)  
Lipid Profile                      Triglyceride(TGL)(mg/dl)  
                                         Total Cholesterol (TC)(mg/dl)  
     High Density Lipoprotein Cholesterol(HDLc)(mg/dl)  
     Low Density Lipoprotein Cholesterol(LDLc)(mg/dl)  
VeryLow Density Lipoprotein 
Cholesterol(VLD)(mg/dl) 
 
Thyroid Profile      Thyroid Stimulating 
Hormone(µIU/L) 
 
                               Free Thyroxine (FT4) (pg/ml)  
                               Free Triiodothyronine (FT3) (ng/ml)  
Spot  Urine Protein Creatinine ratio (UPCR)  









You are requested to participate in a study conducted in the 
Department of Biochemistry, Chennai Medical College Hospital & 
Research Centre, Irungalur, Trichy, Tamilnadu titled “A study on eGFR, 
Protein –Creatinine ratio, Thyroid and Lipid profile in assessing risk 
factor for renal dysfunction ”. Your participation in the study is 
voluntary 
 There will be no cost for  participating in the study 
 Your participation is not a compulsion 
 You have the right to withdraw from the study at any time. 
 
Nature of Study: 
 If any abnormalities are identified, you will be informed for 
further consultation. 
 The results of this study will be kept confidential 
We believe that the results of this study will be beneficial for 
advancements in medicine & Science.  We assure you that we will not 
use these result for any other purpose. 
 
Consent 
I Mr /Mrs / Ms______________________________________________________________ 
residing at _____________________________________________________________________ 
____________________________________________________________on this day 
___________________  after having read the consent form carrying 
information for the above mentioned study and I hereby give my 
consent to take 4ml of my blood sample for the purpose of doing serum 
electrolytes. I was explained about the procedure in detail and give my 
consent for participating in the study and for using the results for 
Medical & Scientific purposes. 
 
 
Signature of the participant     Signature of Witness 
Signature of the Investigator   
 
 
Chennai Medical College Hospital & Research Centre 
Irungalur, Trichy – 621 105.  
சென்னை மருத்துவக்கல்லூரி மருத்துவமனை மற்றும் ஆராய்ச்சி னமயம்,  




சென்னை மருத்துவக்கல்லூரி மருத்துவமனை மற்றும் ஆராய்ச்சி னமயத்தின் உயிர் வவதியியல் துனையில் 
நடத்தப்படும் இ.ஜி.எப்ப்.ஆர், புரதம் - கிவரட்டினின் விகிதம், னதராய்டு மற்றும் சகாழுப்பு சுயவிவரம் 
ஆகிவற்றிைால் சிறுநீரக செயல் பிைழ்ச்சியின் ஆபத்து காரணினய மதிப்பிடும் ஒரு ஆய்வில் பங்வகற்குமாறு 
உங்கனை வகட்டு சகாள்கிவைாம்.  
x இப்பரிவொதனைக்கு ெம்மதிப்பது உங்கள் விருப்பத்னத சபாறுத்தது.  
x இச்வொதனைக்கு கட்டணம் கினடயாது.  
x கட்டாயம் ஏதும் இல்னை.  
x பரிவொதனையில் இருந்து எந்வநரமும் விைக தங்களுக்கு முழு உரினம உண்டு.  
 
இந்த ஆய்வின் முடிவுகள் மருத்துவம் மற்றும் விஞ்ஞாை முன்வைற்ைத்திற்கு உதவும் என்று 




நான் திரு/ திருமதி/ செல்வி/______________________________________________________________ 
முகவரி_______________________________________________________________________________
_________________________________________________________நாள்___________________ அன்று 
வமற்கண்ட ஆய்விற்காக தகவல் படிவத்தினை  படித்து, வகட்டு, புரிந்துசகாண்டு இந்த ஆராய்ச்சிக்கு 
வதனவயாை வொதனைக்கு என்னிடம் இருந்து 5 ml இரத்தம் எடுத்து சகாள்ை அனுமதிக்கிவைன். என் 
மைப்பூர்வமாை ெம்மதத்னத அளிப்பவதாடு இந்த ஆய்வின் முடிவுகனை  மருத்துவம் மற்றும் விஞ்ஞாை 
வநாக்கத்திற்கு பயன்படுத்த ஒப்புதல் அளிக்கிவைன்.  
 
 
பங்வகற்பாைர் னகசயாப்பம்   
     
 
நடுநினை ொட்சியின் னகசயாப்பம் 
 
 
ஆய்வாைர்/ ெம்மதம் சபறுபவர் னகசயாப்பம் 
சென்னை மருத்துவக்கல்லூரி மருத்துவமனை மற்றும் ஆராய்ச்சி னமயம்,  
  இருங்கலூர், திருச்சிராப்பள்ளி - 629165 
 
 
